

Item No. 11

“To Be Delivered” Material For City of Sacramento City Council Housing Authority Redevelopment Agency Economic Development Commission Sacramento City Financing Authority Agenda Packet

Submitted By: Patti Bisharat, Director of Government Affairs

For the Meeting of: August 8, 2006

The attached materials were not available at the time the Agenda Packet was prepared.

Title: Direction on the Development of an Ordinance to Implement the Disease Prevention Demonstration Project Which Includes a Needle Purchase Program.

Contact Information: Patti Bisharat, Director of Government Affairs,
(916) 808-5704

Please include this “To Be Delivered” material in your agenda packet. This material will also be published to the City’s Intranet.
For additional information, contact the City Clerk Department at Historic City Hall, 915 I Street, First Floor, Sacramento, CA 95814-2604– (916) 808-7200.



REPORT TO COUNCIL

City of Sacramento

915 I Street, Sacramento, CA 95814-2604
www. CityofSacramento.org

Staff Report
August 8, 2006

**Honorable Mayor and
Members of the City Council**

Title: Direction on the Development of an Ordinance to Implement the Disease Prevention Demonstration Project Which Includes a Needle Purchase Program.

Location/Council District: Citywide

Recommendation: Staff is requesting direction from the Mayor and City Council on whether to draft an ordinance that would implement the Disease Prevention Demonstration Project.

Contact: Patti Bisharat, Director of Government Affairs, 808-8197.

Presenters: Patti Bisharat, Director of Government Affairs.

Department: City Manager's Office

Division: Government Affairs

Organization No: 0310

Description/Analysis

Issue: The issue before the Mayor and City Council is whether it wishes to direct staff to draft an ordinance that would implement a needle purchase program. This item was heard by the Law and Legislation Committee, however, no waiver of the council rules of procedure is necessary to hear this item before the Mayor and Council.

Policy Considerations: The implementation of a needle purchase program by the City would be one tool to help reduce the use of unclean needles by IV drug users along with other services provided by the County to this population.

According to the Sacramento County Public Health Department, studies have shown that access to clean needles for IV drug users decrease the spread of HIV, Hepatitis C, and other blood borne diseases. They also show that jurisdictions which have changed the law with regard to the need for a prescription to purchase syringes have experienced a decrease in accidental occupational needle sticks to law enforcement officers, have not seen an increase in improperly discarded syringes, and have not seen an increase IV drug use.

Environmental Considerations: None.

Rationale for Recommendation: Councilmember Ray Tretheway requested that staff bring forward this report for the Mayor and City Council’s consideration. For this reason, staff is seeking direction from the Mayor and Council on whether to draft an ordinance that would implement a needle purchase program.

Financial Considerations: None

Emerging Small Business Development (ESBD): None.

Approved by: 
Patti Bisharat
Director of Government Affairs

Recommendation Approved:


for 
Ray Kerridge
City Manager

Table of Contents:

Report	pg. 1
Attachments	
1 Background	pg. 3
2 California Health Jurisdictions that Have Authorized SB 1159	pg. 6
3* Research Brief: Syringe Access	pg. 7
4* Effectiveness of Sterile Needle and Syringe Programming in Reducing HIV/AIDS Among Injecting Drug Users	pg. 35
5* High Rates of HIV Infection among Injection Drug Users Participating in Needle Exchange Programs in Montreal: Results of a Cohort Study	pg. 92

* Attachments 3-5 are on file with the City Clerk’s Office

ATTACHMENT 1**Background**

Committee Action: On August 1, 2006, at the request of Councilmember Tretheway, a discussion paper on the Disease Prevention Demonstration Project (SB 1159) was presented to the Law and Legislation Committee requesting direction on developing an ordinance to implement a needle purchase program. The Committee action was two votes in support and two votes in opposition, to move forward with drafting an ordinance.

Background

Under current law, a pharmacist is prohibited from furnishing needles and syringes to a person without a prescription. Anyone found in violation of this law could be criminally prosecuted. The law does provide for exemption from criminal prosecution to public agencies when the agency declares a local emergency. After declaring a local emergency, the public agency is allowed to distribute hypodermic needles or syringes to participants in clean needle or syringe exchange projects authorized by the agency.

Enactment of SB 1159 in 2004

In 2004, SB 1159 was enacted. It established the Disease Prevention Demonstration Project (DPDP) to evaluate the long-term desirability of allowing licensed pharmacists to furnish or sell nonprescription hypodermic needles or syringes to prevent the spread of blood-borne pathogens. This new law permits, between January 1, 2005 and December 31, 2010, a city or a county to enact an ordinance authorizing the DPDP. The DPDP allows a pharmacist, whom is registered with the DPDP in its local jurisdiction, to furnish or sell 10 or fewer hypodermic needles or syringes to a person 18 years of age or older without a prescription. It also allows, during the same time period, the legal possession of 10 or fewer hypodermic needles or syringes if acquired through an authorized source.

More specifically, the bill requires any pharmacy that chooses to sell nonprescription hypodermic needles and syringes to:

- Register with the local health department and certify that it will provide the purchaser with written information or verbal counseling regarding accessing drug treatment, accessing testing and treatment for HIV and hepatitis C, and safely disposing of sharps waste.
- Store hypodermic needles and syringes so that they are only available to authorized personnel.
- Provide for the safe disposal of hypodermic needles or syringes via an onsite safe hypodermic needle and syringe collection and disposal program or by furnishing or making available for purchase mail-back sharps disposal containers that meet state and federal standards for disposal of medical waste.

In addition this bill:

- Makes it unlawful to discard or dispose of a hypodermic needle or syringe upon the grounds of a playground, beach, park, or any public or private elementary, vocational, junior high, or high school. It also specifies that the requirement does not apply to the containment, treatment, and disposal of medical sharps waste from medical care or first aid services rendered on school grounds, nor to the containment, treatment, and disposal of hypodermic needles or syringes used for instructional or educational purposes on school grounds.
- Specifies that a person who knowingly violates the above provision is guilty of a misdemeanor, and upon conviction is punishable by a fine of between \$200 and \$2,000, by imprisonment in a county jail for up to six months, or both.
- Excludes hypodermic needles or syringes that have been containerized for safe disposal in containers that meet state and federal standards for disposal from unlawful possession provisions of the law.
- Repeals current law that requires a pharmacist to keep detailed records of nonprescription sale hypodermic needles and syringes.
- Requires the Department of Health Services (DHS), on or before January 15, 2010, to provide to the Governor and the Legislature a report on the impact of allowing pharmacists to furnish or sell nonprescription hypodermic needles or syringes, as specified.

Arguments on SB 1159

At the time SB 1159 was moving through the California Legislature there were arguments made for and against SB 1159.

The arguments in support of SB 1159 were as follows:

- This bill will prevent the spread of HIV and hepatitis among injection drug users, their sexual partners, and offspring.
- It will result in millions of dollars in averted healthcare costs.
- Peace officers will benefit from this bill due to the likely reduction in accidental needlestick injuries while on the job.
- It will facilitate the safe collection and disposal of all household sharps waste, including those used for the medical treatment of diabetes.

The arguments in opposition to SB 1159 were as follows:

- This bill will encourage continued illegal drug use and make it more difficult for law enforcement to convict illegal drug users.
- They believe the measure could potentially increase the amount of contaminated needles and syringes left in parks, beaches, and other public areas.
- This bill contemplates a needle distribution program that is outside of the statutory framework established by AB 136 (Mazzoni, Chapter 762, Statutes of 1999) and thereby evades the accountability inherent in existing needle exchange programs.

Statistics and Information for the Council's Consideration

The following information was provided by Sacramento County Health Department.

- There are approximately 15,000 daily intravenous (IV) drug users in Sacramento County.
- IV drug users who continue to use and share syringes have a 90 percent chance of becoming infected with hepatitis C within one year.
- HIV infection is much lower, less than 2 percent in current IV drug users.
- In 2003, there were 3,282 people living with HIV or AIDS in Sacramento County.
- IV drug use or having sex with an IV drug user is the second most common risk factor for both men and women.
- New hepatitis C cases reported to Sacramento County Public Health have averaged 1042 a year for the past 6 years. In 2004, there were 744 cases of hepatitis C reported to the County Health Department.
- Preventing one case of HIV saves \$12,000 a year in medication alone. (Cost to Sacramento County per case per year).
- Preventing one case of hepatitis C saves \$9,000 a year. (Cost to Sacramento County per case per year).
- The cost for 10 syringes in Sacramento is \$3.39/\$4.79 depending on the brand.

Disease Prevention Demonstration Project Ordinance

The question before the Mayor and City Council is whether it wishes to direct staff to draft an ordinance to implement a DPDP. If the Council approves the implementation of a DPDP the County Health Officer (CHO) will be the administrator of the program. The City will not incur any costs as a result of the program.

If the ordinance is adopted, any pharmacy that wishes to participate in the program would register with CHO. The CHO would provide the necessary educational materials to pharmacy for distribution at the time the needles are purchased. The County would also provide information to the pharmacy on its requirements per SB 1159. The CHO is also willing to report back to the Committee at anytime, either every 6 months or one year, whatever the desire of the Committee.

What Are Other Jurisdictions are Doing?

Currently, forty-five states allow the sale of syringes without a prescription. In California, sixteen counties have authorized SB 1159 and now have needle purchase programs. (See Attachment 2). We have contacted Yolo, Solano, and Yuba County and they have indicated that they have not experienced any negative issues with the program. The Sacramento County Board of Supervisors and the City Councils of Elk Grove, Rancho Cordova, and Galt have voted against an ordinance to implement a DPDP.

California Health Jurisdictions that have authorized SB 1159 – Disease Prevention Demonstration Project

Contra Costa County – Authorized: December 14, 2004

Yuba County – Authorized: January 11, 2005

The City of West Hollywood – Authorized: February 22, 2005

Marin County – Authorized: March 1, 2005

City of Los Angeles – Authorized March 7, 2005

Santa Cruz County – Authorized: March 15, 2005

Alameda County – Authorized: March 29, 2005

San Francisco City and County – Authorized: April 11, 2005,

Yolo County – Authorized: May 3, 2005

Los Angeles County – Authorized: June 14, 2005

San Mateo County – Authorized: August 4, 2005

Solano County – Authorized: September 27, 2005

Sonoma County – Authorized: September 27, 2005

Humboldt County – Authorized: October 4, 2005

Santa Barbara County – Authorized: November 20, 2005

Santa Clara County – Authorized: January 10, 2006

The Lindesmith Center – Drug Policy Foundation, Sacramento

Research Brief: Syringe Access

Updated March 2001
by Julie Ruiz-Sierra

Please forward comments
to: jruiz@drugpolicy.org

Research Brief: Syringe Access

- I Introduction
 - II The Human and Fiscal Costs of AIDS Continue to Rise
 - III Increasing IDU Access to Sterile Injection Equipment is a Proven Disease-Prevention Strategy
 - IV Syringe Exchange Programs
 - V Pharmacy Sale of Syringes
 - VI Alternate Access Methods
 - VII Syringe Disposal
 - VIII Barriers to Syringe Access
 - IX Notes
-

I Introduction: Improving access to sterile syringes as a public health measure is widely supported.

Increasing the availability of sterile syringes through syringe exchange programs (SEPs), pharmacies, and other outlets reduces unsafe injection practices such as needle sharing, curtails transmission of HIV/AIDS and hepatitis, increases safe disposal of used syringes, and helps injecting drug users (IDUs) obtain drug information, treatment, detoxification, social services, and primary health care.¹ Although many states and municipalities in the United States have acted to improve access to sterile syringes, the possession, distribution, and sale of syringes remains a criminal offense in much of the country, and the federal government has not lifted its ban on the use of funds for SEPs. By contrast, national and local governments in Western Europe, Australia, Canada, and even some developing countries have made sterile syringes widely accessible.²

Every established medical, scientific, and legal body to study the issue concurs in the efficacy of improved access to sterile syringes to reduce the spread of infectious diseases: the National Academy of Sciences, American Medical Association, American Public Health Association, National Institutes of Health Consensus Panel, Centers for Disease Control and Prevention, Office of Technology Assessment of the U.S. Congress, American Bar Association, President Bush's and President Clinton's AIDS Advisory Commissions, and others. In July 1997, the U.S. Conference of Mayors formally endorsed federal and state policy changes to improve access to sterile syringes. In October 1999, the American Medical Association, the American Pharmaceutical Association, the Association of State and Territorial Health Officials, the National Alliance of State and Territorial AIDS Directors, and the National Association of Boards of Pharmacy issued a joint statement in support of removing legal barriers to pharmacy sale of syringes without a prescription.³

Public opinion is moderately in favor of SEPs. A 1996 Kaiser Family Foundation poll found 66% popular support, and Hart Research polls found 54-55% support from 1995 through 1997, although only about 1/3 of the public support syringe deregulation.⁴

Fifteen of the top twenty most widely circulated U.S. newspapers have editorialized in favor of SEPs or syringe deregulation.⁵

II The Human and Fiscal Costs of AIDS Continue to Rise

Minorities are disproportionately affected: In 1999, more African Americans were reported with AIDS than any other racial/ethnic group. AIDS is the second leading cause of death among African Americans aged 25 to 44 and half of those deaths were caused by injections with contaminated needles.⁶

In 1999, Latinos represented 13% of the U.S. population, but accounted for 19% of the total number of new AIDS cases that year. AIDS is the fourth leading cause of death among Latinos aged 25 to 44 and half of those deaths were caused by injections with contaminated needles.⁷

Among IDUs, African Americans are five times as likely and Latinos are at least one and a half times as likely as whites to get AIDS.⁸

Injection Drug Use is Driving the AIDS Epidemic: By June 2000, 36% (270,721) of U.S. AIDS cases reported to the Centers for Disease Control and Prevention had occurred among IDUs, their sexual partners, and offspring⁹.

As of June 2000, 57% of all children born with AIDS (and over 2/3 of Latino children born with AIDS) were the children of IDUs or their sexual partners.¹⁰

Approximately 50% of new HIV infections occur among IDUs, their sexual partners, and offspring.¹¹

IDUs are especially susceptible to Hepatitis C: IDUs have one of the highest rates of Hepatitis C infection of any group studied and account for 43% of reported acute Hepatitis C infections in the United States between 1992 and 1995.¹²

Hepatitis C is transmitted in the same manner as other blood-borne pathogens among IDUs (direct needle sharing or contaminated injection equipment) but is acquired more rapidly than other viral infections, with one study reporting that 50 to 80% of new injectors test positive for HCV antibodies within a year of beginning injection.¹³ Surveys of adult IDUs consistently report seroprevalence levels of 70 – 90%, or saturation levels in this population.¹⁴

Approximately 4 million persons nationwide have contracted Hepatitis C and an estimated 8000 to 10,000 deaths occur annually from Hepatitis-related chronic

liver disease, at an estimated cost of more than \$600 million per year. Without effective preventive and therapeutic measures, the number of deaths from chronic Hepatitis infection is expected to triple in the next 10 to twenty years.¹⁵ Treatment of last resort is a liver transplant at an average cost of \$300,000. Short of a transplant, standard care for a person with cirrhosis of the liver or liver cancer costs \$20,000 a year.¹⁶

III Increasing IDU Access to Sterile Injection Equipment is a Proven Disease Prevention Strategy

In clinical settings, viable proliferating HIV-1 virus has been recovered from syringes stored at room temperature for periods of up to 30 days.¹⁷

The Centers for Disease Control and Prevention recommend that, to reduce the risk of infectious disease, IDUs unable to stop using drugs should "use a new, sterile syringe to prepare and inject drugs" and practice safe injection techniques.¹⁸

It is estimated that injection drug use accounts for some 920 million to 1.68 billion injections annually in the United States.¹⁹ In 1999, SEPs exchanged 19 million syringes. While this is a good start, more sources of sterile syringes are clearly necessary.

"Indirect sharing" of injection equipment (water, cookers, and cotton) has recently been appreciated as having a potential for the transmission of blood-borne pathogens.²⁰

By the late 1980s, virtually all developed countries other than the United States had made legal access to sterile injection equipment a primary component of AIDS prevention.²¹ Several developing countries are beginning to do likewise.²²

IV Syringe Exchange Programs

As a form of disease vector control, syringe exchange reduces the time that needles and syringes spend in circulation. The less time that potentially contaminated injecting equipment circulates among drug users, the less chance it has of being contaminated and afterwards reused by an uninfected user.²³

The first SEP in the United States began operating in 1986²⁴. Despite a proliferation of SEPs—in mid-1997, 113 operated in 71 cities in 29 states, Washington, D.C., and Puerto Rico²⁵; Currently, an estimated 164 SEPs operate in the United States — only about 10% of U.S. IDUs have access.²⁶

In 1999 U.S. SEPs exchanged some 19 million syringes.²⁷

Syringe exchange decreases risky injection behavior by as much as 73%.²⁸

A study of high-risk IDUs recruited in Oakland, California demonstrated that IDUs who attended syringe exchange programs were 2 1/2 times more likely to stop sharing needles than non attending IDUs after just six months.²⁹ SEPs have been shown to decrease the number of injections per syringe by 44 to 85% and to greatly increase one time use of syringes.³⁰

Syringe exchange decreases HIV seroprevalence among IDUs: A worldwide survey found that HIV seroprevalence among IDUs decreased 5.8% per year in cities with SEPs, and increased 5.9% per year in cities without SEPs.³¹

IDUs in New York City who used SEPs were two-thirds less likely to become infected with HIV than those who did not.³²

All but two of the seroincidence studies to-date on SEPs have shown reduced incidence of HIV among participants.³³ A 1997 study in Vancouver and a 1995 study in Montreal, Canada, often cited by critics of SEPs, determined that SEPs play a crucial role in HIV prevention, but are not in and of themselves sufficient.³⁴

SEPs help reduce the spread of hepatitis.³⁵ Participants in a Tacoma SEP were six to seven times less likely to contract hepatitis B or C.³⁶ A New Haven SEP was associated with a minimum 33% reduction in HIV incidence³⁷ and a similar reduction in hepatitis B.³⁸ Studies of SEP participants in Australia found a concurrent 50% decline in needle sharing behavior and a decline in HCV antibody prevalence from 22% to 13% in a 3-year period.³⁹

SEPs are cost-effective for society: SEPs have a median annual budget of \$169,000.⁴⁰ The lifetime cost of treating one person with AIDS is over \$100,000,⁴¹ and new treatments expected to extend the lives of people with HIV will, at \$10-20,000 per year, be far more expensive.⁴² The average SEP more than pays for itself by preventing the transmission of HIV to two people each year.

Using a very conservative model, a *Lancet* article estimates that 4,400 to 10,000 HIV infections among U.S. IDUs could have been avoided between 1987 and 1995 if the federal government had implemented syringe exchange nationally, saving over \$500 million in health care costs. Action taken in early 1997 could have prevented an additional 11,000 infections by the year 2000, saving over \$600 million.⁴³

An economic analysis of governmental expenditures to cover the sterile syringe needs for a hypothetical cohort of 1 million IDUs estimated that complete coverage could be achieved for a total societal cost of \$423 million dollars, of which one third would be out-of-pocket expenses paid by IDUs. Although this expenditure seems costly at first glance, it would avert 1.3 billion in medical expenses for a net savings of \$916 million dollars.⁴⁴

For every year without increased IDU access, as many as 12,350 will become infected with HIV, leading to an estimated 1.3 billion in future medical costs.⁴⁵

These estimates, which focus exclusively on the costs of HIV treatment, necessarily underestimate the economic benefit conferred by SEPs because they do not account for prevented cases of Hepatitis.⁴⁶

By controlling infectious disease and referring IDUs into treatment, SEPs may reduce local expenditures on corrections and law enforcement.⁴⁷

“Satellite” or secondary exchange, a phenomenon in which participants distribute sterile syringes they acquire through SEPs to an extended IDU network increases the coverage and effectiveness of SEPs.⁴⁸

Access to sterile syringes does not encourage people to increase drug use or to start injecting drugs.

Seven major government-funded reports concur that access to sterile syringes does not increase drug use.⁴⁹ No reports contradict this finding.

Three years after a San Francisco SEP opened, the mean age of IDUs increased while the minimum age remained stable.⁵⁰ A New Haven SEP found similar results.⁵¹

Amsterdam, which has hosted a government-sponsored SEP for over thirteen years, has seen no increase in a steadily aging population of IDUs.⁵²

The number of new users choosing to inject drugs has decreased in New York City since the establishment of SEPs.⁵³

Access to sterile syringes does not hinder other drug treatment efforts: In fact, many people visit SEPs not only to exchange syringes, but also to get referrals to detoxification and treatment,⁵⁴ as well as to obtain primary health care.⁵⁵ 97% of U.S. SEPs surveyed in 1996 offered referrals to drug treatment programs and 80% provided education to reduce the risk sexually transmitted diseases.⁵⁶

In 1991–92, a Tacoma SEP was the largest single source of recruitment to methadone maintenance programs in the country;⁵⁷ in 1992–93, nearly 20% of participants in a New Haven SEP initiated drug treatment, and hundreds approached the SEP solely for treatment referral.⁵⁸

After a SEP opened next to a methadone clinic in Sydney, Australia, there was no increase in dropouts or positive urine tests among patients at the methadone clinic, nor was there a decrease in the number of people seeking admission.⁵⁹

During a three-year period, 51% of the participants offered referrals to a drug rehabilitation program in a Baltimore, Maryland, SEP entered treatment. A recent study comparing patients referred this program to standard referral patients showed both groups had comparable retention and success rates despite the fact that the SEP patients had a greater severity of baseline drug use.⁶⁰

The legal status of SEPs affects their ability to act as conduits to other services. A survey of 101 U.S. SEPs found that those with legal status were significantly more likely to provide testing for HIV and TB, acupuncture, and referral to social service, STD treatment, birth control, childcare, employment, and mental health agencies.⁶¹

“[W]ell designed and implemented syringe exchange programs have demonstrated efficacy in engaging populations at severe risk for HIV and reducing the further spread of HIV among injection drug users, their sexual partners and children... After reviewing the research to date, the senior scientists of the department and I have unanimously agreed that there is conclusive scientific evidence that syringe exchange programs, as part of a comprehensive strategy, are an effective public health intervention that reduces the transmission of HIV and does not encourage the use of illegal drugs.”

-David Satcher,
Surgeon General of the United States⁶²

V Pharmacy Sale of Syringes

Pharmacy sale has been shown to reduce risky injection behavior by 40%.⁶³

Pharmacy sale of syringes can reach IDUs around the clock and in rural or suburban areas that may not be able to sustain SEPs. Access to sterile syringes through pharmacies may reduce NIMBY ("Not In My Backyard") issues, while reaching those who may not feel comfortable attending SEPs.

Diabetic IDUs who can legally buy syringes at pharmacies had significantly lower rates of HIV than non-diabetic IDUs—9.8% versus 24.3%—even though the duration and intensity of drug use were similar.⁶⁴

Since Connecticut changed its paraphernalia and prescription laws in 1992 to allow for possession and sale of up to ten syringes, needle sharing among IDUs dropped 40% and needle stick injuries to police decreased by 66%.⁶⁵ As of 1995, over 80% of pharmacies voluntarily sold syringes over the counter, and most IDUs obtained syringes at pharmacies, rather than on the street, where equipment is often unsterile and possibly infected.⁶⁶

Pharmacy sale is standard throughout Western Europe, much of Central and Eastern Europe, Oceania, and increasingly in U.S. states.⁶⁷ Many pharmacies also sell IDU-specific packs that include syringes, alcohol swabs, and other sterile items, such as cotton and water, which are often shared when not adequately available. Many packs also contain condoms and HIV prevention information.⁶⁸

Pharmacists are health care professionals who can provide needed advice regarding disease prevention and safe disposal of syringes to all purchasers. Although pharmacy sales have been deregulated in several states, studies show this does not immediately translate into access for IDUs. Further efforts are needed to educate pharmacists about the vital public health role they play and to dispel myths and fears about IDUs.⁶⁹

VI Alternate Access Methods

Physician prescription of sterile injection equipment is a new intervention that has tremendous potential to complement existing public health efforts to prevent the transmission of HIV, is clearly legal in 48 states and territories, and has strong support from the American Medical Association.⁷⁰

Automated syringe exchange: Another approach to syringe access in European countries in addition to SEPs and legal pharmacy sales without a prescription is the vending machine. Similar to soda vending machines, syringe vending machines accept used syringes and mechanically deliver sterile ones in exchange. Syringe vending machines have been introduced in over a dozen European and Australian cities.⁷¹ In one program introduced in Marseille, France in 1996, machines regularly attracted a segment of the IDU population that was not reached via SEPs or pharmacy sales after only one year in operation.⁷²

Single-use or Difficult-to-Reuse Syringes are technological innovations meant to self-destruct after one use. Although these syringes have an intuitive appeal given public health service recommendations that syringes be used only once, early evaluation suggests they are incompatible with injection drug use practices and may actually negatively affect HIV risks in IDU populations.⁷³ Single-use

syringes are more costly than regular syringes⁷⁴ and would not be necessary if sufficient supplies of regular syringes were available.

VII Syringe Disposal

Fear of discarded needles is a primary factor in community opposition to programs that are intended to increase IDU access to sterile syringes such as pharmacy sales and SEPs. Despite low absolute risk of contracting HIV from a needle stick, the sheer volume of syringes used every year and high level of public concern mean that communities must address the issue of safe disposal.⁷⁵ A variety of unique approaches to community disposal (including puncture resistant containers for household trash disposal, drop boxes, and biohazard disposal sites at hospitals and pharmacies) already employed with great success around the world can serve as models for the implementation of more.⁷⁶

IDU access to sterile syringes does not increase the number of improperly discarded syringes. In fact, some neighborhoods report a decrease in improperly discarded syringes.⁷⁷ Studies in Portland, Oregon⁷⁸ and Baltimore, Maryland⁷⁹ found similar or decreased numbers of improperly discarded syringes. Significantly, one study identified an increase in improperly discarded syringes *after* public fears about SEP impact on the community forced the closure of a program in Windham, Connecticut.⁸⁰

SEPs and pharmacies provide convenient locations for IDUs to properly dispose of syringes. A pilot program in Baltimore allowing IDUs to dispose of syringes in red mailboxes shows preliminary success.⁸¹ It is estimated that in the first ten months of operation, the red box program collected nearly 3000 syringes, 11% of which were infectious.⁸²

- **Community disposal programs can prevent costly needle-stick injuries.** Outside the health care field, waste handlers/sanitation workers, housekeeping staff, police and firefighter are the workers who experience the largest number of occupational needle stick injuries. One privately owned municipal waste-disposal company estimated a total cost of \$4400 for the direct and indirect costs of medical care and follow up for each employee with a needle-stick injury.⁸³

VIII Barriers to Syringe Access

Progress has been made, but there are still major barriers to obtaining sterile syringes in the United States. Under the Terms of Public Law 105-78⁸⁴, federal funds to support needle exchange programs were conditioned on a determination by the Secretary of Health and Human Services that such programs reduce the transmission of human immunodeficiency virus (HIV) and do not encourage the use of illegal drugs. In April 1998 the Secretary of Health and

Human Services, Donna E. Shalala, made that determination. The Act's restriction on federal funding, however, has not been lifted.⁸⁵

"A meticulous scientific review has now proven that needle exchange programs can reduce the transmission of HIV and save lives without losing ground in the battle against illegal drugs. It offers communities that decide to pursue needle exchange programs yet another weapon in their fight against AIDS."

-Donna E. Shalala,
Secretary of Health and Human Services⁸⁶

Drug paraphernalia and prescription laws are stalling state-level syringe deregulation efforts. While only 5 states still require a prescription for the purchase of syringes,⁸⁷ 47 states and Washington, D.C., have drug paraphernalia laws limiting the possession and/or distribution of syringes.⁸⁸

Paraphernalia laws impose a "chilling" effect that causes IDUs not to carry sterile injection equipment for fear of arrest and significantly increases high-risk sharing behaviors.⁸⁹

"Legal sanctions on injection equipment do not reduce illicit drug use, but they do increase the sharing of injection equipment and hence the spread of AIDS."

—U.S. National Commission on AIDS⁹⁰

In 1994, the cost of incarcerating 100 IDUs for a paraphernalia possession conviction in Massachusetts alone, excluding court costs, could have put *more than sixteen times* that number IDUs (1,629) through detoxification programs.⁹¹

Deregulation efforts are underway: Many states and municipalities have adapted or reinterpreted drug paraphernalia laws to allow for the operation of SEPs. A 1996 U.S. survey found that in states with drug paraphernalia laws, 27 SEPs were state-authorized and 13 were legal based on local interpretations of state laws or public health emergency powers.⁹²

Based on Connecticut's success, Maine, Minnesota, and New York⁹³ changed their paraphernalia and prescription laws to allow over-the-counter purchase of up to ten syringes; Rhode Island has legalized pharmacy sale of syringes and set no limit on how many may be purchased.⁹⁴

Perhaps the biggest barrier is fear.

"For most of the countries that have not implemented appropriate HIV prevention programs, however, the problem is not one of resources, but one of political attitudes... Rather than taking a public health approach to the problems of HIV infection among IDUs, many countries have applied moralistic approaches

coupled with law enforcement, or have attempted to prevent public health problems primarily by eliciting fear about using drugs."⁹⁵

IX Notes

¹ See: Drucker E, Lurie P, Wodak A, Alcabes P. Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV. *AIDS* 1998;12(Supp. A):S217-S230. Centers for Disease Control and Prevention. *New Attitudes & Strategies: A comprehensive Approach to Preventing Blood-Borne Infections Among Injection Drug Users*. October 25, 2000. Normand J, Vlahov D, Moses LE, eds. *Preventing HIV Transmission: The Role of Sterile Needles and Bleach (Note: only portions of this report are available online.)* Washington, DC: National Academy Press; 1995. Lurie P, Reingold A. *The Public Health Impact of Needle Exchange Programs in the United States and Abroad* (prepared for the Centers for Disease Control and Prevention). Berkeley, CA: University of California, School of Public Health, and San Francisco, CA: University of California, Institute for Health Policy Studies; 1993. Des Jarlais DC, Friedman SR, Sotheman JL, Weston J, Marmor M, Yancovitz SR, Frenk B, Beatrice S, Mildvan D. Continuity and change within an HIV epidemic: Injecting drug users in New York City, 1984 through 1992. *JAMA*. 1994;271:121-127.

² Ball AL, Rana S, Dehne KL. HIV Prevention Among Injection Drug Users: Responses in Developing and Transitional Countries. *Public Health Reports*, June 1998: 113 (Supp.1):170-181.

³ American Medical Association, American Pharmaceutical Association, The Association of State and Territorial Health Officials, National Alliance of State and Territorial AIDS Directories. "HIV Prevention and Access to Sterile Syringes." Joint Resolution. October 1999. U.S. Conference of Mayors. *Needle Exchange: Moving beyond the Controversy*. Washington, DC: U.S. Conference of Mayors; 1997. American Medical Association 6/97 Statement on Syringe Exchange. Lurie P, Reingold A. *The Public Health Impact of Needle Exchange Programs in the United States and Abroad* (prepared for the Centers for Disease Control and Prevention). Berkeley, CA: University of California, School of Public Health, and San Francisco, CA: University of California, Institute for Health Policy Studies; 1993. Normand J, Vlahov D, Moses LE, eds. *Preventing HIV Transmission: The Role of Sterile Needles and Bleach*. Washington, DC: National Academy Press; 1995. National Commission on Acquired Immune Deficiency Syndrome. *The Twin Epidemics of Substance Use and HIV*, Washington, DC: National Commission on Acquired Immune Deficiency Syndrome; 1991. U.S. General Accounting Office. *Needle Exchange Programs: Research Suggests Promise as an AIDS Prevention Strategy*. Washington, DC: U.S. General Accounting Office; 1993. National Institutes of Health Consensus Panel. *Interventions to Prevent HIV Risk Behaviors*. Washington, DC: National Institutes of Health; 1997. Surgeon General David Satcher's report: Evidence-Based Findings for the Efficacy of Syringe Exchange Programs. U.S. Department of

Health and Human Services. March 17, 2000. Other agencies supporting SEPs include: AIDS National Interfaith Network, American Academy of Pediatrics, American Academy of Psychiatrists in Alcoholism and Addictions, American College of Preventive Medicine, American Psychiatric Association, American Society of Addiction Medicine, Association for Professionals in Infection Control and Epidemiology—South Jersey Chapter, Brotherhood Crusade, California Latino Civil Rights Network, Denver Medical Society, Feminist Majority Foundation, Illinois Alcoholism and Drug Dependence Association, Illinois State Medical Society, Medical Society of New Jersey, National Association for the Advancement of Colored People, National Association of Psychiatric Health Systems, National Association of Social Workers, National Association of State Alcohol and Drug Abuse Directors, National Black Caucus of State Legislatures, National Black Nurses Association, National Black Police Association, National Nurses Association, National Urban Coalition, National Urban League, New Hampshire Medical Society, Office for Church in Society, People of Color Against AIDS Network, San Francisco Medical Society, Office for Church in Society, Texas Sheriffs' Association, United Church of Christ, World Health Organization, and others. "An impressive body of evidence suggests powerful effects from needle exchange programs. The number of studies showing beneficial effects on behaviors such as needle sharing greatly outnumber those showing no effects. There is no longer doubt that these programs work, yet there is a striking disjunction between what science dictates and what policy delivers. Can the opposition to needle exchange programs in the United States be justified on scientific grounds? Our answer is simple and emphatic—no. Studies show reduction in risk behavior as high as 80%, with estimates of a 30% or greater reduction of HIV in IDUs. The cost of such programs is relatively low. Such programs should be implemented at once."—NIH Consensus Panel.

⁴ A Kaiser Family Foundation survey found that 66% of all Americans are in favor of providing clean needles to IDUs: 66% of those age 18-29, 63% of those over 65; 56% of Republicans, 67% of independents, 71% of Democrats; 62% of Evangelicals, 69% of non-Evangelicals, 67% of Catholics. Henry J. Kaiser Family Foundation. *The Kaiser Survey on Americans and AIDS/HIV*. Menlo Park, CA: Henry J. Kaiser Family Foundation; March, 1996. Drug Strategies. *Americans Look at the Drug Problem*. Conducted annually by Hart Research Associates. A separate poll found 55% in support of SEPs (Human Rights Campaign poll, conducted April 8-10, 1997, by Tarrance Group and Lake Sosin Snell & Associates). A 1997 poll conducted for the Family Research Council by the Polling Company found 62% opposition to SEPs; that poll, however, presented SEPs and drug treatment as either/or policy choices. In the Southern Focus Poll, a random digit dial telephone poll conducted in 1997, 61% of respondents agreed that making clean needles available to IDUs would reduce the spread of HIV (University of North Carolina-Chapel Hill, Department of Health Behavior and Health Education, School of Public Health.)

⁵ Newspapers that have editorialized in favor of SEPs and/or syringe deregulation include: *Arizona Republic*, *Asbury Park Press*, *Asheville Citizen-Times*, *Atlanta Journal Constitution*, *Bakersfield Californian*, *Baltimore Sun*, *Boston Globe*, *Capital Times*, *Chapel Hill Herald*, *Chicago Sun-Times*, *Chicago Tribune*, *Cleveland Plain Dealer*, *Denver Post*, *Detroit Free Press*, *Fresno Bee*, *Gazette Telegraph* (Colorado Springs), *Hartford Courant*, *Los Angeles Times*, *Milwaukee Sentinel*, *New Haven Register*, *New York Newsday*, *New York Times*, *News and Observer* (Raleigh, NC), *Oakland Tribune*, *Philadelphia Inquirer*, *Providence Daily Journal*, *Providence Journal Bulletin*, *Rocky Mountain News*, *Sacramento Bee*, *St. Petersburg Times*, *San Francisco Chronicle*, *Seattle Times*, *Star Tribune* (Minneapolis), *USA Today*, *Vancouver Sun*, *Washington Post*, *Washington Times*. *The Wall Street Journal* is the only major U.S. newspaper that has editorialized against SEPs.

⁶ Centers for Disease Control and Prevention. HIV/AIDS Among African Americans Fact Sheet. Updated: November, 2000. Day D, *Health Emergency 2001: The Spread of Drug-Related AIDS and Hepatitis C Among African Americans and Latinos*. Princeton, NJ: Dogwood Center Publications, 2000.

⁷ Centers for Disease Control and Prevention. HIV/AIDS Among Hispanics in the United States Fact Sheet. Updated: January, 2001. Day D, *Health Emergency 2001: The Spread of Drug-Related AIDS and Hepatitis C Among African Americans and Latinos*. Princeton, NJ: Dogwood Center Publications, 2000.

⁸ Day D, *Health Emergency 2001: The Spread of Drug-Related AIDS and Hepatitis C Among African Americans and Latinos*. Princeton, NJ: Dogwood Center Publications, 2000.

⁹ Centers for Disease Control and Prevention. U.S. HIV and AIDS cases reported through June 2000. HIV/AIDS Surveillance Report. 2000; Midyear Edition Vol. 12(1):12-13. Categories include: IDUs, people who have had sex with an IDU, and children whose mothers are IDUs or have had sex with an IDU.

¹⁰ Centers for Disease Control and Prevention. U.S. HIV and AIDS cases reported through June 2000. HIV/AIDS Surveillance Report. 2000; Midyear Edition Vol.12(1):22.

¹¹ Holmberg SD. The estimated prevalence and incidence of HIV in 96 large U.S. metropolitan areas. *American Journal of Public Health*. 1996;86:642-654.

¹² Alter MJ, Moyer LA. The Importance of Preventing Hepatitis C Virus Infection Among Injection Drug Users in the United States. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S6-S10. Of the cases of HCV occurring in persons younger than 30 years of age, most can be attributed to IDU.

¹³ Alter MJ, Moyer LA. The Importance of Preventing Hepatitis C Virus Infection Among Injection Drug Users in the United States. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S6-S10. This may be because percutaneous transmission is more efficient for HCV than for other viral infections, see: MacDonald MA, et al. Hepatitis C Virus Antibody Prevalence Among Injecting Drug Users at Selected Needle and Syringe Programs in Australia, 1995-1997. *Medical Journal Australia*. Vol. 172. January 2000; Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe Exchange and Risk of Infection with Hepatitis B and C Viruses. *American Journal of Epidemiology* 1999;149(3):203-213.; Garefin RS, Doherty MC, Moterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and Incidence of Hepatitis C Virus Infection Among Young Adult Injection Users. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S11-S19.

¹⁴ Thorpe L, et al. Hepatitis C Virus Infection: Prevalence, Risk Factors, and Prevention Opportunities among Young Injection Drug Users in Chicago, 1997-1999. *Journal of Infectious Diseases*. Vol. 183. pp. 1588-94. 2000. High rate of HCV persistence coupled with its ability to produce chronic liver disease indicate that current IDU populations will experience the bulk of future HCV-associated morbidity and mortality in the United States.

¹⁵ Alter MJ, Moyer LA. The Importance of Preventing Hepatitis C Virus Infection Among Injection Drug Users in the United States. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S6-S10.

¹⁶ Day D, *Health Emergency 2001: The Spread of Drug-Related AIDS and Hepatitis C Among African Americans and Latinos*. Princeton, NJ: Dogwood Center Publications, 2000.

¹⁷ Abdala N, Stephens PC, Griffith BP, Heimer R. Survival of HIV-1 in Syringes. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1999; 20(1):73-80. The likelihood of viral survival increases as the volume of infected blood left behind in syringe increases. This research supports validity of SEP's because not only do they increase supply of sterile syringes, but they also remove potentially contaminated syringes from circulation. See also: Shah SM, Shapshak P, Rivers JF, Stewart RV,

Weatherby NL, Xin KQ, Page JB, Chitwood DD, Mash DC, Vlahov D, McCoy CB. Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: A preliminary report. *Journal of Acquired Immune Deficiency Syndromes*. 1996;11:301-306.

¹⁸ Centers for Disease Control and Prevention. Publication of HIV-prevention bulletin for health-care providers regarding advice to persons who inject illicit drugs. *Morbidity and Mortality Weekly Report*. 1997;46:510.

¹⁹ Lurie P, Jones TS, Foley J. A Sterile Syringe for Every Drug User Injection: How Many Injections Take Place Annually, and How Might Pharmacists Contribute to Syringe Distribution? *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998: 18 (Supp.1):S45-S51. Estimates were calculated by multiplying the estimated number of IDUs by the average number of daily injections by 365 days. Estimates of the number of IDUs in the United States vary between 900,000 (CDC) and 1.64 million (NASADAD). The national average number of daily injections (2.8) was derived from regional SEP survey data.

²⁰ Gershon RRM. Infection Control Basis for Recommending One-Time Use of Sterile Syringes and Aseptic Procedures for Injection Drug Users. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998: 18 (Supp.1):S20-S24; Koester S. Following the Blood: Syringe Reuse Leads to Blood-Borne Virus Transmission Among Injection Drug Users [letter]. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998: 18 (Supp.1):S139-140. Although each IDU may use his or her own sterile syringe, multiple variations in the drug preparation and injection process can cause an IDU to inadvertently compromise the effectiveness of that use: an IDU might return his just used syringe to the drug mixing container and cotton filter to obtain any drug residue that was left behind from the initial injection; water used for rinsing syringes might be subsequently used for dissolving drugs into solution; or a single contaminated syringe might be used to mix and distribute each participating IDU's share of the drug.

²¹ Lurie P, Reingold A. *The Public Health Impact of Needle Exchange Programs in the United States and Abroad (prepared for the Centers for Disease Control and Prevention)*. Berkeley, CA: University of California, School of Public Health, and San Francisco, CA: University of California, Institute for Health Policy Studies; 1993:61. Sweden is the only European country with a prescription law. The two other countries in Europe or Oceania to enact such laws—Austria and France—repealed them in the mid-1980s.

²² *Asian Harm Reduction Network Newsletter*. 1996;1:1-8. For further information, contact Paul Deany at Macfarlane Burnet Centre for Medical Research, POB 254, Fairfield VIC 3078 Australia (Tel: +61 3 9282 2213; Fax: +61 3 9482 3123; E-mail: deany@burnet.mbcmrunimelb.edu.au). Ball AL, Rana S, Dehne KL. HIV Prevention Among Injection Drug Users: Responses in Developing and Transitional Countries. *Public Health Reports*, June 1998; 113 (Supp.1):170-181.

²³ Drucker E, Lurie P, Wodak A, Alcabes P. Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV. *AIDS* 1998;12(suppl A):S217-S230. Heimer R. Syringe Exchange Programs: Lowering the Transmission of Syringe-Borne Diseases and Beyond. *Public Health Reports*, 1998; 113 (Supp.1): 67-74.

²⁴ Heimer R. Syringe Exchange Programs: Lowering the Transmission of Syringe-Borne Diseases and Beyond. *Public Health Reports*, 1998; 113 (Supp.1): 67-74.

²⁵ Paone D, Des Jarlais DC, Clark J, Shi Q, Krim M, Purchase D. Update: Syringe-exchange programs—United States, 1996. *Morbidity and Mortality Weekly Report*. 1997;46:565-568. States with above-ground SEPs include: Alaska, California, Colorado, Connecticut, Hawaii, Illinois, Kansas, Maryland, Massachusetts, Michigan, Minnesota, New York, Ohio, Oregon, Pennsylvania, Rhode Island, Texas, Washington, and Wisconsin.

²⁶ Purchase D. North American Syringe Exchange Network. Personal Communication, Tacoma, Washington, June 1997. "The behavior placing the public health at greatest risk may be occurring in legislative and other decision-making bodies." National Institutes of Health Consensus Panel. *Interventions to Prevent HIV Risk Behaviors: Draft Statement*. Washington, DC: National Institutes of Health; 1997.

²⁷ Des Jarlais DC, personal communication, March 1, 2001.

²⁸ Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. *Lancet*. 1996;348:987-991.

²⁹ Blumenthal RN, Kral AH, Gee L, Erringer EA, Edlin B. The effect of syringe exchange use on high-risk injection drug users: a cohort study. *AIDS* 2000, 14:605-611.

³⁰ Heimer R, et al. Syringe Use and Reuse: Effects of Syringe Exchange Programs in Four Cities. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S37-S44.

³¹ Hurley SF. Effectiveness of needle-exchange programmes for prevention of HIV infection. *Lancet* 1997;349:1797. Survey included primarily U.S. cities and found that cities with SEPs had an 11% lower rate of increase in seroprevalence each year.

³² Des Jarlais DC, Marmor M, Paone D, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. *Lancet*. 1996;348:987-991. Participants in a Portland SEP decreased their renting and sharing of syringes by two-thirds (Oliver K, et al. Behavioral and community impact of the Portland syringe exchange program. In: National Research Council and Institute of Medicine. *Proceedings, Workshop on Needle Exchange and Bleach Distribution Programs*. Washington, DC: National Academy Press; 1994:35-46). Prevention Point, a San Francisco SEP, disposed of approximately 8,600 HIV-contaminated syringes in one month in 1992 (Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. *JAMA*. 1994;271:119).

³³ Paone D. Presented at New York Statewide HIV Conference, February 1997. Of 16 HIV seroincidence studies, 14 showed a decrease, 1 (Montreal) showed an increase explained by basic operational problems, and 1 (Vancouver) showed a still-unexplained increase.

³⁴ Strathdee SA, Patrick DM, Currie SL, Cornelisse PGA, Rekart ML, Montaner JSG, Schechter MT, O'Shaughnessy MV. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. *AIDS*. 1997;11:F59-F65. See also: Remis RS, Bruneau J, Hankins CA. Enough Sterile Syringes to Prevent HIV Transmission Among Injection Drug Users in Montreal? *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S57-S59. A recent study of the Vancouver data found no causal association between the SEP and HIV transmission. See: Schechter MT, et al. Do Needle exchange Programs Increase the Spread of HIV Infection Among Drug Users?: An investigation of the Vancouver outbreak. *AIDS*. Vol.13, No.6. pp. F45-F51. 1999.

³⁵ Normand J, Vlahov D, Moses LE, eds. *Preventing HIV Transmission: The Role of Sterile Needles and Bleach*. Washington, DC: National Academy Press; 1995:240-243. See also: Hagan H, et al. The incidence of HBV infection and syringe exchange programs. *JAMA*. 1991;266:1646-1647. Letter.

-
- ³⁶ Hagan H, Des Jarlais DC, Friedman SR, Purchase D, Alter MJ. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. *American Journal of Public Health*. 1995; 85:1531-1537.
- ³⁷ Kaplan EH. Probability models of needle exchange. *Operations Research*. 1995; 43:558-569.
- ³⁸ Heimer R, Khoshnood K, Jariwala FB, Duncan B, Harima Y. Hepatitis in used syringes: the limits of sensitivity of techniques to detect HBV DNA, HCV RNA, and antibodies to HB core and HCV antigens. *Journal of Infectious Diseases*. 1996;173:997-1000.
- ³⁹ MacDonald MA, et al. Hepatitis C Virus Antibody Prevalence Among Injecting Drug Users at Selected Needle and Syringe Programs in Australia, 1995-1997. *Medical Journal Australia*. Vol. 172. January 2000.
- ⁴⁰ Lurie P, Reingold A. *The Public Health Impact of Needle Exchange Programs in the United States and Abroad (prepared for the Centers for Disease Control and Prevention)*. Berkeley, CA: University of California, School of Public Health, and San Francisco, CA: University of California, Institute for Health Policy Studies; 1993:11.
- ⁴¹ Hellinger FK. Forecasts of the costs of medical care for persons with HIV: 1992–1995. *Inquiry*. 1992;29:356.
- ⁴² Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. *JAMA* 1997;277:145-153. Sperling J, Jennings TS. Formulary considerations for selection of protease inhibitors. *Pharmacy and Therapeutics*. 1997;229-240.
- ⁴³ Lurie P, Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. *Lancet*. 1997;349:604-608. In another paper, the authors provide data for 16 cities (Lurie P, Drucker E. *An opportunity lost: estimating the number of HIV infections associated with lack of a national needle exchange programme in the United States*. *Lancet* 1997, 349:604-608.)

City	Preventable HIV Infections 1987-1995	Unnecessary treatment costs 1987-1995	Preventable HIV Infections 1996-2000	Unnecessary treatment costs 1995-2000
Atlanta	186	\$10,349,040	234	\$13,019,760
Baltimore	499	\$27,764,360	632	\$35,164,480
Boston	182	\$10,126,480	209	\$11,628,760
Chicago	561	\$31,214,040	710	\$39,504,400
Dallas	39	\$2,169,960	44	\$2,448,160
Detroit	152	\$8,457,280	188	\$10,460,320
Gary, IN	14	\$778,960	18	\$1,001,520
Houston	260	\$14,466,400	328	\$18,249,920
Los Angeles	95	\$5,285,800	100	\$5,564,000
Miami	297	\$16,525,080	360	\$20,030,400
N.Y. City	2,308	\$128,417,120	2,605	\$144,942,200
Newark	397	\$22,089,080	388	\$21,588,320
Philadelphia	641	\$35,665,240	810	\$45,068,400
San Juan	315	\$17,526,600	382	\$21,254,480
Seattle	48	\$2,670,720	60	\$3,338,400
Wash., D.C.	646	\$35,943,440	817	\$45,457,880

⁴⁴ Holtgrave, et al. "Cost and Cost-Effectiveness of Increasing Access to Sterile Syringes and Needles as an HIV Prevention Intervention in the United States." *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998: 18 (Supp.1):S133-S138.

⁴⁵ Ibid.

⁴⁶ Alter MJ, Moyer LA. The Importance of Preventing Hepatitis C Virus Infection Among Injection Drug Users in the United States. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998: 18 (Supp.1):S6-S10.

⁴⁷ Hernandez ER, Lurie P, Williams N, Stafford K, Rudy J. Needle exchange programs may reduce local government spending for law enforcement. Paper presented at 11th International Conference on AIDS, Vancouver, Canada; 1996. Analysis suggested that 1) referrals from SEPs to drug treatment would take more IDUs out of criminal market and 2) reduced rate of infectious disease among IDUs would lead to lower health care expenditures in jails.

⁴⁸ Valente TW, Foreman RK, Junge B, Vlahov D. Satellite Exchange in the Baltimore Needle Exchange Program. *Public Health Reports*, 1998; 113 (Supp.1): 90-96.

⁴⁹ Normand J, Vlahov D, Moses LE, eds. *Preventing HIV Transmission: The Role of Sterile Needles and Bleach*. Washington, DC: National Academy Press; 1995:224-226, 248-250. Paone D, Des Jarlais DC, Gangloff R, Milliken J, Friedman SR. Syringe Exchange: HIV prevention, key findings, and future directions. *International Journal of the Addictions*. 1995;30:1647-1683. Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. *JAMA*. 1994;271:115-120. The seven reports are: National Commission on Acquired Immune Deficiency Syndrome. *The Twin Epidemics of Substance Use and HIV*, Washington, DC: National Commission on Acquired Immune Deficiency Syndrome; 1991. U.S. General Accounting Office. *Needle Exchange Programs: Research Suggests Promise as an AIDS Prevention Strategy*, Washington, DC: U.S. General Accounting Office; 1993. Lurie P, Reingold A. *The Public Health Impact of Needle Exchange Programs in the United States and Abroad (prepared for the Centers for Disease Control and Prevention)*. Berkeley, CA: University of California, School of Public Health, and San Francisco, CA: University of California, Institute for Health Policy Studies; 1993. Drug Policy Foundation, comp. *The Clinton Administration's Internal Reviews of Research on Needle Exchange Programs: Previously Unreleased Documents Plus Background Material*. Washington, DC: Drug Policy Foundation; 1993. Office of Technology Assessment. *The Effectiveness of AIDS Prevention Efforts*. Washington, DC: Office of Technology Assessment; 1995. National Research Council and Institute of Medicine. *Proceedings, Workshop on Needle Exchange and Bleach Distribution Programs*. Washington, DC: National Academy Press; 1994.

⁵⁰ Watters JK, Estilo MJ, Clark GL, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. *JAMA*. 1994;271:118. From 1987 to 1992, the mean age of IDUs increased from 36 to 42.

⁵¹ Heimer R, Lopes M. Needle exchange in New Haven reduces HIV risks, promotes entry into drug treatment, and does not create new drug injectors. *JAMA*. 1994;271:1825-1826. Letter. Kaplan EH, Khoshnood K, Heimer R. Client shift or needle exchange: what caused the HIV prevalence drop in needles returned to New Haven's needle exchange

program. *American Journal of Public Health*. 1994;84:1991-1994. Heimer R, Kaplan EH, O'Keefe E, Khoshnood K, Altice F. Three years of needle exchange in New Haven: what have we learned? *Journal of AIDS and Public Policy*. 1994;9:59-74. Studies found no increase in the rate of enrollment of juveniles or IDUs with less than one year of injecting.

⁵² Buning EC. Effects of Amsterdam needle and syringe exchange. *International Journal of the Addictions*. 1991;26:1303-1311.

⁵³ Paone D, Des Jarlais DC, Clark J, Murillo S, Shi Q. Presentation at College for Problems of Drug Dependence Conference, sponsored by National Institute on Drug Abuse, San Juan, Puerto Rico, 1996.

⁵⁴ Heimer R, Lopes M. Needle exchange in New Haven reduces HIV risks, promotes entry into drug treatment, and does not create new drug injectors. *JAMA*. 1994;271:1825-1826. Letter.

⁵⁵ Heimer R, Kaplan EH, O'Keefe E, Khoshnood K, Altice F. Three years of needle exchange in New Haven: what have we learned? *AIDS and Public Policy Journal*. 1994;9:59-74.

⁵⁶ Paone D, Clark J, Shi Q, Purchase D, Des Jarlais DC. Syringe exchange in the United States, 1996: A national profile. *American Journal of Public Health*, 1999;89(1):43-6.

⁵⁷ Hagan H, Des Jarlais DC, Purchase D, Friedman SR, Reid T, Bell TA. An interview study of participants in the Tacoma, Washington, syringe exchange. *Addiction*. 1993;88:1694-1695.

⁵⁸ Heimer R, Eicher A, Eno R, et al. Needle exchange programs as a conduit to drug treatment: the New Haven experience. Paper presented at the 11th International Conference on AIDS, Vancouver, Canada, 1996. Heimer R, Lopes M. Needle exchange in New Haven reduces HIV risks, promotes entry into drug treatment, and does not create new drug injectors. *JAMA*. 1994;271:1825-1826. Letter.

⁵⁹ Wolk J, Wodak A, Guinan J, Macaskill P, Simpson JM. The effect of a needle and syringe exchange on a methadone maintenance unit. *British Journal of Addictions*. 1990;85:1445-1450.

⁶⁰ Brooner R, Kidorf M, King V, Beilenson P, Svikis D, Vlahov D. Drug Abuse Treatment Success Among Needle Exchange Participants. *Public Health Reports*, 1998; 113 (Supp.1): 129-139.

⁶¹ Paone D, Des Jarlais DC, Clark J, Shi Q, Krim M, Purchase D. Update: syringe-exchange programs—United States, 1996. *Morbidity and Mortality Weekly Report*. 1997;46:565-568.

⁶² Evidence-Based Findings for the Efficacy of Syringe Exchange Programs. Report, U.S. Department of Health and Human Services. March 17, 2000.

⁶³ Vlahov D. Deregulation of the sale and possession of syringes for HIV prevention among injection drug users. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*. 1995;10:71-72; Editorial.

⁶⁴ Nelson KE, Vlahov D, Cohn S, Lindsay A, Solomon L, Anthony JC. Human immunodeficiency virus infection in diabetic intravenous drug users. *JAMA*. 1991;266:2259-2261. Unlike other IDUs diabetics are trained not to aspirate and different injection practices may account for differential infection rates. See e.g., Gershon RRM. Infection Control Basis for Recommending One-Time Use of Sterile Syringes and Aseptic Procedures for Injection Drug Users. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S20-S24.

⁶⁵ Vlahov D. Deregulation of the sale and possession of syringes for HIV prevention among injection drug users. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1995;10:71; Editorial. Groseclose SL, Weinstein B, Jones TS, Valleroy LA, Kassler WJ. Impact of increased legal access to needles and syringes on practices of injecting-drug users and police officers—Connecticut, 1992-1993. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*. 1995;10:82-96.

⁶⁶ Vlahov D. Deregulation of the sale and possession of syringes for HIV prevention among injection drug users. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*. 1995;10:71-72; Editorial. Valleroy L, Weinstein B, Jones TS, Groseclose SL, Rolfs RT, Kassler WJ. Impact of increased legal access to needles and syringes on community pharmacies: needle and syringe sales—Connecticut, 1992–1993. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*. 1995;10:73-81.

⁶⁷ Lurie P, Reingold A. *The Public Health Impact of Needle Exchange Programs in the United States and Abroad (prepared for the Centers for Disease Control and Prevention)*. Berkeley, CA: University of California, School of Public Health, and San Francisco, CA: University of California, Institute for Health Policy Studies; 1993:68. Ganz A, Byrne C, Jackson P. Role of community pharmacies in prevention of AIDS among injecting drug misusers: findings of a survey in England and Wales. *British Medical Journal*. 1989;299: 1076-1079. Bless R, et al. *Urban Policies in Europe* 1993. Amsterdam: Amsterdam Bureau of Social Research and Statistics; 1993.

⁶⁸ Lurie P, Jones TS, Foley J. A Sterile Syringe for Every Drug User Injection: How Many Injections Take Place Annually, and How Might Pharmacists Contribute to Syringe Distribution? *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998: 18 (Supp.1):S45-S51. For more information on IDU pharmacy packs, contact HIT (Political Palace; 9 Slater St.; GB-Liverpool, L14BW; United Kingdom).

⁶⁹ Case, P., et al. Access to Sterile Syringes in Maine; Pharmacy Practice After the 1993 Repeal of the Syringe Prescription Law. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998: 18 (Supp.1):S94-S101; Centers for Disease Control and Prevention/Academy for Educational Development. IDU/HIV Prevention Fact Sheet: Pharmacy Sales of Sterile Syringes. June 2000; Gleghorn AA, Gee G, Vlahov D. Pharmacists' Attitudes About Pharmacy Sale of Needles/Syringes and Needle Exchange Programs in a City Without Needle/Syringe Prescription Laws. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998: 18 (Supp.1):S89-S93; Jones TS, Taussig J. Should Pharmacies Sell Sterile Syringes to Injection Drug Users? *Journal of the American Pharmaceutical Association*. Vol. 39, No. 1. January/February 1999; Kaiser Daily HIV/AIDS Report. Syringe Access: Pharmacy-Based Sales Part of Broad-Based HIV Prevention Strategy. December 10, 1999; Paulson, A. "Syringe Access: Pharmacy-Based Sales Part of Broad-Based HIV Prevention Strategy." Kaiser Daily Report. December 1999; Singer M, Baer HA, Scott G, Horowitz C, Weinstein B. Pharmacy Access to Syringes Among Injecting Drug Users: Follow-up Findings from Hartford, Connecticut. *Public Health Reports*, 1998; 113 (Supp.1): 81-89. U.S. Conference of Mayors HIV/AIDS Program. The Role of Pharmacies in Preventing HIV Among Injection Drug Users. [AIDS Information Exchange](#). December 1999. Weinstein B, et al. Peer Education of Pharmacists and Supplying Pharmacies With IDU Packets to Increase Injection Drug Users' Access to Sterile Syringes in Connecticut [Letter to the Editor]. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998: 18 (Supp.1):S146-S147.

⁷⁰ Burris S, Lurie P, Abrahamson D, Rich J. Physician Prescribing of Sterile Injection Equipment to Prevent HIV Infection: Time for Action. *Annals of Internal Medicine*. 2000:133218-226.

⁷¹ These include: Amsterdam, Basel, Berlin, Bern, Bologna, Bremen, Copenhagen, Dortmund, Frankfurt, Luxembourg, Nuremberg, Rotterdam, Sydney, Zurich, and some smaller cities. Lurie P, Reingold A. *The Public Health Impact of Needle Exchange Programs in the United States and Abroad (prepared for the Centers for Disease Control and Prevention)*. Berkeley, CA: University of California, School of Public Health, and San Francisco, CA: University of California, Institute for Health Policy Studies; 1993:66,71. Bless R, et al. *Urban Policies in Europe* 1993. Amsterdam: Amsterdam Bureau of Social Research and Statistics; 1993. Syringe exchanges by automat. *International Journal on Drug Policy*. 1989;1:6.

⁷² Obadia Y, Feroni I, Perrin V, Vlahov D, Moatti J-P. Syringe Vending Machines for Injection Drug Users: An Experiment in Marseille, France. *American Journal of Public Health* 1999;89(12):1852-1854.

⁷³ Des Jarlais DC. "Single-Use" Needles and Syringes for the Prevention of HIV Infection Among Injection Drug Users. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S52-S56. Kaplan EH. Would Difficult-to-Reuse Needles Reduce the Spread of HIV? Center for Interdisciplinary Research on AIDS *Policy Updates*. Volume 1(4). November 1, 1998. Single-use syringes are misnamed, as all current designs to prevent reuse can be defeated. Single-use syringes may reduce the probability of *a particular* needle becoming infected, but if they are introduced via a one-for-one exchange for regular syringes, such that the total number of syringes and injections remains the same, then they actually *increase* the probability of the reusable syringes available at any given time becoming infected. Mathematical models demonstrate that in order for the number of needles that are currently infectious to remain the same, any reduction in the number of regular syringes consumed per unit time must be met by an increase in the rate of difficult to reuse syringes introduced that is larger by at least 40%. (To offset the impact of removing 1000 syringes from circulation, 1400 more expensive difficult to reuse syringes must be introduced.)

⁷⁴ Kaplan EH. Would Difficult-to-Reuse Needles Reduce the Spread of HIV? Center for Interdisciplinary Research on AIDS *Policy Updates*. Volume 1(4).

⁷⁵ Centers for Disease Control and Prevention/Academy for Educational Development. IDU/HIV Prevention Fact Sheet: Syringe Disposal. June 2000.

-
- ⁷⁶ Macalino GE, et al. Community Based Programs for Safe Disposal of Used Needles and Syringes. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S111-S119.
- ⁷⁷ Normand J, Vlahov D, Moses LE, eds. *Preventing HIV Transmission: The Role of Sterile Needles and Bleach*. Washington, DC: National Academy Press; 1995:237. Oliver KJ, Friedman SR, Maynard H, Magnuson L, Des Jarlais DC. Impact of a needle exchange program on potentially infectious syringes in public places. *Journal of Acquired Immune Deficiency Syndromes*. 1992;5:380.
- ⁷⁸ Lurie P, Reingold A. *The Public Health Impact of Needle Exchange Programs in the United States and Abroad (prepared for the Centers for Disease Control and Prevention)*. Berkeley, CA: University of California, School of Public Health, and San Francisco, CA: University of California, Institute for Health Policy Studies; 1993:388.
- ⁷⁹ Doherty MC, Garfein RS, Vlahov D, et al. Discarded needles do not increase soon after the opening of a needle exchange program. *American Journal of Epidemiology*. 1997;145:730-737.
- ⁸⁰ Broadhead RS, Van Hulst Y, Heckathorn DD. The Impact of a Needle Exchange's Closure. *Public Health Reports* 1999, Vol. 114:439-447.
- ⁸¹ Riley E, Vlahov D, Beilenson P, Smith L, Doherty M, Koenig M, Jones TS. Operation Red Box: a pilot project of needle and syringe drop boxes for injection drug users in East Baltimore. Presented by Elise Riley at the 8th International Conference on the Reduction of Drug-Related Harm, March 27, 1997.
- ⁸² Reily E, Beilenson P, Vlahov D, Smith L, Koenig M, Jones TS, Doherty M. Operation Red Box: A Pilot Project of Needle and Syringe Drop Boxes for Injection Drug Users in East Baltimore. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S120-S125.
- ⁸³ Macalino GE, et al. Community Based Programs for Safe Disposal of Used Needles and Syringes. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S111-S119.
- ⁸⁴ Department of Health and Human Services Appropriations Act, 1998 (Pub. L. 105-78, Title II, Nov. 13, 1997, 111 Stat. 1477.)

⁸⁵ Department of Health and Human Services. Press Release: Research Shows Needle Exchange Programs Reduce HIV Infections Without Increasing Drug Use. April 20, 1998.

⁸⁶ Secretary of Health Donna E. Shalala, quoted in Department of Health and Human Services. Fact Sheet: Needle Exchange Programs: Part of a comprehensive HIV prevention strategy. April 20, 1998.

⁸⁷ Gostin LO. The Legal Environment Impeding Access to Sterile Syringes and Needles: The Conflict Between Law Enforcement and Public Health. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S60-S70; Gostin LO, Lazzarini Z, Jones TS, Flaherty K. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users: a national survey on the regulation of syringes and needles. *JAMA*. 1997;277:53-62. The five states are: California, Delaware, Illinois, Massachusetts, New Hampshire, and New Jersey. Three states—Connecticut, Massachusetts, and Rhode Island—specifically exempt SEP operators and participants from prescription laws for syringes obtained from the SEP. New York, Connecticut, Maine, and Minnesota (as of 1988) allow over-the-counter sales of up to ten syringes. Rhode Island places no limit on the amount of syringes that may be purchased over the counter. Several localities in, for example, Michigan and Florida, require prescriptions for syringe transactions. Ohio, Oregon, Nevada, Texas, Virginia, and Washington also have some provisions restricting the sale of syringes. Also see Gostin LO, Lazzarini Z. Prevention of HIV/AIDS among injection drug users: the theory and science of public health and criminal justice approaches to disease prevention. *Emory Law Journal*. 1997;46:588-696; Burriss S, Deregulation of Hypodermic Needles and Syringes as a Public Health Measure: A Report on Emerging Policy and Law in the United States. Prepared by the AIDS Coordinating Committee of the American Bar Association, December, 2000.

⁸⁸ Burriss S, Deregulation of Hypodermic Needles and Syringes as a Public Health Measure: A Report on Emerging Policy and Law in the United States. Prepared by the AIDS Coordinating Committee of the American Bar Association, December, 2000. Gostin LO. The Legal Environment Impeding Access to Sterile Syringes and Needles: The Conflict Between Law Enforcement and Public Health. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S60-S70. Gostin LO, Lazzarini Z, Jones TS, Flaherty K. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users: a national survey on the regulation of syringes and needles. *JAMA*. 1997;277:53-62. Four territories—American Samoa, Guam, Northern Mariana Islands, and Puerto Rico—have no restrictions. All but one state—South Carolina—have paraphernalia statutes or local ordinances—Alaska and Iowa—restricting sale and possession of syringes. Three states—Massachusetts, Ohio and Virginia—have additional laws specifically restricting the sale of syringes. Oregon and Wisconsin specifically exclude syringes from their laws. Three states—Hawaii, Maryland,

Massachusetts, along with Washington, DC, have exceptions for SEP operators and participants. Washington state recognizes such an exception based on case law. New York, Maine, and Minnesota have modified their laws to allow possession of up to ten syringes; Connecticut now permits possession of up to 30.

⁸⁹ Burriss S, Deregulation of Hypodermic Needles and Syringes as a Public Health Measure: A Report on Emerging Policy and Law in the United States. Prepared by the AIDS Coordinating Committee of the American Bar Association, December, 2000. Gostin LO. The Legal Environment Impeding Access to Sterile Syringes and Needles: The Conflict Between Law Enforcement and Public Health. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S60-S70. Bluthenthal, R.N., et al. Drug Paraphernalia and Injection-Related Infections Disease Risk among Drug Injectors. *Journal of Drug Issues*. Vol. 29, No. 1. pp. 1-16. 1999. Rich J, et al. Strict Syringe Laws in Rhode Island Are Associated With High Rates of Reusing Syringes and HIV Risks Among Injection Drug Users [Letter to the Editor]. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S140-S141.

⁹⁰ National Commission on Acquired Immune Deficiency Syndrome. *The Twin Epidemics of Substance Use and HIV*. Washington, DC: National Commission on Acquired Immune Deficiency Syndrome; 1991:2.

⁹¹ Case P, Meehan T, Jones TS. Arrests and Incarceration of Injection Drug Users for Syringe Possession in Massachusetts: Implications for HIV Prevention. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology* 1998; 18 (Supp.1):S71-S75. See also: Rich J, Dokson L, Dickenson BP. The Economic Cost of Strict Syringe Control. *Medicine and Health Rhode Island*. 1998; 81(6):207-208.

⁹² Burriss S, Finucane D, Gallagher H, Grace J. The legal strategies used in operating syringe exchange programs in the United States. *American Journal of Public Health*. 1996;86:1161-1166.

⁹³ Ibid.

⁹⁴ Ibid.

⁹⁵ Des Jarlais DC, Friedman S. Fifteen Years of Research on Preventing HIV Infection among Injection Drug Users: What We Have Learned, What We Have Not Learned,

What We Have Done, What We Have Not Done. *Public Health Reports*, 1998; 113
(Supp.1): 182-187.



EVIDENCE FOR ACTION TECHNICAL PAPERS

**EFFECTIVENESS OF STERILE NEEDLE
AND SYRINGE PROGRAMMING
IN REDUCING HIV/AIDS AMONG
INJECTING DRUG USERS**



WHO Library Cataloguing-in-Publication Data

Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users.

(Evidence for action technical papers)

1.HIV infections - prevention and control. 2.Acquired immunodeficiency syndrome - prevention and control 3.Syringes - supply and distribution 4.Needles - supply and distribution 5.Needle-exchange programs 6.Review literature 7.Evidence-based medicine I.World Health Organization.

ISBN 92 4 159164 1 (NLM classification: WC 503.6)

© World Health Organization 2004

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Marketing and Dissemination, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in Switzerland

EVIDENCE FOR ACTION TECHNICAL PAPERS

**EFFECTIVENESS OF STERILE NEEDLE
AND SYRINGE PROGRAMMING
IN REDUCING HIV/AIDS AMONG
INJECTING DRUG USERS**



ACKNOWLEDGEMENTS

This review was authored by Dr. Alex Wodak and Ms Annie Cooney.

A large international network of researchers and colleagues have made important contributions to the development of this publication. These researchers and colleagues include: Francisco Bastos, Anindya Chatterjee, Nick Crofts, Don Des Jarlias, Kate Dolan, Catherine Hankins, Ed Kaplan, Richard Needle, Swarup Sarkar, Gerry Stimson, Steffanie Strathdee, Don Sutherland, and Owen Westcott.

We also acknowledge the many individuals from many countries around the world who have attempted to fund and encourage research in this area, assist the difficult process of translating research findings into policy, operate services despite funding inadequacy and work with injecting drug users and communities.

Andrew Ball, Monica Beg, Manuela Moeller, Richard Steen and Gundo Weiler from WHO edited the publication, which was developed under the supervision of Isabelle de Zoysa, Director of Prevention, Department of HIV/AIDS, WHO.

WHO acknowledges the generous contribution of the Australian Agency for International Development (AusAID) to the development of this publication.

CONTENTS

Preface	4
1. Introduction	5
1.1. Terms of reference	6
2. Methodology	7
3. Results	9
3.1. The effectiveness of bleach and decontamination strategies	9
3.1.1. Strength of association HIV	9
3.1.2. Replication of findings	9
3.1.3. Specificity of association	9
3.1.4. Temporal sequence	9
3.1.5. Biological plausibility	9
3.1.6. Biological gradient	10
3.1.7. Coherence of the evidence	10
3.1.8. Experimental evidence	10
3.1.9. Reasoning by analogy	10
3.1.10 Cost effectiveness	10
3.1.11 Absence of negative consequences	10
3.1.12 Feasibility of implementation, expansion and coverage	10
3.1.13 Unanticipated benefits	11
3.1.14 Special populations	11
3.2. The effectiveness of needle syringe programmes	11
3.2.1. Strength of association	11
3.2.2. Replication of findings	12
3.2.3. Specificity of association	12
3.2.4. Temporal sequence	12
3.2.5. Biological plausibility	13
3.2.6. Biological gradient	14
3.2.7. Coherence of the evidence	14
3.2.8. Experimental evidence	14
3.2.9. Reasoning by analogy	15
3.2.10 Cost-effectiveness	15
3.2.11 Absence of negative consequences	16
3.2.12 Feasibility of implementation, expansion and coverage	16
3.2.13 Unanticipated benefits	17
3.2.14 Special populations	17
3.3. The effectiveness of the sale of needles and syringes from pharmacies and vending machines in preventing HIV infection among injecting drug user	18
3.3.1. Strength of association	18
3.3.2. Replication of findings	19
3.3.3. Specificity	19
3.3.4. Temporal sequence	19
3.3.5. Biological plausibility	20
3.3.6. Biological gradient	20

3.3.7	Coherence of the evidence	.20
3.3.8	Experimental evidence	.20
3.3.9	Reasoning by analogy	.20
3.3.10	Cost effectiveness	.20
3.3.11	Absence of negative consequences	.21
3.3.12	Feasibility of implementation, expansion and coverage	.21
3.3.13	Unanticipated benefits	.21
3.3.14	Special populations	.21
3.4	Evidence for needle syringe disposal	.22
3.4.1	Summary of papers of disposal of needles and syringes	.22
3.5	Injecting paraphernalia legislation	.22
3.5.1	Strength of association	.22
3.5.2	Replication of results	.22
3.5.3	Specificity	.23
3.5.4	Temporal sequence	.23
3.5.5	Biological plausibility	.24
3.5.6	Biological gradient	.24
3.5.7	Coherence	.24
3.5.8	Experimental evidence	.24
3.5.9	Reasoning by analogy	.24
3.5.10	Cost effectiveness	.24
3.5.11	Absence of negative consequences	.25
3.5.12	Feasibility of implementation, expansion and coverage	.25
3.5.13	Unanticipated benefits	.25
3.5.14	Special populations	.25
4.	Discussion	.26
5.	Conclusions	.28
5.1	There is compelling evidence that increasing the availability and utilization of sterile injecting equipment by IDUs reduces HIV infection substantially	.28
5.2	There is no convincing evidence of any major, unintended negative consequences	.28
5.3	Needle syringe programmes are cost-effective	.28
5.4	Needle syringe programmes have additional and worth while benefits apart from reducing HIV infection among IDUs	.28
5.5	Bleach and other forms of disinfection are not supported by good evidence of effectiveness for reducing HIV infection	.28
5.6	Pharmacies and vending machines increase the availability and probably of the utilization of sterile injecting equipment by IDUs	.29
5.7	Injecting paraphernalia legislation is a barrier to effective HIV control among IDUs	.29
5.8	Needle syringe programmes on their own are not enough to control HIV infection among IDUs	.29
6.	Recommendations	.30

PREFACE

The global environment for a response to HIV has shifted substantially towards a massive scaling up of prevention, treatment and care interventions. In particular, the world made an unprecedented commitment during the United Nations Special Session on HIV/AIDS in 2001 to halting and reversing the epidemic by 2015. In support of this, additional resources to fund an expanded response have become available through the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Countries face the challenge of translating these commitments into practical programmes, including a range of comprehensive interventions to address HIV transmission related to injecting drug use. Although a huge body of scientific literature details the effectiveness of interventions, public health professionals often experience difficulties in accessing and interpreting this knowledge base.

This publication, together with other Evidence for Action technical papers, aims to make the evidence for the effectiveness of selected key interventions in preventing HIV transmission among injecting drug users accessible to a policy-making and programming audience. The interventions reviewed range from providing information and sterile injecting equipment to the impact of drug dependence treatment on HIV prevention. Each publication summarizes the published literature and discusses implications for programming with a particular focus on resource-limited settings.

1. INTRODUCTION

Following an epidemic of hepatitis B and hepatitis C (and HIV as discovered later) among injecting drug users (IDUs) in Edinburgh, Scotland between 1982 and 1984, a pharmacist decided to provide sterile injecting equipment, a decision that was soon overruled by authorities ⁽¹⁾.

After an outbreak of hepatitis B among IDUs in Amsterdam in 1983, an organization of IDUs asked municipal health authorities to provide sterile injection equipment ⁽²⁾. This request was initially rejected but the decision was soon reversed, allowing for the establishment of the first official needle syringe programme in the world. The HIV/AIDS pandemic soon became the rationale for this programme and similar programmes were rapidly established in many other parts of the world. Needle syringe programmes now operate officially in over 40 countries. Evaluation of the effectiveness and safety of these programmes began soon after they were first established and a vast literature was rapidly generated.

Providing access to and encouraging utilization of sterile needles and syringes for IDUs is now generally considered to be a fundamental component of any comprehensive and effective HIV-prevention programme. A wide variety of measures have been developed to improve access to and utilization of sterile injecting equipment, including needle syringe programmes (NSP), strategies for disinfecting needles and syringes where they are reused or shared, pharmacy-based distribution, sale or exchange schemes, vending machines and other distribution programmes, policies and programmes to encourage more appropriate disposal of used needles and syringes and injecting paraphernalia legislation. Much effort has been expended on improving knowledge, changing attitudes and reducing risk behaviour, but unless the means for behaviour change also become more readily available, improved knowledge and attitudes will not result in reduced risk. Likewise, unless efforts to increase access to sterile injecting equipment are buttressed by other efforts to support behaviour change, risk reduction will remain unaffected. Interventions to improve access to sterile injecting equipment have been implemented in many countries throughout the developed world and to a lesser extent in transitional and developing countries. In the absence of an effective and widely deployed vaccine against HIV, measures to improve access to sterile needles and syringes will remain the most effective tool available to reduce the spread of this virus among (and from) IDUs.

This review examines whether sterile needle and syringe programmes have been demonstrated scientifically to reduce the spread of HIV among IDUs. The evidence is evaluated for the first time according to the criteria originally proposed by Bradford Hill ⁽³⁾ to allow a causal relationship to be inferred from observed associations. Several additional criteria, which focus on the feasibility and sustainability of interventions, rather than causality, have been added subsequently by various authors.

The reliability of research conclusions without support from randomized controlled clinical trials in both clinical medicine and public health is often questioned. However, the difficulty of conducting a strictly randomized controlled trial to evaluate a public health intervention such as a NSP should not be underestimated ^(4,5). Potential sources of bias and confounding are impossible to control because of insurmountable ethical and logistical impediments. For example, in countries and states where NSPs are illegal, IDUs who attend these facilities are known to differ substantially in terms of socioeconomic characteristics and drug use patterns (such as frequency of injecting and needle-sharing) compared to other IDUs who do not attend these facilities.

Furthermore, randomization of IDUs in jurisdictions where NSPs are illegal is fraught with virtually overwhelming legal, ethical and logistical obstacles. Where NSPs operate legally, ethical and logistical problems of randomizing IDUs to NSP use or non-use prevail as denial of access (to a control group) is a major insurmountable issue. In the absence of randomization, some other major methodological problems become even more significant, including the accurate measurement of needle-sharing and injection frequency. In addition, evaluation studies have inevitably been conducted at different stages of HIV epidemics with wide variations in seroprevalence and seroincidence. Where seroprevalence is low, an evaluation may fail to detect effective HIV prevention because so few infections occur. Where evaluation is conducted in high seroprevalence settings, studies may fail to detect effective prevention by NSPs because many infections are sexually transmitted.

In addressing these methodological concerns, a report from the United States National Academy of Sciences' Institute of Medicine concluded that to reject NSPs, based on limitations of the design of single studies, ignores both the preponderance and pattern of the evidence and 'is both poor scientific

judgment and bad public health policy' ⁽⁶⁾. The Institute argued 'that the improbability of being able to carry out the definitive study... does not necessarily preclude the possibility of making confident scientific judgments' and (citing the words of the biostatistician A. Bradford Hill) that 'incomplete' scientific evidence 'does not confer upon us a freedom to ignore the knowledge we already have, or to postpone the action that it appears to demand'. Bradford Hill argued that if certain criteria are met in a number of observational studies evaluating an association, then there is an increased probability that a statistical association is causal.

The criteria proposed by Bradford Hill to infer causality are: strength of association, replication of findings (or consistency), specificity of association, temporal sequence, biological plausibility of the association, biological gradient (or a dose-response relationship), coherence with established facts or other knowledge, experimental evidence (if available) and argument by analogy⁽⁹⁾. Although originally proposed for observational studies, in recent years these criteria have increasingly been used to assess evidence from studies evaluating interventions. The original criteria and five additional criteria, (unanticipated benefits, cost-effectiveness, absence of negative consequences, special populations and feasibility of implementation and coverage) will be applied to all of the terms of reference of this project (see below), although the literature for some interventions is not nearly as extensive as that for evaluating NSPs.

1.1 Terms of reference

The general brief for this report was to evaluate the evidence on the effectiveness of sterile needle and syringe programming (including other injecting paraphernalia) for HIV prevention among IDUs in different settings and contexts, and to recommend how the evidence can guide public health policy-makers in programming for HIV prevention among IDUs. The report was to include all of the following sub-categories:

- ▶ needle and syringe decontamination strategies;
- ▶ needle and syringe exchange;
- ▶ pharmacy, vending and other distribution programmes;
- ▶ needle and syringe disposal; and
- ▶ injecting paraphernalia legislation.

In addressing the key section of the paper, evidence on effectiveness, reference should be made to crucial studies that examine the effectiveness and cost-effectiveness of specific interventions. For each key study, descriptions should be provided of the study, methodology, sampling, outcomes, study limitations, interpretation and how easily findings can be generalized, with a comment on standard of proof. Less rigorous studies may be referred to in order to illustrate certain points not covered in other studies or to raise issues for further investigation. Recommendations should be made for further studies if necessary. Finally, every effort should be made to ensure coverage of the international literature, including grey literature, by including (bi-/multi-lingual) co-authors who are able to access non-English language literature and can access grey literature from different global regions.

2. METHODOLOGY

A search of the published scientific literature was carried out using Medline data bases and International Pharmaceutical Abstracts, supplemented by online bibliographies such as those produced by the Drug Policy Alliance^(7,8) and the United States Department of Health and Human Services⁽⁹⁾. The search for NSP literature exploded the keywords needle and syringe exchange, HIV infections and substance abuse, intravenous. Literature on bleach and decontamination was identified by exploding the keywords disinfection, HIV infections and acquired immunodeficiency syndrome for the period 1989–2002. The result was then combined with each of the keywords substance abuse (intravenous), syringes and needles. Separate searches were performed for syringe disposal, pharmacy and vending distribution and legislation by exploding and combining the keywords needles, syringes, pharmacy, pharmacists, vending machines, legislation and substance abuse (intravenous). Several comprehensive reviews on the effectiveness of needle and syringe exchange⁽⁶⁻¹⁰⁾ and on bleach and decontamination strategies^(6,11) were also drawn on extensively. Conference abstracts were reviewed, and searches of the Internet were conducted, especially for the first, third, fourth and fifth terms of reference, but resources were not available to permit hand searching of other grey literature.

The Bradford Hill guidelines or causal criteria were identified as an appropriate framework to evaluate the literature on each of the five topics^(3,12) and further reference was made to Spitzer for their definition and application⁽¹³⁾. Five additional criteria (cost-effectiveness, absence of negative consequences, unanticipated benefits, feasibility of implementation and coverage, and special populations) were also applied in view of their applicability to public health interventions.

The null hypothesis used for this study was that measures to increase the availability and utilization of sterile injecting equipment, disinfection or bleach decontamination of injecting equipment do not reduce HIV risk behaviour, HIV seroprevalence or HIV seroincidence of IDUs.

The criteria were categorized as either Bradford Hill causal criteria or additional feasibility and implementation criteria. The criteria were defined as follows:

A. Bradford Hill causal criteria

Strength of association. The strength of a supposed association between an exposure factor and an outcome is gauged by the appropriate statistic used to measure the protective effect of an intervention. The preferred statistic, where available, is relative risk (RR) or odds ratio (OR) with associated confidence intervals.

Replication of findings. Also referred to as “consistency,” this criterion examines whether different studies conducted in different locations by different investigators have reported similar findings.

Specificity of association. Specificity is said to be present when the alleged exposure factor (or intervention) is exclusive to the outcome and when the outcome has no other known cause or associated risk factors. For example, have NSPs had the unique effect of reducing HIV incidence, or have they had multiple other effects? And has a reduced seroincidence only occurred in locations where NSPs have been introduced?

Temporal sequence. For a cause-and-effect relationship to be supported, was the introduction of an intervention followed by a reduction in the outcome factor? Did the introduction of NSPs precede a reduction in needle-sharing, other risk behaviours or HIV incidence? Conversely, in locations where NSPs were closed, did risk behaviour and HIV incidence increase subsequently?

Biological plausibility. This criterion refers to the presence or absence of a likely biological mechanism linking the risk exposure or intervention to the observed findings.

Biological gradient. Evidence that increasing exposure to an intervention or risk factor results in a commensurate positive or negative change in an outcome is indicative of a biological gradient.

Experimental evidence. This criterion often provides the strongest support for causation and examines whether preventive action, in this case increased availability and utilization of sterile injecting equipment, actually reduces needle-sharing, which in turn reduces HIV incidence and/or prevalence.

Reasoning by analogy. Causality is supported by analogy if there are similar associations or causal relationships in other clinical or epidemiological areas of relevance. This may involve 'apposite' studies where, say, NSP use leads to lower HCV or HBV incidence compared to non-NSP use.

Coherence. When the evidence from different disciplines and different sources "hangs well together," this criterion is considered to be fulfilled. For example, lack of supportive laboratory findings would count against coherence. Are there documented examples of HIV incidence declining without NSPs? Does the apparently lower impact of NSPs on HCV incidence damage the evidence for effective HIV prevention?

Special populations. How successful are NSPs in reaching special populations that have been identified as particularly at risk (such as young IDUs) or of considerable public health significance (such as 'bridge populations' like homosexual male IDUs or commercial sex workers who also inject drugs)?

B. Additional feasibility and implementation criteria

Cost effectiveness. Although estimated in a number of different ways, authorities pay increasing attention these days to the magnitude of benefit achieved from allocation of scarce public resources. Is the introduction of NSPs and other interventions cost-effective in all parts of the world and at different stages of an HIV epidemic?

Absence of negative consequences. Consideration of possible inadvertent adverse consequences is an important part of evaluating clinical and public health interventions. The presence of unintended negative consequences has a major impact on adoption or expansion of interventions. Fear that increased availability of sterile needle syringe programmes might exacerbate illicit drug use has been a major factor delaying adoption and expansion of these programmes.

Feasibility of implementation, expansion and coverage. Is it feasible to implement NSPs in diverse settings, including resource-poor settings, and to expand these to a scale commensurate with public health need?

Unanticipated benefits. Does the introduction of NSPs lead to other unintended and welcome benefits (such as increased referral to drug treatment)?

3. RESULTS

3.1 The effectiveness of bleach and decontamination strategies

3.1.1 Strength of association HIV:

Three field studies (resulting in four reports) assessing the effect of bleach as a disinfectant for injecting equipment on HIV seroprevalence among IDUs⁽¹⁴⁻¹⁷⁾ (Table 1) concluded that disinfection of needles with bleach appeared to offer no protection, or at best little protection, against HIV infection. The study populations were small and the measures of association had wide confidence intervals. Moreover, two studies assessed the effect of bleach on HCV prevalence^(18, 19) and neither found a significant protective effect of bleach on HCV seroconversion. At best, one of the studies⁽¹⁸⁾ suggests a small (and probably insignificant) reduction of HCV infection.

There is insufficient evidence to consider that the criterion of 'strength of association' has been fulfilled.

3.1.2 Replication of findings

All three field studies that were identified⁽¹⁴⁻¹⁷⁾ concluded that the use of bleach did not offer adequate protection against HIV infection. (The laboratory evidence, in contrast, suggests disinfection with bleach can, under certain conditions, provide protection against HIV).

There is insufficient evidence to consider that the criterion of 'replication of findings' has been fulfilled.

3.1.3 Specificity of association

The cleaning of needles and syringes does not have a unique impact on reducing HIV infection among IDU because this intervention might reduce infection with all other types of micro-organisms. Numerous factors affect HIV transmission among IDUs and cleaning of injection equipment takes place in many different ways: for example, it has been shown that sharing of paraphernalia other than needles may modify infection rates⁽²⁰⁻²¹⁾, and adherence to cleaning protocols is often poor^(22, 23).

There is insufficient evidence to consider that the criterion of 'specificity of association' has been fulfilled.

3.1.4 Temporal sequence

As insufficient evidence was found to support strength of association; it is not surprising that no relevant literature on temporal sequence was identified.

There is insufficient evidence to consider that the criterion of 'temporal sequence' has been fulfilled.

3.1.5 Biological plausibility

HIV detected in used syringes, and remains viable (i.e. can infect subsequent persons)

The link between HIV infection and subsequent development of AIDS has been conclusively demonstrated. It has also been shown that HIV-1 is present in blood contaminated needles and syringes (particularly if visibly contaminated) from IDUs^(21, 24-26). Furthermore, HIV remains viable at room temperature for up to four weeks⁽²⁷⁾. It is well accepted that HIV can be transmitted by injection of infected blood⁽²⁸⁾. Sharing of syringes and needles is also a common behaviour: in an Australian study of NSPs, 31% of respondents were found to have shared a syringe in the previous month⁽²⁹⁾. A similar proportion of IDUs (35%) in New Haven, United States of America admitted to sharing needles before an NSP was introduced⁽³⁰⁾. Higher proportions have been reported among IDUs in prisons^(31, 32). It has also been shown that those IDUs who share needles have higher rates of HIV antibodies⁽³³⁾.

Bleach (hypochlorite) is an effective disinfectant

The efficacy of bleach as a disinfectant for inactivating HIV has been shown in numerous laboratory studies⁽³⁴⁻⁵⁰⁾. These studies, summarized in Table 2, may not all be directly comparable, having used different simulated environments, virus and/or culture medium types, viral loads and activation measures. However, there is general agreement that bleach can be effective in inactivating HIV. Higher concentrations of bleach, although not always necessary, are more effective. Contact time with bleach and the presence of other matter, such as clotted blood in syringes, are also important factors influencing efficacy.

There is sufficient evidence to consider that the criterion of 'biological plausibility' has been fulfilled.

3.1.6 Biological gradient

A biological gradient for the efficacy of bleach in inactivating HIV has been shown in laboratory studies only. However, no biological gradient has been demonstrated in field studies.

There is insufficient evidence to consider that the criterion of 'biological gradient' has been fulfilled.

3.1.7 Coherence of the evidence

The evidence for biological plausibility (see above) is a very strong foundation for this criterion. However, the lack of evidence in field studies is a significant weakness. Several factors may account for the lower efficacy of bleach observed in the field compared to the laboratory:

a) Other paraphernalia: shared needles and syringes is not the only source of potentially infectious material. Sharing of injection paraphernalia (e.g. water, spoons, filters, tourniquets and swabs) is common and may influence infection rates ^(20, 21).

b) Poor cleaning techniques: adherence to cleaning protocols is often inadequate even when cleaning guidelines have been disseminated widely ^(22, 23).

There is insufficient evidence to consider that the criterion of 'coherence of the evidence' has been fulfilled.

3.1.8 Experimental evidence

No relevant literature was identified.

There is insufficient evidence to consider that the criterion of 'experimental evidence' has been fulfilled.

3.1.9 Reasoning by analogy

Cleaning and sterilization of equipment for multiple use by multiple users: cleaning and sterilizing of equipment for use during surgical procedures is safe and well accepted. However, in surgical settings there are clearly defined practices and numerous safeguards to ensure adequate compliance. On occasions when infection control practices have not been followed infection has been a risk for subsequent patients.

Cleaning of equipment by lay persons outside healthcare settings: such as the disinfection of contact lenses.

There is sufficient evidence to consider that the criterion of 'reasoning by analogy' has been fulfilled.

3.1.10 Cost effectiveness

No relevant literature was identified.

There is insufficient evidence to consider that the criterion of 'cost effectiveness' has been fulfilled.

3.1.11 Absence of negative consequences

Although high concentrations of bleach reduced culture target cell viability and p24 antigen production in a laboratory study ⁽⁵¹⁾, lower concentrations did not reduce target cell viability and appeared to permit HIV-1 infection and replication in cell cultures. These lower concentrations would be similar to those left in syringes after cleaning, and may provide a false sense of security regarding the risk of HIV infection for drug injectors.

Accidental injection of bleach remaining in needles and syringes is believed to be non-toxic. External contact produces only minor local irritation. Eye exposure requires copious irrigation. Although massive ingestion can cause abdominal distress, caustic injury and hyperchloremic acidosis ⁽⁵²⁾, IDUs would not normally be exposed to such accidental ingestion.

There is sufficient evidence to consider that the criterion of 'absence of negative consequences' has been fulfilled.

3.1.12 Feasibility of implementation, expansion and coverage

Several studies have shown that with proper education, IDUs can follow protocols for use of bleach ^(23, 53-55).

There is sufficient evidence to consider that the criterion of 'feasibility of implementation, expansion and coverage' has been fulfilled.

3.1.13 Unanticipated benefits

No relevant literature was identified.

There is insufficient evidence to consider that the criterion of 'unanticipated benefits' has been fulfilled.

3.1.14 Special populations

Correctional inmates: Drug injection and HIV infection are both common in jails and prisons^(56, 57). HIV has been shown to be transmitted in prison populations^(32, 58). Despite the official adoption of policies to make bleach available to inmates, disinfectant availability for inmates may be poor⁽⁵⁷⁾. Few other HIV-prevention measures are available to inmates (including NSPs).

There is sufficient evidence to consider that the criterion of 'special populations' has been fulfilled.

3.2 The effectiveness of needle syringe programmes

3.2.1 Strength of association

There were 48 studies dating from 1989 to 2002 that were identified with NSP implementation as an intervention and HIV seroconversion, HIV seroprevalence or HIV risk behaviours among IDUs examined as outcome variables. Some studies assessed multiple outcomes. Out of 11 studies that evaluated HIV seroconversion or seropositivity as outcomes 6 found that NSP use was protective⁽⁵⁹⁻⁶⁴⁾; outcomes in 3 studies were negatively associated with NSP use^(65, 66) and 2 studies showed no effect^(67, 68) (Tables 3a-c).

HIV risk behaviour outcomes were examined in 33 studies (with some authors reporting on more than one study or outcome). The majority focused on syringe sharing, borrowing, lending or reuse (23 positive^(63, 69-90), 1 negative⁽⁹¹⁾ and 5 indeterminate⁽⁹²⁻⁹⁵⁾), while 6 studies examined diverse outcomes including 'injection frequency' (1 positive)⁽⁷³⁾, 'proportion of syringes exchanged' (1 indeterminate)⁽⁹⁷⁾, 'syringe return rate or exchange rate' (3 positive)⁽⁹⁸⁻¹⁰⁰⁾ and 'mortality among NSP users versus non-users' (1 indeterminate)⁽¹⁰¹⁾ (Tables 4a-c).

Overall, these studies provide strong evidence to reject the null hypothesis that attendance at NSP does not confer protection against HIV. However, it

is not possible to exclude the possibility that selection bias may account for the findings in studies comparing IDUs who attend NSPs with those who do not.

Several authors have offered explanations for the counterintuitive finding of some studies that HIV was more prevalent in attenders compared with non-attenders^(67, 102-105). It is well known that NSPs in many settings attract high-risk IDUs, who may therefore have a higher risk of HIV seroconversion before ever attending the programme. This self-selection factor may help explain why cities such as Montreal and Vancouver have observed higher HIV seroconversion rates among NSP attenders compared to non-attenders^(67, 106).

As pointed out by Bastos et al.⁽¹⁰³⁾, evaluations of NSPs typically employ dichotomous categorizations (such as NSP attenders vs non-attenders, frequent vs infrequent attenders). This simplistic approach overlooks the fact that non-attenders may have only used sterile injecting equipment, obtaining these from sources other than NSPs. For example, in an analysis of NSP attenders in Amsterdam, a city where sterile syringes are readily available through pharmacies, irregular NSP attenders, but not non- or frequent attenders, were at highest risk of HIV seroconversion⁽⁹⁶⁾. The authors concluded that irregular NSP attenders had the least exposure to sterile injection equipment and consistent prevention messages, which placed them at highest risk of infection.

Studies examining NSP effectiveness have generally relied on self-reported outcome measures. At least one study compared self-reported risk behaviour with actual programme data and concluded that self-reported risk behaviour data underestimated the protective association of NSP attendance by 18%⁽¹⁰⁷⁾.

Strong as the evidence is for NSP effectiveness, these data are confounded by the presence or absence of alternative availability of sterile injecting equipment through pharmacies. A systematic review⁽¹⁰⁾ identified 42 published studies evaluating NSP effectiveness. The potential confounding of pharmacy access to syringes for these studies⁽⁸⁹⁾ was examined. There were 28 studies that concluded that NSP use had positive effects (reduced risk-behaviour or seroconversion), 12 showed no effectiveness and 2 found negative effects. Of the 14 studies with no effect or negative effects 13 compared clients with non-clients of NSPs. When these 13 studies were examined carefully and an additional 12 studies that compared

users with nonusers of NSPs were considered, all 13 studies with negative or null findings were found to have been conducted in settings where IDUs had legal access to syringes from pharmacies as well as NSPs. By way of contrast, in settings with NSPs but without additional legal access to sterile injecting equipment, there were no negative or null findings. Five studies found positive effects (reduced risk behaviour and/or seroconversion) despite legal access through NSPs and pharmacies. Nevertheless, the relationship between pharmacy access (yes/no) and positive vs negative findings was significant at the $p=0.002$ level. Finally, when studies in settings where legal pharmacy access was available were excluded, 23 of the remaining 24 studies showed positive effects for NSP use (Table 4d.).

There is sufficient evidence to consider that the criterion of 'strength of association' has been fulfilled.

3.2.2 Replication of findings

The above findings strongly support the effectiveness of NSPs as interventions that reduce risk behaviour such as syringe sharing among IDUs and HIV infection. The number of studies showing protective effects far outweighs those with ambiguous or negative effects. The preponderance of positive findings is strengthened by their replication by different authors, at different stages of the HIV epidemic, at different times and geographical locations and with diverse study designs. Furthermore, in instances where NSP use has been statistically associated with increased HIV incidence or higher-risk behaviours, convincing arguments for possible sources of confounding have been presented.

The efficacy of individual NSPs has been reported in at least 10 different countries, including several resource-poor countries. In addition, ecological studies have found strong associations between NSP implementation and lower HIV incidence and prevalence in comparisons involving diverse countries. Most notably, the Return on Investment study⁽⁶⁴⁾ compared HIV prevalence in 103 cities in 24 countries and 16 of these countries had NSPs. HIV seroprevalence was found to have declined by a mean annual 18.6% for 36 cities with NSPs compared to an 8.1% increase in 67 cities without NSPs. Hurley et al.⁽⁶²⁾ compared HIV seroprevalence among IDUs in 52 cities without NSPs and 29 cities with NSPs in Asia, Europe, North America, South America and the South Pacific. On average, seroprevalence increased by 5.9% per year in the 52 cities without NSPs and

decreased by 5.8% per year in the 29 cities with NSPs.

In a recent systematic review, results favouring the efficacy of NSP use were recorded from six studies with longitudinal/prospective designs, four studies with multiple cross-sectional designs, eight observational studies, five ecological studies and several modelling studies⁽¹⁰⁾.

There is sufficient evidence to consider that the criterion of 'replication of findings' has been fulfilled.

3.2.3 Specificity of association

Many studies have demonstrated multiple additional health benefits of NSPs apart from a reduction in HIV infection. These additional benefits include improved entry to primary health care and drug treatment, prevention of other blood-borne viral infections, reduced proximal bacterial infection (e.g. abscess and cellulitis) and reduced distal bacterial infection (e.g. subacute bacterial endocarditis, brain abscess). NSPs offer a 'package' of different services, including education about protection against other blood-borne viruses and sexually acquired HIV, education about cleaning injection equipment and information about drug treatment.

Reductions in risk behaviour and HIV seroconversion could be the result of these other services (such as acquiring clean syringes from pharmacies, using condoms and other safer sexual practices) rather than the needle and syringe exchange, distribution or sale. Although reduced HIV infection is not the only benefit of NSPs, the other benefits are less well documented and do not seem to be as powerful as the impact on HIV infection. There do not appear to be any well documented accounts of declining HIV incidence in a population with high prevalence levels in the absence of NSPs. Although the existence of these additional benefits is attractive from a public health and policy perspective, the effect of NSPs does not appear to be specific to HIV prevention.

There is sufficient evidence to consider that the criterion of 'specificity of association' has not been fulfilled.

3.2.4 Temporal sequence

While NSPs are not the only intervention credited with achieving reduced risk behaviour, in the large majority of settings where an NSP was introduced, a subsequent reduction in risk behaviour, and where measured, HIV seroconversion, has been reported.

As discussed above (3.2.1 Strength of association), in settings where NSP implementation has been followed by increased risk behaviour and/or seroconversion among actual NSP users, the availability of pharmacy access to clean syringes has been shown to confound study results⁽⁶⁹⁾. NSP clients have also been shown at baseline in two studies to be at greater risk of HIV seroconversion than non-clients^(67, 106). It is now thought that the findings in these studies resulted from selection bias and other factors. A unique study in Windham, Connecticut observed "reversal" effects on risk behaviour among IDUs when an NSP was closed down. Significant increases in syringe reuse and syringe-sharing occurred post-closure compared with pre-closure⁽¹⁰⁸⁾. Any resulting change in HIV infection rates was not measured. These observations are consistent with the expected direction of temporal sequence.

A number of studies measured behaviour at multiple points over time and all supported an appropriate temporal sequence. In New York City, 584 IDUs attending NSPs were interviewed on three occasions and HIV drug risk behaviour was found to decline with the continuing use of NSPs⁽¹⁰⁹⁾. Heimer and colleagues, in their evaluation of the New Haven needle exchange, demonstrated that the prevalence of HIV in syringes decreased following an increase in the exchange rate⁽⁶⁰⁾. In a large multiple cross-sectional study of 1304 untreated IDUs in Oakland, the United States, needle- and syringe-sharing declined over time concurrent with an increase in NSP use and distribution of supplies⁽⁶⁵⁾.

Analysis of trends in HIV risk behaviours among over 5000 IDUs in New York City from 1990 to 1997 led to the conclusion that all three injection risk behaviours studied declined significantly (all $p < 0.01$) accompanied by a substantial increase in syringe exchange participation. Seroprevalence among IDUs also declined from about 45% in 1991 to about 30% in 1996⁽¹¹⁰⁾. There do not appear to be any published studies reporting an unexpected temporal sequence.

There is sufficient evidence to consider that the criterion of 'temporal sequence' has been fulfilled.

3.2.5 Biological plausibility

Although the minimum quantity (infectious dose) of HIV necessary to result in infection is not known, viable HIV has been detected in syringes stored at

room temperature for up to four weeks⁽²⁷⁾. Field studies confirm that HIV can be detected in blood contaminated syringes for some weeks. The presence of HIV-1 RNA in needles and syringes indicates the risk associated with sharing of needles and syringes, and presumably also paraphernalia and wash waters by IDUs. A study of needles and syringes obtained from shooting galleries in Miami found that 39% of rinses from 36 needles and syringes containing visible blood had detectable amounts of HIV-1 RNA when quantified and analysed for the presence of antibodies for viral proteins. Antibodies to HIV-1 polypeptides were detected in 94% of the same sample⁽²⁵⁾. Earlier studies found HIV-1 in 3% of blood-contaminated needle and syringes collected from exchange programmes in Sydney⁽²⁶⁾, 10% of needle and syringes from shooting galleries in South Florida⁽²⁴⁾, 50% of used needles and syringes obtained from shooting galleries in Miami^(21, 111, 112) and in New Haven, Connecticut HIV-1 was detected in 67.5% of used "street" syringes and in 91.7% of needles from a shooting gallery⁽⁶⁰⁾.

Further evidence of a biologically plausible link between the use of shared injecting equipment and HIV seroconversion among IDUs is provided by field studies of the biological mechanisms of HIV transmission among IDUs. Practices such as registering, "booting" and "backloading" have been shown to increase the risk of HIV-1 transmission by directly placing blood within the needle and syringe⁽¹¹³⁻¹¹⁵⁾. Chitwood et al. used logistic regression analysis that adjusted for age, gender and race to determine risk factors associated with HIV-1 seroconversion among IDUs. They found that sharing needles and syringes in the year prior to conversion was the primary independent risk factor and it was much stronger than sexual factors⁽¹¹⁶⁾. Other studies have broadened the definition of sharing to shared injection paraphernalia such as cookers, cottons and rinse water and to the practice of "frontloading".

IDUs with a history of diabetes have a significantly lower HIV seroprevalence rate (9.8%) compared with non-diabetic IDUs (24.3%) ($p=0.03$). This result highlighted that increased access to sterile syringes and less use of contaminated equipment were important factors contributing to lower HIV infection rates⁽¹¹⁷⁾.

One study investigated where IDUs obtain needles and syringes from prior to the implementation of NSPs. A cross-sectional study of 741 current IDUs in

Baltimore found that most (85%) participants obtained at least some needles from street needle sellers⁽¹¹⁸⁾. Participants who sold needles reported that it was easy to make used needles appear to be unused, and some admitted to selling used syringes as new. The authors concluded that street needle sellers were an important source of needles for drug injectors, and few injectors were able to determine whether these needles were actually sterile.

There is sufficient evidence to consider that the criterion of 'biological plausibility' has been fulfilled.

3.2.6 Biological gradient

Heimer et al.⁽⁶⁰⁾ found in their syringe tracking study in New Haven that HIV prevalence in syringes decreased as the exchange rate increased. Few studies have investigated a possible relationship between increased implementation of NSPs and reduced HIV infections.

There is insufficient evidence to consider that the criterion of 'biological gradient' has been fulfilled.

3.2.7 Coherence of the evidence

The arguments for coherence of the evidence span several of the Bradford Hill criteria, including biological plausibility, strength of association and replication. To minimize repetition, material that has already been presented will not be repeated in this section.

There is strong evidence that HIV can be transmitted when contaminated injection equipment is shared and such sharing is the strongest risk factor predicting HIV seroconversion among IDUs. Studies of IDU risk behaviour in settings without NSPs show that most engaged in needle-sharing and other unsafe injecting practices. For example, in a cross-sectional survey of active IDUs in Baltimore, Maryland almost 50% of respondents said their usual source for needles and syringes was street dealers and a further 4.1% said their usual source was "friends/neighbours" or "shooting galleries"⁽¹¹⁹⁾. A number of studies investigating the main risk factors for HIV seroconversion found syringe-borrowing to be an independent determinant⁽¹²⁰⁾ while some studies also found that "backloading" and "frontloading" were independent predictors.

Modelling studies have demonstrated that obtaining clean needles from NSPs reduces the circulation

time of each syringe, whether for reuse by the same IDU or for sharing with other IDUs. Evaluations of numerous NSPs in many countries have concluded that IDUs who attend NSPs reduce their HIV risk behaviours compared with those who do not attend, and that the evidence is particularly consistent in areas where non-attenders cannot obtain clean needles from any other sources (such as pharmacies or vending machines). Even in areas where pharmacy and other access to sterile syringes is available, the large majority of studies show that NSP use is significantly associated with a decline in risk behaviour⁽⁶⁹⁾.

Evidence that a reversal to the status quo occurs after an intervention is withdrawn adds further to the coherence of arguments for causality. The positive effects of NSPs were observed when a needle exchange in Windham, Connecticut was closed. A significantly higher percentage of former exchange users reported obtaining syringes from an unreliable source and syringe sharing more than doubled, compared to pre-closure⁽¹⁰⁸⁾. Some large ecological studies show a clear association with NSP implementation and declining HIV incidence and prevalence over time.

Evidence for the efficacy of NSPs in stemming the spread of HIV has been questioned because of an apparent lack of effect for HCV. HIV entered drug injecting populations in New York during the mid-1970s and Australia in the early 1980s while prevention measures such as NSPs only began to be established in the early 1980s. In contrast, hepatitis C first spread among IDUs in the 1960s and therefore had a comparatively higher baseline prevalence by the time NSPs were instigated⁽¹²¹⁾. Hepatitis C is about an order of magnitude more infectious by blood-blood contact than HIV^(121, 122). Despite some reported disparities there is increasing evidence that use of syringe exchanges has led to significant reductions in both hepatitis B and C⁽¹²³⁾.

There is sufficient evidence to consider that the criterion of 'coherence of the evidence' has been fulfilled.

3.2.8 Experimental evidence

An appropriate experiment could theoretically be provided by an RCT whereby IDUs were randomly allocated to an experimental group who would be issued with an adequate supply of sterile syringes at an exchange and a control group who would not be provided with sterile syringes. The experiment

would need to take place in a setting isolated from potential access (by controls) to pharmacy or vending machine syringe acquisition. Other possible confounding factors would need to be measured and controlled for such as rate of incarceration, availability and quality of drug treatment (especially methadone treatment for heroin dependence), utilization of strategies to reduce sexual transmission (such as condoms and treatment of sexually transmitted infections) and overlap with "bridge" populations (men who have sex with men and commercial sex workers). As already discussed, there are strong logistical and ethical arguments against conducting such experiments.

There is insufficient evidence to consider that the criterion of 'experimental evidence' has been fulfilled.

3.2.9 Reasoning by analogy

The provision of sterile injecting equipment to reduce HIV infection among IDUs has many similarities with condom provision to reduce sexual transmission of HIV. These interventions both have high biological plausibility. Condom provision is well accepted to have strong support from empirical evidence of effectiveness⁽¹²⁴⁾. It could be argued that both are implemented less vigorously than would be justified by the evidence of effectiveness, safety and cost-effectiveness. Concern has often been expressed that condom provision might inadvertently increase unsanctioned sexual activity such as reducing the age of initiation, and increasing the frequency of sexual activity, especially among unmarried partners. There is no convincing evidence to support these concerns despite numerous and diligent attempts to detect these or other unintended negative consequences⁽¹²⁴⁾. Drug use and sexual activity are sensitive issues in virtually all countries, especially when these occur among teenagers. Like NSPs, condom provision has considerable benefits apart from reduction of HIV infection, such as reducing the incidence of sexually transmitted infections and unwanted pregnancies. Condom provision and NSPs are both cost-effective interventions.

There is sufficient evidence to consider that the criterion of 'reasoning by analogy' has been fulfilled.

3.2.10 Cost-effectiveness

Many studies have demonstrated that the implementation of NSP is cost-effective and cost-saving. In a retrospective analysis, Lurie & Drucker estimated that the number of HIV infections that could have been prevented in the United States had NSPs been implemented during the early stages of the HIV/AIDS epidemic was between 4394 (with a 15% incidence reduction due to NSPs) and 9666 (with a 33% incidence reduction). The cost to the United States health care system of treating these HIV infections was calculated at between US\$ 244 million and US\$ 538 million respectively⁽¹⁰²⁾.

Furthermore, Lurie et al. also estimated the cost per syringe distributed for five syringe distribution strategies (a NSP, a pharmacy-based NSP, free pharmacy distribution of pharmacy kits, sale of such pharmacy kits to IDUs and sale of syringes in pharmacies)⁽¹²⁵⁾. All five strategies could distribute syringes at relatively low unit cost, with NSPs being the most expensive and syringe sales the cheapest. At an annual seroincidence exceeding 2.1% all strategies were estimated to be cost saving.

Others have used mathematical modelling to estimate the cost per HIV infection averted by NSPs. Holtgrave et al. estimated that 100% coverage of a previously unmet need for sterile syringes for IDUs in the United States would require 954.8 million syringes at a cost of US\$ 423 million. This would prevent 12 350 cases of HIV, with subsequent HIV treatment costing approximately US\$ 1.3 billion⁽¹²⁶⁾. Total societal expenditure of US\$ 277 million was estimated for NSP costs with US\$ 145.8 million for pharmacy-based sales. It was estimated that one third of the cost would comprise out-of-pocket payments by IDUs purchasing syringes from pharmacies. This amounts to a cost saving of US\$ 34 278 per HIV infection averted, well under the estimated lifetime medical costs of treating an HIV infected individual (US\$ 108 469).

Using conservative estimates, it was predicted that the Hamilton NSP in Canada⁽¹²⁷⁾ would prevent 24 cases of HIV infection over five years, thereby providing cost savings of US\$ 1.3 million after the programme expenses were taken into account. This translates into a savings cost ratio of 4:1.

The cost-effectiveness of the Edmonton Streetworks NSP in Canada was estimated at CAD\$ 9500 per HIV infection delayed for one year⁽¹²⁸⁾. The discounted cost per case averted was less than the cost of a case of AIDS.

A variety of HIV prevention strategies was compared for cost-effectiveness in an east coast city of the United States. Cost per HIV infection prevented was lowest for needle exchange and counselling/education (about US\$ 4000)⁽¹²⁹⁾.

The cost per HIV infection averted for a year by an NSP in New York City was estimated to be US\$ 2667. This is far below the estimated cost of lifetime medical treatment for one HIV-infected individual (prior to protease inhibitors)—US\$ 56 000 to US\$ 80 000. Thus, the net cost savings per HIV infection averted for an NSP in New York City could be estimated to be US\$ 53 000 to US\$ 77 000⁽¹³⁰⁾.

Another analysis of New York State-approved NSPs concluded that syringe exchange is a cost-effective and cost-saving strategy for reducing HIV transmission⁽¹³¹⁾ with an estimated 87 HIV infections averted across seven programmes at a total cost of US\$ 1.8 million, resulting in a cost-effectiveness ratio of almost US\$ 20 947 per HIV infection averted.

A cost-effectiveness study of NSPs in Svetlogorsk, Belarus evaluated a comprehensive strategy that included NSPs, safe sex counselling, condom promotion, bleach distribution and referral for STD services. The average cost per HIV infection averted was estimated at only US\$ 68 (estimated range: US\$ 54 to US\$ 100)⁽¹³²⁾. If the cost of the associated mass-media campaign is included, the cost per HIV infection averted rises to a range of US\$ 240 to US\$ 442, still notably cost-effective. This is a very significant study because it confirms that the cost-effectiveness of NSPs as an HIV prevention measure also applies in a resource-poor setting.

A cost-effectiveness study assessed whether prevention interventions targeted at high-risk populations have a greater effect on the number of HIV infections prevented than if they are targeted to low-risk populations. Assuming that the programme reduces risk behaviours by a modest 10%, the study showed that US\$ 1 million in annual prevention spending over five years could prevent about 100 HIV infections in high-risk populations with HIV prevalences of 10-15% (such as IDUs)⁽¹³³⁾. The same study also highlights the fact that there are certain cases where a simple cost-effectiveness analysis does not reflect the value of a programme. For example, some programmes benefit more risk groups than just their audience.

A cost effectiveness analysis applied a simplified Yale Needle Circulation Model to four hypothetical NSPs in four United States cities with differing HIV prevalence and incidence rates. Reductions in HIV

incidence rates varied across cities from 17% to 70% across the four hypothetical settings. Higher reductions were associated with more needles per client-year and greater efficiency was associated with low cost per needle exchanged. The estimated cost savings per HIV infection averted ranged from US\$ 12 000 to US\$ 99 000⁽¹³⁴⁾.

Most cost effectiveness studies have been conducted in developed countries, with far fewer conducted in resource-poor settings.

There is sufficient evidence to consider that the criterion of 'cost effectiveness' has been fulfilled.

3.2.11 Absence of negative consequences

Studies have searched for and found no convincing evidence of the following unintended complications associated with NSPs: greater injection frequency^(69, 73), increased illicit drug use^(135, 136), a rise in syringe-lending to other IDUs^(67, 69), recruitment of new IDUs^(60, 73, 137), social network formation⁽¹³⁸⁾, greater numbers of discarded used needles^(108, 139, 140), less motivation to change, i.e. reduce, drug use⁽¹⁴¹⁾ and increased transition from non-injecting drug use to IDU⁽¹³⁶⁾.

There is sufficient evidence to consider that the criterion of 'absence of negative consequences' has been fulfilled.

3.2.12 Feasibility of implementation, expansion and coverage

The implementation of NSPs has been shown to be successful in a variety of settings. The historical development of NSPs in Germany has been described, concluding that establishing programmes in larger cities was easier than meeting demand in smaller cities and more conservative states. Establishing NSPs in German prisons was considered desirable but only possible as pilot projects on a limited basis⁽¹⁴²⁾. An ecological study of IDUs in seven United States metropolitan areas demonstrated that the IDUs were more likely to have used a reliable source for obtaining their most recent syringe in cities with a NSP (OR=5.3; 95% CI 3.3-8.5)⁽⁸⁴⁾.

NSPs have been successfully established in a few resource-poor settings, such as Hanoi in Viet Nam⁽¹⁴³⁾, Kathmandu in Nepal⁽⁷⁷⁾, and northern Thailand⁽¹⁴⁴⁾. A report on NSPs in northern Thailand mentioned cooperation from government agencies and

nongovernment agencies in addition to the local communities as key factors for successful implementation ⁽¹⁴⁴⁾. The Hanoi NSP gained local acceptance by holding workshops with key community people, including the local police, using outreach services to distribute needles and syringes rather than at established exchange sites, using appropriate methods to collect used injection equipment, and by training and recruitment of ex-user outreach workers ⁽¹⁴³⁾.

Successful implementation has also been achieved in some transitional countries such as Svetlogorsk, Belarus (eastern Europe) ^{(132) (145)} and Sverdlovsk Oblast, Russia ⁽⁶⁸⁾. The latter was achieved through a process of "many months of negotiation and discussion with all relevant agencies" including the Ministry for Internal Affairs, (which is responsible for law enforcement). These processes also encompassed educating officials at seminars at which international research evidence of best practice was presented, a study tour to visit harm reduction programmes in Britain and a series of training workshops for workers at the pilot sites. It was necessary to provide an early evaluation report to satisfy politicians and health-care providers so that the project could continue. A number of international organizations were also involved to encourage policy-makers and health practitioners to implement harm-reduction strategies, and in particular to champion NSPs ⁽⁶⁸⁾.

An evaluation of a Hawaiian NSP showed that the following characteristics were required to achieve sustainable high coverage: broad-based political support; allocation of public funds; progressive expansion and removal of counter-productive aspects; peer-educators; links to other services for drug users, especially drug treatment; and periodic formal evaluation ⁽¹⁴⁶⁾.

It is noteworthy that implementation of NSP in the early stages of an HIV epidemic (when seroprevalence is still low), combined with multiple prevention initiatives including community outreach, has been shown to have maximum impact ⁽¹⁴⁷⁾.

Early and vigorous implementation has been demonstrated in a number of countries. The first NSP was established in Australia in 1986 and within a couple of years, a national network of programmes had been implemented with a throughput of 30 million needles and syringes in 2000 for a population of less than 20 million ⁽⁶⁴⁾. However, in many countries implementation has been delayed and the scale has been inadequate. This is especially true in developing and transitional countries, or countries that

respond to illicit drugs with a predominantly supply control perspective ⁽¹⁰³⁾.

There is sufficient evidence to consider that the criterion of 'feasibility of implementation, expansion and coverage' has been fulfilled.

3.2.13 Unanticipated benefits

A number of studies have demonstrated additional benefits resulting from NSP use, apart from a reduction in injecting risk behaviour and HIV infection. At the New Haven and Seattle exchanges, increased enrolment in drug treatment was reported as well as higher treatment retention rates compared with non-users of NSPs ⁽¹⁴⁸⁻¹⁵⁰⁾. An evaluation study in Baltimore found that NSP attendance was independently associated with entry into drug treatment for HIV-infected IDUs ⁽¹⁵¹⁾. In San Francisco, Bluthenthal ⁽⁶⁶⁾ found that NSP clients attitudes and motivation to change their drug-using patterns was positive, and concluded that NSP is a possible link to drug treatment ⁽¹⁴¹⁾.

Gibson found NSP use to be associated with substantially reduced injecting or cessation of injecting compared to IDUs who had never attended an NSP ⁽¹⁵⁰⁾.

During a pilot NSP conducted in a Swiss women's prison for a year, no injection abscesses were observed and there were no instances of aggressive or threatening behaviour among inmates using syringes ⁽³¹⁾.

There is sufficient evidence to consider that the criterion of 'unanticipated benefits' has been fulfilled.

3.2.14 Special populations

Prisons:

A pilot intervention project was carried out in a Bern prison accommodating up to 110 women, of whom a high proportion injected drugs while imprisoned. Sterile injection equipment was made available from a one-to-one automatic dispenser. Before distribution of injection material, nearly half of the prisoners who injected drugs reported sharing injecting material regularly, whereas sharing virtually ceased during the experiment. A total of 5335 syringes were exchanged during the project (0.2 syringes/day per inmate) ⁽³¹⁾.

Mathematical modelling has been proposed as a useful technique for estimating HIV transmission in

prisons⁽⁶⁷⁾. Using conservative assumptions, where measurement of relevant variables for the model was unavailable, a relatively large number of HIV infections were estimated to occur in prisons through sharing of injection equipment. Importantly, these observations were made even in a country where HIV prevalence among IDUs is low.

By December 2000, 19 prisons in 3 countries had syringe exchange programmes. All evaluations of these programmes have been favourable and without reported unintended negative consequences⁽¹⁵²⁾.

Young IDUs:

Young IDUs have been found to be at higher risk of acquiring HIV. Multivariate analysis in one study showed recent onset injecting to be an independent predictor for seroconversion⁽¹⁵³⁾. A study of IDUs in Rio de Janeiro, Brazil found that younger age was the principal factor associated with high injecting risk behaviour⁽¹⁵⁴⁾. In most countries, young people appear to be under-represented among IDUs attending NSPs. This may be because attendance at an NSP amounts to a relatively public identification as an IDU.

A study which investigated an HIV prevention programme for homeless young adult IDUs in San Francisco, United States found significant differences between IDUs who frequented a secondary NSP intervention site and a comparison group who did not⁽¹⁵⁵⁾. The comparison group were more at risk of sharing syringes (AOR = 3.748; 95% CI, 1.406-9.988) and reusing syringes (AOR = 2.769; 95% CI, 1.120-6.847).

"Bridge" populations

Several studies have observed that women who attend NSPs and engage in sex work typically report greater HIV risk than women non-sex workers attending NSPs. A study comparing sex workers with non-sex workers in five United States cities found that sex workers were significantly more likely to inject more frequently ($P < 0.0005$), to reuse syringes more than twice ($P < 0.005$), to engage in "backloading" syringes ($P < 0.005$) and to obtain syringes from non-NSP sources ($P < 0.05$)⁽¹⁵⁶⁾. Current sex workers in a Vancouver study engaged in heavier drug use, reported a greater variety of injection and non-injection drugs and injected substantially more frequently than both sexually active and non-sexually active women⁽⁶⁷⁾. They also engaged more frequently in risky injection practices, such as renting, buying or borrowing used syringes and using shooting galleries than other women. Extensive HIV infection has occurred among commercial sex work-

ers in some countries before a generalized epidemic, e.g. Thailand^(157, 158).

IDU men who have sex with men constitute another "bridge" population. A Brazilian study that aimed to determine risk factors for HIV-1 among IDUs ($n = 123$) in Rio de Janeiro found that being a male who has had sex with men in the previous five years was a significant independent risk factor for HIV infection. The authors concluded that homosexual/bisexual male drug injectors may have been a "bridge" group through which HIV entered drug-injecting networks in that city⁽¹⁵⁹⁾.

Developing countries

Successful NSP interventions have been set up either as pilot programmes or ongoing services in a number of developing countries, including three remote villages in northern Thailand⁽¹⁴⁴⁾, Hanoi, Viet Nam⁽¹⁴³⁾ and Dhaka and Rajshahi, Bangladesh⁽¹⁶⁰⁾. Evaluation results for these studies were reported above under 'Strength of association' and they were further discussed under 'Feasibility of implementation, expansion and coverage'.

There is sufficient evidence to consider that the criterion of 'special populations' has been fulfilled.

3.3 The effectiveness of the sale of needles and syringes from pharmacies and vending machines in preventing HIV infection among injecting drug users

3.3.1 Strength of association

Nine studies were identified that examined the effect of pharmacy sales and syringe vending machines in reducing a number of risk behaviour outcomes (including less syringe borrowing, sharing and injecting, never borrowing injecting equipment and less syringe re-use) and HIV seroprevalence among IDUs^(117, 119, 161-167) (Table 5).

Access to sterile needles and syringes from community pharmacies and syringe vending machines was shown in all nine studies to be effective in reducing risk behaviour and HIV seroprevalence. Evaluation results were also positive and significant in locations

where there were no syringe exchange programmes available ^(167, 168). In Hong Kong Special Administrative Region (Hong Kong SAR), no prescription is required to purchase syringes at pharmacies and there is a network of methadone clinics that has been well established since the 1970s. Health department reports show that only 2% (12/602) of cases with HIV infection are attributable to IDUs with a history of needle-sharing. HIV prevalence of less than 1% has been reported consistently in a number of community surveys ⁽¹⁶⁸⁾.

Some countries have sought to increase the availability of sterile syringes by installing vending machines that sell or exchange syringes. This strategy can provide 24-hour availability and improve access in locations that are difficult to service. A study in Berlin found that 77% of IDUs used vending machines regularly (> 4 times a week) ⁽¹⁶⁹⁾. In Marseille, France it was reported that 21.3% of IDUs used vending machines as a primary source of syringes ⁽¹⁶⁵⁾. Primary users of vending machines were less likely to be HIV positive (OR 0.5; 95% CI 0.2, 0.9) but this was not significant after adjustment ⁽¹⁶⁵⁾. The introduction of vending machines in an open prison for males in Hamburg, Germany resulted in significant decrease in needle-sharing and no new individuals with HIV infection were identified during the programme ⁽¹⁶⁶⁾.

No indeterminate or negative studies were identified for either pharmacy sales or vending machines.

There is sufficient evidence to consider that the criterion of 'strength of association' has been fulfilled.

3.3.2 Replication of findings

Pharmacy and vending machine access to sterile needle syringes among IDUs has been evaluated in a number of countries including Australia, Canada, France, Germany and the United States, each with different HIV prevalence rates in IDU populations and with different settings. Study setting (legislative environment) influenced the availability and access to sterile needles and syringes with no legal restrictions on the sale and possession of sterile injecting equipment in most settings. In these areas, positive results were consistent.

In a systematic review of studies evaluating cities with low HIV seroprevalence among IDUs (less than 5% over five years) Des Jarlais and colleagues found that one of the common characteristics was legal

pharmacy sale as a source of sterile injecting equipment ⁽¹⁴⁷⁾.

A study carried out in Georgia in 1998 attributed a low HIV infection rate, despite high prevalence of injecting drug use, to the ready availability of syringes in pharmacies and the lack of social stigma associated with injecting drug use ⁽¹⁷⁰⁾.

There is sufficient evidence to consider that the criterion of 'replication of findings' has been fulfilled.

3.3.3 Specificity

Several outcomes (including reduced needle-sharing, borrowing and sharing of drug-injecting equipment) have been identified as a direct result of increased sales of sterile needles and syringes from pharmacies and vending machines.

However, a study in Vancouver by Strathdee et al. highlighted the importance of deregulation of syringe sales in pharmacies in order to increase access to sterile injection equipment and thereby maintain low HIV seroprevalence ⁽⁶⁶⁾. HIV prevalence in Vancouver during 1996 was reported to have increased to 23.2% and this was attributed to a number of factors including IDUs having inadequate access to drug and alcohol treatment, methadone maintenance and counselling services. The authors note that without adequate and appropriate community-wide interventions such as addiction treatment, detoxification and counselling services, stand-alone measures to increase access to sterile injection equipment appear to be a necessary but not a sufficient factor in reducing risk-taking behaviour and maintaining low HIV seroprevalence ⁽⁶⁶⁾. These and other data support the value of the intervention. However, there is inadequate data to conclude that the outcome benefits are specific to HIV.

There is insufficient evidence to consider that the criterion of 'specificity' has been fulfilled.

3.3.4 Temporal sequence

On the basis of available evidence, increased pharmacy sales and availability of vending machines occurred first and changes in risk behaviour followed. A survey of more than 2000 IDUs in London in the United Kingdom between 1990 and 1993 found that HIV prevalence among IDUs declined from 12.8% to 6.9%. This coincided with increased availability of sterile syringes in pharmacies and needle exchange programmes (NEPs) after 1987 ⁽¹⁶³⁾.

A prospective surveillance study performed before and after introducing the legal sale of sterile syringes in pharmacies in Connecticut in the United States (in July 1992) found a significant increase in pharmacy syringe sales⁽¹⁷¹⁾. Over the same period there was a decrease in syringe-sharing in the past 30 days (21%), a decline in obtaining syringes from the streets (14%), and fewer IDUs reporting ever having shared syringes (43% fewer)⁽¹⁶⁴⁾.

Prior to the liberalization of the sale of syringes in France in 1987, syringe sharing was reportedly routine practice among IDU due to the scarcity of syringes. Post-liberalization, the purchase of syringes at pharmacies increased such that over half (52%) of IDUs recruited from the streets in France and 40% undergoing treatment only used syringes they purchased and never shared with others⁽¹⁶¹⁾.

There is sufficient evidence to consider that the criterion of 'temporal sequence' has been fulfilled.

3.3.5 Biological plausibility

The biological basis of reducing HIV infection by increasing access to sterile syringes through pharmacy sales and vending machines has been discussed in section 3.1.5.

There is sufficient evidence to consider that the criterion of 'biological plausibility' has been fulfilled.

3.3.6 Biological gradient

Increasing participation and sales by pharmacies of sterile syringes led to a corresponding decrease in risk behaviour^(162, 164, 172). This is consistent with a biological gradient but unless supported by additional evidence, cannot be considered to constitute sufficient evidence.

There is insufficient evidence to consider that the criterion of 'biological gradient' has been fulfilled.

3.3.7 Coherence of the evidence

As discussed above, the arguments in favour of pharmacy sales and vending machines span several criteria and are impressively consistent. However, the quantity of data is far less impressive than evaluation of NSPs.

There is sufficient evidence to consider that the criterion of 'coherence of the evidence' has been fulfilled.

3.3.8 Experimental evidence

There is no experimental evidence (such as an RCT) to support the efficacy of pharmacy sales and vending machine availability of sterile syringes. As discussed elsewhere, RCT evaluation of pharmacy sales and vending machine availability of sterile syringes is not feasible logistically and is generally considered to be unethical. Many public health interventions have not been evaluated by RCT for similar reasons and have nevertheless been fully accepted as effective and safe.

There is insufficient evidence to consider that the criterion of 'experimental evidence' has been fulfilled.

3.3.9 Reasoning by analogy

In many countries before the HIV/AIDS epidemic, condoms were only available from pharmacies following a specific request from a customer. When the magnitude of potential health, social and economic costs of uncontrolled HIV infection began to be better appreciated, condom availability was increased in many parts of the world. In most developed countries these days, condoms are now readily available from a wide variety of outlets, including pharmacies, supermarkets and vending machines. As with availability of sterile needles and syringes, once the principle that increased utilization of sterile injecting equipment and condoms is accepted and programmes to achieve this are implemented, evaluations of novel methods to further increase utilization are exceedingly difficult to undertake. We were unable to find evidence supporting a decline in sexual risk behaviours in connection with increasing "industrial" supply of condoms.

There is sufficient evidence to consider that the criterion of 'reasoning by analogy' has been fulfilled.

3.3.10 Cost effectiveness

A cost-effectiveness study by Lurie et al.⁽¹²⁵⁾ of five different pharmacy-based syringe distribution strategies (Section 3.2.10) found that the cost per syringe distributed ranged from US\$ 0.15 for syringe sales to US\$ 0.97 for NSP⁽¹²⁵⁾. At an estimated cost of treating an HIV-infected person in a lifetime of US\$ 55 640, it was estimated that if annual HIV seroincidence for IDUs is greater than 2.1% then all strategies will be cost saving to society. The syringe sale option would be cost saving if HIV seroincidence for IDUs is greater than 0.3%.

The costs and cost-effectiveness of a policy of increased availability of sterile syringes that would include NSPs (25%) and pharmacy sale of syringes (75%)⁽¹²⁶⁾ were estimated based on 1996 prices and populations in the United States. The total cost of complete coverage (100%) of providing sterile syringes to IDUs was approximately US\$ 423 million. This was estimated to avert 12 350 new HIV infections in one year with a gross societal cost of over US\$ 1339 million, representing a net saving of over US\$ 916 million. Thus, the economic benefits are substantial and far greater than the costs. Hence, funding would save society long-term costs.

There is sufficient evidence to consider that the criterion of 'cost effectiveness' has been fulfilled.

3.3.11 Absence of negative consequences

Some pharmacists have expressed concern about the possibility of a negative impact of pharmacy sales of sterile syringes on pharmacy business and increased robberies or shoplifting. However, fewer than 20% have experienced these negative effects^(171, 172).

In the United States, barriers to pharmacy sales have been removed without concurrent relaxation of strictly enforced drug paraphernalia laws, which raises concern about a possible increase in arrests and fines of IDUs.

No evidence was identified that increased pharmacy sales or the installation of vending machines have caused non-IDUs to become users.

There is sufficient evidence to consider that the criterion of 'absence of negative consequences' has been fulfilled.

3.3.12 Feasibility of implementation, expansion and coverage

Pharmacy sale of sterile needles and syringes without a medical prescription is permitted in many developed and developing countries.

In New South Wales, Australia⁽¹⁷³⁾ and Connecticut, the United States⁽¹⁷¹⁾ legal access to the sale and possession of sterile needles and syringes was increased with a subsequent significant increase in sales and greater willingness of pharmacists to sell or supply sterile injecting equipment to suspected IDUs. Between 58% and 75% of pharmacists in

locations where sale and possession of syringes is not prohibited said they were willing to sell syringes without a prescription⁽¹⁷¹⁻¹⁷⁶⁾ compared with 16%-23% of pharmacists working in areas where it is illegal to possess drug-injecting equipment^(177, 178). Increased pharmacy sales in the United Kingdom, Connecticut and in New South Wales have also been followed by a corresponding increase in the use of sterile injecting equipment by IDUs⁽¹⁷²⁻¹⁷⁴⁾.

There is sufficient evidence to consider that the criterion of 'feasibility of implementation, expansion and coverage' has been fulfilled.

3.3.13 Unanticipated benefits

From a public health perspective, improved access to sterile needles and syringes from pharmacies and vending machines is likely to reduce other blood borne viral infections such as Hepatitis B and C. However, no papers specifically evaluating pharmacies and vending machines from this perspective were identified.

There is insufficient evidence to consider that the criterion of 'unanticipated benefits' has been fulfilled.

3.3.14 Special populations

Even in locations where it is legal for pharmacies to sell needles and syringes without prescription, pharmacists may still refuse to sell at their discretion⁽¹⁷⁹⁾. Biases have been found in some studies against IDUs who were younger or from racial minorities and these provided barriers to access to sterile injecting equipment⁽¹⁷⁵⁾. Interviews with 108 IDUs from Houston, Texas in 2000 revealed significant differences between IDUs from different ethnic groups with 0% (0/15) of African-Americans, 26% of Anglo-Americans and 35% of Hispanics purchasing syringes from pharmacies⁽¹⁶⁷⁾.

The introduction of vending machines in an open prison for males in Hamburg, Germany resulted in a significant decrease in needle-sharing. No new HIV infections were identified during the programme⁽¹⁶⁶⁾.

In a study in France in 1997, primary users of vending machines were more likely to be younger (<30 years) (AOR 1.3; 95%CI 1.1, 1.8); less likely to have lived in a house they personally owned or rented (AOR 0.7; 95%CI 0.5, 0.9); less likely to have been in drug maintenance treatment (AOR 0.7; 95%CI 0.5, 0.9) and less likely to have shared needles or injection equipment (AOR 0.5; 95%CI 0.4, 0.8)⁽¹⁶⁵⁾.

There is sufficient evidence to consider that the criterion of 'special populations' has been fulfilled.

3.4 Evidence for needle syringe disposal

3.4.1 Summary of papers of disposal of needles and syringes

The few papers published on disposal of used needles and syringes do not allow evaluation of the diverse strategies adopted in various countries according to the Bradford Hill criteria (Table 6). In many countries, NSPs and other outlets for sterile injection equipment are vulnerable to public criticism. Widespread disposal of used injection equipment in public places undermines the political sustainability of sensitive syringe and pharmacy programmes. For example, an NSP was closed in Windham, Connecticut in May 1997 following public controversy in which it was blamed, among other things for discarded syringes. However, post-closure surveys of outdoor drug-use areas found that the closure of the exchange did not in fact reduce the volume of discarded syringes and other drug-injecting debris⁽¹⁰⁸⁾.

The papers identified show that diverse measures have been adopted to improve disposal practices and some have met with approval by a wide variety of groups. There are no published reports thus far that indicate that used injection equipment discarded in a public place has led to infection with a blood-borne virus (personal communication Dr Andrian Reynolds). Criminal penalties for possessing needles and syringes may have the inadvertent effect of deterring IDUs from disposing of used injection equipment responsibly.

There is insufficient evidence to consider that any of the Bradford Hill and additional criteria for needle syringe disposal have been fulfilled.

3.5 Injecting paraphernalia legislation

Before the global HIV/AIDS pandemic was first recognized, a variety of legislative approaches existed for injecting equipment. In some countries, there were no legislative barriers to the sale of sterile injecting equipment. In other countries, legisla-

tion specifically prohibited provision of used injecting equipment to IDUs. The United States had among the most severe restrictions with some states prohibiting possession of injecting equipment and others requiring a doctor's prescription for purchase of sterile injecting equipment. Virtually all publications regarding injecting paraphernalia legislation originate from just one country (the United States) and may not be generalizable to other countries. However, for the purposes of this review it has been assumed that these findings are more widely generalizable. The null hypothesis considered in this section is that injection paraphernalia legislation that restricts sterile needle and syringe availability does not reduce HIV infection.

3.5.1 Strength of association

There is a significant positive correlation between legal restrictions on syringe access and HIV seroincidence and seroprevalence^(61, 180). HIV infection among IDUs is more likely to occur in legal environments where sterile injection equipment is more severely restricted. However, these findings may be subject to confounders, measurement error (HIV seroincidence and seroprevalence), and recall bias (legal restrictions on syringe access).

In jurisdictions in the United States, where drug paraphernalia laws were strictly enforced, higher prevalence of HIV infection was observed despite lower risk-taking behaviour. Legal barriers in Maryland and Texas in the United States resulted in a high prevalence of HIV with up to 25% of IDUs infected in Baltimore, Maryland⁽¹¹⁹⁾ and 35% of IDUs infected in Houston, Texas⁽¹⁶⁷⁾. These findings overall suggest that injecting paraphernalia legislation that restricts needle and syringe availability inadvertently increases HIV infection. There is no convincing evidence that this legislation reduces HIV prevalence.

There is insufficient evidence to consider that the criterion 'strength of association' has been fulfilled.

3.5.2 Replication of results

The two studies^(61, 180) evaluating the impact of injecting paraphernalia legislation only reported data from one country (the United States) and thus may not be generalizable to other countries. While these papers used different methods (meta-analysis and cross-sectional ethnography), both types of studies concluded that HIV infection was significantly more

common in areas with restrictive legislation than in areas where NSPs could operate legally and/or there was no legislative restriction on the purchase or sale of syringes.

The impact of restrictive legislation has also been assessed on secondary outcomes such as IDU's behaviour and NSP or pharmacy provision of sterile syringes^(64, 171). These were retrospective ecological studies of IDU self-reported behaviour, NSP directors' reports, and pharmacists' beliefs. One study included a prospective sampling of pharmacists' actions after the repeal of prescription laws⁽¹⁷¹⁾. Replication of findings is hard to assess due to the limited number of papers assessing the same outcome variables. However, removal of legislation appears to have had a positive impact on the operation of NSPs and increased the availability of sterile syringes. Additionally, the simultaneous repeal of prescription and possession laws seems to have a greater effect than repeal of only one of these⁽⁶⁴⁾.

These findings suggest that, overall, injecting paraphernalia legislation that restricts needle and syringe availability inadvertently increases HIV infection, while there is no convincing evidence that this legislation reduces HIV infection.

There is insufficient evidence to consider that the criterion 'replication of results' has been fulfilled.

3.5.3 Specificity

HIV incidence is influenced by multiple factors apart from legislation, including the existence of legal and illegal NSPs, drug treatment and the numerous other factors that influence the sexual transmission of HIV (such as the prevalence of sexually transmitted infections, the rate of sexual partner change). In some cities where sterile needles and syringes are readily available, HIV epidemics appear to have been averted⁽⁶²⁾. It is much easier to evaluate the effectiveness of needle syringe programmes than legislation because programmes have a more direct impact on benefits and side effects whereas legislation has a relatively indirect influence. When legislation creates an enabling environment, programme activity may still be delayed or perfunctory in scope. In contrast, restrictive legislation banning needle syringe programmes is sometimes ignored with sizeable unsanctioned programmes established, albeit with some difficulty.

In the two studies relating HIV outcomes and legislation^(61, 180), there was no randomization of study

participants or geographical areas and therefore conditions other than a change in the law may have reduced the use of sterile syringes and HIV seroconversion. The authors of these papers identified no other benefits or disadvantages of injecting paraphernalia legislation.

As discussed elsewhere in this report, extensive evidence is available to reject the null hypothesis that providing sterile needles and syringes does not prevent the transmission of HIV. Legislation and law enforcement are major factors limiting the supply of and access to sterile syringes⁽¹⁸¹⁾. Despite the limited number of studies evaluating the impact of legislation on IDU access to sterile syringes and HIV incidence and prevalence, it is reasonable to conclude that restrictive legislation reduces access to sterile needles and syringes, thereby increasing HIV transmission. Therefore, there is inadequate data to establish that injecting paraphernalia legislation specifically affects HIV (as opposed to other microorganisms).

There is insufficient evidence to consider that the criterion 'specificity' has been fulfilled.

3.5.4 Temporal sequence

Neither study of HIV outcomes^(61, 180) evaluated a possible temporal sequence.

Temporal relationships were studied in an assessment of risk behaviours immediately after a change in legislation. Following legislative changes, purchase of syringes from a pharmacy increased and syringe sharing and reported street-purchase of syringes decreased⁽¹⁶⁴⁾. In a second study in several cities in Connecticut in the United States with a high prevalence of HIV among IDUs, legislative change was followed by an increase in the number of syringes sold in pharmacies⁽¹⁷¹⁾.

Two studies reported different results regarding the use of NSPs by IDUs. In the state of New York in the United States, NSP participation increased after the programme was legalized⁽¹⁸²⁾, but in the state of Connecticut NSP participation decreased after the law was changed to allow the sale, purchase and possession of needles and syringes without a medical prescription and to enable the implementation of NSPs. However, the observed drop in the number of visits to and the number of clients using the New Haven NSP from the month the new decriminalization measure came into effect was probably due to an increase in the use of pharmacies as a

source of sterile syringes, and possible referral to treatment⁽¹⁸³⁾.

There is insufficient evidence to consider that the criterion 'temporal sequence' has been fulfilled.

3.5.5 Biological plausibility

As discussed elsewhere, biological plausibility for sterile needle and syringe programmes is high (Sections 3.1.5 and 3.2.5). There is compelling evidence that the re-use and sharing of injection equipment increases the likelihood of HIV infection. It has also been demonstrated that providing sterile needles and syringes with considerable encouragement to only inject with such equipment reduces both risk behaviour and HIV infection. Therefore, there is an inherent biological implausibility that measures that reduce the availability of sterile injecting equipment could be expected to reduce HIV infection. This conclusion is supported by two HIV outcome studies,^(61, 180) which have demonstrated reduced availability of sterile needles and syringes in restrictive legal environments.

There is insufficient evidence to consider that the criterion 'biological plausibility' has been fulfilled.

3.5.6 Biological gradient

No relevant literature was identified.

There is insufficient evidence to consider that the criterion 'biological gradient' has been fulfilled.

3.5.7 Coherence

In United States, states where legal restrictions on syringe access were repealed such as Connecticut, Maine and New York pharmacy sales increased, self-reported needle-sharing declined and over time HIV incidence and prevalence also declined^(61, 180). There is no evidence to support the hypothesis that restrictive injecting paraphernalia legislation reduces HIV infection.

There is sufficient evidence to consider that the criterion 'coherence' has not been fulfilled .

3.5.8 Experimental evidence

No relevant literature was identified.

There is insufficient evidence to consider that the criterion 'experimental evidence' has been fulfilled.

3.5.9 Reasoning by analogy

In many respects the legislative environment for the commercial sex industry is analogous to injection paraphernalia legislation. In restrictive legislative environments, public health authorities have limited influence over the nature and extent of safer sex behaviour. In more pragmatic legislative environments where HIV control is a higher priority, public health authorities are able to encourage brothel operators and commercial sex workers to virtually eliminate higher-risk sexual behaviour. Similarly, public health authorities in less restrictive legislative environments are able to rapidly establish an effective network of NSPs, pharmacies, vending machines and other outlets for the exchange, sale and distribution of sterile injection equipment. According to this reasoning, injecting paraphernalia legislation could be expected to increase rather than reduce HIV infection.

Legislative environments that restrict the implementation of a public health intervention are unlikely to ever result in the protection of public health.

There is insufficient evidence to consider that the criterion 'reasoning by analogy' has been fulfilled.

3.5.10 Cost effectiveness

Lurie and Drucker⁽¹⁰²⁾ have demonstrated that the repeal of injection paraphernalia legislation in the United States would reduce substantially the cost of health care for HIV/AIDS. As discussed above (Sections 3.2.10 and 3.3.10), providing sterile needles and syringes and encouraging their utilization by IDUs has been shown to be cost-effective. Injecting paraphernalia legislation has been demonstrated to restrict the adoption and implementation of a cost-effective intervention. To that extent, injecting paraphernalia legislation may be considered to impede a cost-effective programme.

There is sufficient evidence to consider that the criterion 'cost effectiveness' has not been fulfilled.

3.5.11 Absence of negative consequences

Heimer and colleagues found that following the repeal of legislation that had restricted the sale and possession of needles and syringes in Connecticut, participation by IDUs in the pre-existing New Haven exchange declined⁽¹⁸³⁾. However, as described above,

this could be attributed to a number of other factors, especially increased use of pharmacies.

There is insufficient evidence to consider that the criterion 'absence of negative consequences' has been fulfilled.

3.5.12 Feasibility of implementation, expansion and coverage

More than two decades experience of restrictive injecting paraphernalia legislation in the United States demonstrates that laws of this kind can be implemented and extended to cover most if not all of a large country. Of the 50 states and territories in the United States, 51 jurisdictions recently had paraphernalia laws, 14 had syringe prescription laws or regulations and only 13 had legislation authorizing NSPs ⁽¹⁸⁴⁾.

There is sufficient evidence to consider that the criterion 'feasibility of implementation, expansion, and coverage' has been fulfilled.

3.5.13 Unanticipated benefits

No literature was identified showing unanticipated benefits of restrictive injecting paraphernalia legislation.

There is insufficient evidence to consider that the criterion 'unanticipated benefits' has been fulfilled.

3.5.14 Special populations

In Manipur, India a study of current and former IDUs found that fear of arrest and harassment were the main reasons IDUs did not carry their own syringes or bleach ⁽¹⁸⁵⁾. Similarly, IDUs in Malaysia also reported fear of arrest for possessing drug injection paraphernalia as the main reason for sharing syringes ⁽¹⁸⁶⁾. These studies from a developing and a middle-income country are very important, although they do not specifically refer to sub-populations of IDUs.

There is insufficient evidence to consider that the criterion 'special populations' has been fulfilled.

4. DISCUSSION

The AIDS pandemic was first recognized more than two decades ago. Within a few years the causative organism was identified and the enormity of the health, social and economic costs of uncontrolled HIV infections was recognized. In many countries HIV epidemics started among IDUs, spreading rapidly to general populations, and evidence for the effectiveness and safety of some HIV prevention strategies in this population began to accumulate.

Beginning in some developed countries, NSPs were rapidly identified as a valuable strategy for keeping HIV under control among IDUs. Although a wide variety of different activities and operational methods are now subsumed by the term 'needle syringe programme', there is sufficient commonality to allow evaluation of this large and growing literature. Large numbers of research studies with widely differing designs in diverse countries have been reported. An increasing number of countries commenced NSPs and then began to expand them to scale. Although evidence supporting the effectiveness and safety of NSPs grew, HIV has continued to spread even more rapidly among and from IDUs than the adoption and later expansion of NSPs.

Some excellent and comprehensive reviews of the evidence for NSPs have appeared^(6, 187-193). All have confirmed the effectiveness of NSPs in reducing HIV spread. This conclusion was drawn with increasing confidence in more recent reviews as more and better quality data have become available. This study represents the first international review of NSPs. It is also the first systematic review to consider the extent to which evidence for NSPs fulfils the Bradford Hill criteria. These criteria, originally devised to assess inferences of causality drawn from observational studies, have been used increasingly in recent years to assess intervention studies. This review has attempted to apply the Bradford Hill criteria rigorously and conservatively but in so doing has often encountered the problem of 'double negatives' in drawing conclusions. Accordingly, readers are encouraged to review the wording of all conclusions relating to Bradford Hill criteria carefully. Each of these refers specifically to a null hypothesis.

The bleach literature falls into two clear parts: some of the laboratory data are impressive, but there is a depressing consistency about the field study findings, which raise serious concerns about the effectiveness of this approach.

The overwhelming majority of studies evaluating the effectiveness and safety of NSPs are highly supportive. But in spite of the impressive volume and quality of this supporting evidence, some still question the efficacy and safety of NSPs. A somewhat tendentious interpretation of a handful of negative studies from Montreal⁽⁶⁵⁾ and Vancouver⁽⁶⁶⁾ is relied upon by critics of the proposition that NSPs are effective and safe, despite subsequent papers providing plausible alternative explanations for these negative findings^(67, 102-105). The benefits of NSPs are much easier to demonstrate when these are the only outlets for sterile injecting equipment. Another methodological issue is the tendency for studies to measure baseline and outcome variables dichotomously, substantially reducing the power of these studies.

The quantity and quality of the literature on pharmacy availability of sterile injecting equipment is not as impressive as the literature on NSPs. It is also more difficult to interpret because of the often confounding effect of NSPs and thus not easy to estimate the specific contribution of pharmacy availability. However, studies evaluating pharmacy availability in the absence of NSPs make it abundantly clear that pharmacies are also effective. The paucity of data for vending machines is even more marked than for pharmacies. However, there is a common finding that pharmacy and vending machine outlets often attract a somewhat different population from those attending NSPs. The attitude of pharmacists to IDUs is critical to the success or failure of pharmacy availability of sterile injecting equipment. There is a need to consider outlet density and type more as a system rather than in terms of its component parts.

The literature on the disposal of used injecting equipment is also somewhat disappointing. Although there is no convincing evidence that NSPs have exacerbated the disposal of used injecting equipment in public places, there is little doubt that discarded used injecting equipment seriously undermines the sustainability of this vulnerable intervention that is so critical to public health.

Although the phenomenon of injecting paraphernalia legislation is not unique to the United States, virtually the entire literature on this subject has been generated in that country. It is also hard to interpret this literature because to some extent, the existence and number of NSPs is independent of injecting paraphernalia legislation. Many NSPs have been started without official sanction and sometimes legislative constraints have not existed or have been repealed, and yet few NSPs have been established.

Nonetheless, it is clear that injecting paraphernalia legislation has been a critical obstacle in many states of the United States and this is probably also true, but to a lesser extent, in a number of other countries. Several states in the United States have repealed restrictive laws demonstrating that it is quite feasible to do so. However, several layers of obstacles to the establishment of an effective national NSP system have then often become evident, including an unsupportive federal political environment, compounded by state, city and neighbourhood opposition and additional funding inadequacy. Although these legislative and political problems have been more carefully studied in the United States than in any other country, there are many other countries with similar deep-rooted opposition or ambivalence to effective deployment of NSPs. Legalization of NSPs has improved programme operation, including increasing supplies, staffing, hours of operation, and availability of additional services such as counselling or referral to drug treatment programmes ^(182, 194, 195).

This review should be considered in the light of several limitations. The only literature reviewed was in the English language. Most of this literature originated from developed countries, which although peer reviewed, may still be subject to one or more forms of publication bias. The overwhelming majority of studies were quantitative and there were very limited qualitative data to illuminate the findings of the quantitative studies. The literature regarding the second term of reference (needle syringe programme effectiveness) is so vast that there is little need to also review the relevant grey literature. Any subsequent reviews of bleach and decontamination, pharmacy and vending machines, disposal and injecting paraphernalia legislation, should make greater use of grey literature. The white literature on these areas is small and often less than impressive in quality.

This review was also inevitably limited by inherent deficiencies in the quality of the existing literature. For example, much of the literature classifies injecting drug users as persons who either attend or do not attend NSPs, whereas in reality this phenomenon is dimensional rather than categorical. In addition, outcome measures are usually categorical, although again the phenomenon is usually dimensional. For example, sharing is usually measured as either present or absent during a particular period, rather than estimated on a continuum ⁽¹⁰³⁾.

5. CONCLUSIONS

5.1 There is compelling evidence that increasing the availability and utilization of sterile injecting equipment by IDUs reduces HIV infection substantially.

Overall, there is convincing evidence that NSPs, assessed conservatively, fulfil six of the nine Bradford Hill criteria (strength of association, replication of findings, temporal sequence, biological plausibility, coherence of the evidence and argument by analogy) and all of the five additional criteria (cost effectiveness, absence of negative consequences, feasibility of implementation, expansion and coverage, unanticipated benefits and special populations). Measured against any objective standards, the evidence to support the effectiveness of NSPs in substantially reducing HIV must be regarded as overwhelming.

5.2 There is no convincing evidence of any major, unintended negative consequences.

Specifically and after almost two decades of extensive research, there is still no persuasive evidence that needle syringe programmes increase the initiation, duration or frequency of illicit drug use or drug injecting.

5.3 Needle syringe programmes are cost-effective.

It is more difficult to generalize from studies of cost effectiveness of needle syringe programmes in one country to other similar countries, let alone from developed countries to resource-poor settings. However a number of careful studies in several developed countries and some transitional countries have demonstrated convincingly that needle syringe programmes are cost-effective.

5.4 Needle syringe programmes have additional and worthwhile benefits apart from reducing HIV infection among IDUs.

There is reasonable evidence that needle syringe programmes can increase recruitment into drug treatment and possibly also into primary health care.

5.5 Bleach and other forms of disinfection are not supported by good evidence of effectiveness for reducing HIV infection.

The evidence supporting the effectiveness of bleach in decontamination of injecting equipment and other forms of disinfection is weak. Field studies cast considerable doubt on the likelihood that these measures could ever be effective in operational conditions, notwithstanding the strength of the laboratory data. At best, these strategies can only be regarded as acceptable in community or correctional settings where the introduction of NSPs is considered impossible because of fear or hostility on the part of community members or authorities. Public health practitioners in these settings should continue to advocate for the introduction of NSPs as the most reliable and evidence-based way of maintaining control of HIV among IDUs. Bleach and disinfection fulfilled only two of the nine Bradford Hill criteria (biological plausibility and analogy) and three of the five additional criteria (absence of negative consequences, feasibility of implementation, expansion and coverage, and special populations).

5.6 Pharmacies and vending machines increase the availability and probably of the utilization of sterile injecting equipment by IDUs.

There is reasonable evidence that pharmacy availability of sterile injecting equipment does provide specific benefits in addition to those derived from NSPs. The population attending pharmacies tends to be less disadvantaged than those attending community-based NSPs, although there is often some considerable degree of overlap. Pharmacy schemes complement the benefits of NSPs although some jurisdictions have relied entirely on pharmacy-based outlets. Vending machines increase access in some geographical locations, to some special populations and at times of the day that are otherwise difficult to provide for. Pharmacy and vending machines fulfilled six of the nine Bradford Hill criteria (strength of association, replication, temporality, biological plausibility, coherence and analogy) and four of the five additional criteria (cost-effectiveness, absence of negative consequences, feasibility of implementation, expansion and coverage and special populations).

5.7 Injecting paraphernalia legislation is a barrier to effective HIV control among IDUs.

Injecting paraphernalia legislation has been a major obstacle to HIV control among IDUs in many states of the United States (and a less well-documented but probable obstacle in some other countries). This legislation has impeded the establishment of a timely and appropriate public health response to the HIV epidemic. In terms of the available evidence that restrictive injecting paraphernalia legislation helps to control HIV infection among IDUs, only two of the nine Bradford Hill criteria (specificity and analogy), and one of the five additional criteria (feasibility of implementation, expansion and coverage) were fulfilled. There is evidence that repeal of this legislation results in worthwhile public health benefits.

5.8 Needle syringe programmes on their own are not enough to control HIV infection among IDUs.

There is no evidence of a protective effect for single interventions strong enough to guarantee HIV control but the aggregate effect of several harm-reduction interventions appears to be generally successful in maintaining HIV control. Sterile needle and syringe availability needs to be considered as a system and has to be supported by a range of complementary measures if communities wish to control HIV infection among and from IDUs.

6. RECOMMENDATIONS

6.1 The studies reviewed in this report present a compelling case that NSPs substantially and cost effectively reduce the spread of HIV among IDUs and do so without evidence of exacerbating injecting drug use at either the individual or societal level. This suggests that authorities responsible for areas threatened by or experiencing an epidemic of HIV infection among IDUs should adopt measures urgently to increase the availability and utilization of sterile injecting equipment and expand implementation to scale as soon as possible. As an approximation it is reasonable to assume that providing 200 sterile needles and syringes per drug injector per year is a figure that is achievable and likely to control HIV infection in this population. It may take several years, starting from scratch, to reach this figure. Higher targets may be needed where seroprevalence has already reached unacceptable levels. The precise quantity of injecting equipment required is not known. Cocaine injectors require more needles and syringes than heroin injectors.

6.2 The higher the seroprevalence of HIV among IDUs, the more HIV sexual transmission becomes an important factor. HIV sexual transmission is more difficult to control than HIV spread through sharing of injection equipment.

6.3 Carefully evaluated pilot programmes of NSPs have their place in allowing the introduction of this invaluable protection of public health but they also possess certain risks. Firstly, the case for NSPs is already so compelling and the international experience so impressive, that there is no longer any real justification for pilot programmes. Pilot programmes may further delay the much-needed expansion phase. If the programme remains frozen at the pilot phase level of implementation, then there is a risk that the programme will remain chronically underfunded, with attendant inadequate coverage.

6.4 NSPs are only one way of increasing the availability of sterile injection equipment and these exist in many forms around the world. Some cities require 'one-for-one' exchange, others attempt to achieve high levels of exchange but accept less than 100%, while authorities in other jurisdictions provide sale or free distribution without attempting to remove used injection equipment from circulation. There is no evidence that any one method is notably more efficacious or cost effective. Many jurisdictions have found that a diversity of approaches is optimal, with

some methods working best in certain locations and conditions and other approaches better suited in other places and conditions. The important point is to aim to reduce the circulation time of needles and syringes.

6.5 Attempts to increase the availability of sterile injecting equipment should be accompanied by endeavours to increase the utilization of sterile injection equipment, reduce the utilization and availability of un-sterile injection equipment and improve the appropriateness of discarding used injecting equipment. These objectives are best met through education of IDUs where peer based, explicit campaigns have generally been found to be highly effective.

6.6 However worthwhile it may be to increase the availability and utilization of sterile injecting equipment with the aim of controlling HIV infection among IDUs, this appears to be a necessary rather than a sufficient intervention. Other activities that complement the benefits of sterile injecting equipment programmes include education of IDUs, increasing the capacity, range and quality of drug treatment (especially substitution treatment) and community development of drug users.

6.8 Pharmacy-based NSPs appear to complement community-based schemes and may provide access to a somewhat different population of IDUs. Vending machines increase coverage geographically and across time zones but have the disadvantage of not providing information, counselling or referral.

6.9 Special populations of IDUs are of great public health significance in HIV control especially "bridge" populations (such as IDUs who are also men who have sex with men or male or female commercial sex workers). In most countries, a large proportion of IDUs spend a considerable proportion of their drug-injecting careers behind bars while a large proportion of prison inmates have a history of drug injecting. Many inmates of correctional facilities continue to inject while they are incarcerated. The limited evidence available from evaluation of the few existing prison NSPs suggests that their benefits are similar to community programmes, while there is no evidence to date that these programmes are inherently unsafe or counter-productive. On the available evidence, there is a strong case for establishing and expanding NSPs in correctional facilities in many countries.

6.10 Disinfection and decontamination schemes are not supported by evidence of effectiveness and should only be advocated as a temporary measure where there is implacable opposition to NSPs in certain communities or situations (e.g. correctional facilities).

6.11 This review has demonstrated significant gaps in research. The quantity and quality of research needs to be improved in bleach and disinfection field studies, pharmacy and vending machine evaluation, measures to reduce inappropriate disposal and injecting paraphernalia legislation in countries other than the United States. More and better qualitative research would illuminate the findings of the numerous quantitative studies. Research should make more use of continuous measures of baseline characteristics, interventions and outcome variables. However, it is important to recognize that the limited implementation of NSPs is not fundamentally due to a lack of adequate research data. Therefore, it is unlikely that increasing the quantity of the same kind of research that already exists is unlikely to increase the implementation of NSPs.

Table 1. Summary of field studies of bleach and HIV

Study	Setting / Intervention:	Outcome: use of bleach	Outcome: HIV risk/prevalence	Comment								
Chaisson, et al. 1987 ⁽¹⁴⁾ . San Francisco	Distribution of bleach (5.25% concentration) with instructions, to IDUs. Also used posters and billboards to promote use of bleach to prevent HIV infection.	Comparing 1987 (after intervention) with 1985 (pre-intervention): <ul style="list-style-type: none"> ▶ Use of bleach increased (47% vs 6%). ▶ Proportion never using bleach decreased (76% vs 36%). ▶ % sharing needles remained the same 	Prevalence of HIV infection increased from 10% (1985 pre-intervention) to 15% (1987 post-intervention).	Modification of sterilization practice occurred in IDUs in treatment (who were not primary target of programme). Conclusion: bleach should only be promoted in conjunction with other risk-modification measures, such as widespread availability of sterile needles and syringes.								
Vlahov, Astemborski, et al. 1994 ⁽¹⁷⁾ . Baltimore, Maryland.	Follow-up of seronegative IDUs (1988- 1992) in setting of bleach/alcohol promotion.	46% of IDUs used disinfection all the time	Disinfection had no protective effect for IDUs who used all the time vs IDU who used less than all the time or never. <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Disinfection use</th> <th style="text-align: left;">HIV seroconversion OR (95%CI)</th> </tr> </thead> <tbody> <tr> <td>None</td> <td>1</td> </tr> <tr> <td>Less than all the time</td> <td>1 (0.36 - 2.82)</td> </tr> <tr> <td>All the time</td> <td>0.87 (0.32 - 2.37)</td> </tr> </tbody> </table>	Disinfection use	HIV seroconversion OR (95%CI)	None	1	Less than all the time	1 (0.36 - 2.82)	All the time	0.87 (0.32 - 2.37)	Conclusion: Over-reliance upon bleach or alcohol disinfection in prevention of new HIV infection among IDUs is unsafe.
Disinfection use	HIV seroconversion OR (95%CI)											
None	1											
Less than all the time	1 (0.36 - 2.82)											
All the time	0.87 (0.32 - 2.37)											
Titus, Marmor, et al. 1994 ⁽¹⁸⁾ . New York City.	Follow-up of seronegative IDUs in setting of bleach/alcohol promotion (reinforced after each research interview). Multi-ethnic	Behaviour change may be enabled by counselling sessions (conducted at the end of interview session) – repeated counselling increased recall.	Use of bleach had no significant effect on risk of HIV seroconversion. <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Disinfection use</th> <th style="text-align: left;">HIV seroconversion OR (95%CI)s</th> </tr> </thead> <tbody> <tr> <td>Never</td> <td>1</td> </tr> <tr> <td>Sometimes</td> <td>6.55 (0.8 - 55.8)*</td> </tr> <tr> <td>Always</td> <td>1.05 (0.1 - 15.9)</td> </tr> </tbody> </table> <p>* The (non-significant) increased risk for IDUs who sometimes used bleach, was not significant after injection frequency was adjusted for.</p>	Disinfection use	HIV seroconversion OR (95%CI)s	Never	1	Sometimes	6.55 (0.8 - 55.8)*	Always	1.05 (0.1 - 15.9)	Efforts to slow transmission of HIV among IDUs should not emphasize bleach.
Disinfection use	HIV seroconversion OR (95%CI)s											
Never	1											
Sometimes	6.55 (0.8 - 55.8)*											
Always	1.05 (0.1 - 15.9)											

Table 2. Laboratory evidence of effect of bleach (hypochlorite) on HIV

Study	Year	Virus(cell assoc/free)	Medium	Dilution	Contact Time	Inactivated Y/N	Comment
Abdala, et al. 2001 ⁽³⁴⁾	2001	Cell-assoc and cell free together 2-20 µL of blood		undiluted	5 sec	yes ¹	Recovery of HIV dependant on blood vol. in syringe, number of rinses, and titre of HIV in blood.
Aranda-Anzaldo, et al. 1992 ⁽⁴⁶⁾	1992	Cell-free		1% 20% undiluted?	30 sec 60 sec 30 sec	Yes No Yes	HIV inactivation depends on concentration and incubation time.
Contoreggi et al. 2000 ⁽⁵¹⁾	2000	Cell assoc(?) Cell assoc(?)	Cult medium Cult medium	High Low		Yes No ²	Suggests that sharing of a bleach-cleaned syringe may increase likelihood of transmitting HIV-1.
Druce et al., 1995 ⁽⁴⁰⁾	1995	Cell free Cell assoc Cell assoc	Cell cult medium Suspended in blood Suspended in blood	2500 ppm 25 000 ppm 2500 ppm 25 000 ppm 25 000 ppm	60 sec 60 sec 5 sec	Yes No Yes	Effectiveness compromised by presence of blood
Druce et al. 1995 ⁽³⁹⁾	1995	Cell assoc			10 sec ³	Yes	30 sec required if syringe left for 3 hours at room temp. Increase thought to be due to presence of dried and clotted blood.
Flynn et al. 1994 ⁽⁴²⁾	1994	Cell-assoc Cell-assoc	Cult medium Suspended in blood	Neat, 1:10; 1:100	60 sec 60 sec	Yes No	
Gordon et al. 1993 ⁽⁴⁵⁾	1993			undiluted?	30 sec	Yes	
Martin et al. 1985 ⁽⁴⁹⁾	1985	Cell-free		0.1%	2 min	Yes	

¹ Not to zero; (HIV still able to be recovered from 1/153 syringes)

² Facilitated growth

³ Needle/syringe surface

Study	Year	Virus(cell assoc/free)	Medium	Dilution	Contact Time	Inactivated Y/N	Comment
Newmeyer et al. 1990 ⁽⁴⁷⁾	1990	Cell-free		Full strength	60 sec	Yes	
Resnick et al. 1986 ⁽⁴⁸⁾	1986			10% dilution	60 sec	Yes	
Shapshak et al. 1993 ⁽⁴⁴⁾	1993			Undiluted?	30 sec	Yes	
Shapshak et al. 1994 ⁽⁴¹⁾	1994	Pelleted cell assoc 50µL of blood	Undiluted	30 sec	Yes		
		Pelleted cell assoc 50µL of blood	Diluted	30 sec	No		
		Pelleted cell assoc 50µL of blood	Undiluted	15 sec	No		
		Pelleted cell assoc 50µL of blood	10%	2 min	Yes		
Spire et al. 1984 (50)	1984		8% serum	Undiluted? 100 ppm	30 sec 30 sec	Yes Yes ⁴ (3.75log TCID ₅₀ HIV/ml)	
Van Bueren et al. 1995 ⁽⁵⁶⁾	1985		80% serum	500 ppm	1-2 min	Yes ⁵ (>4logTCID ₅₀ HIV/ml)	Results stress importance of cleaning prior to infection. Bleach maybe ineffective in the presence of organic matter. If prior cleaning not possible, use high concentration of chlorine (min. 10000 ppm available chlorine)
			80% blood	1000 ppm		No ⁶ (3.75logTCID ₅₀ HIV/ml)	
				2500 ppm		Yes ⁷ (1.5logTCID ₅₀ HIV/ml)	
Weber et al. 1999 ⁽⁵⁵⁾	1999		No blood	5000 ppm (1:10 bleach dilution)	30 sec ⁸	Yes	HSV (not HIV) used, but has similar susceptibilities.
			No blood	500 ppm (1:100 bleach dilution)	30 sec	Yes	
			80% blood	5000 ppm	10 min	No	

⁴ 3.75 log TCID HIV/ml⁵ > 4 log TCID HIV/ml⁶ 3.75 log TCID HIV/ml⁷ 1.5 log TCID HIV/ml⁸ Environmental spills – cleaning of blood spills

Table 3a. Efficacy of needle syringe programming. NSP use and HIV seroprevalence or seroconversion as outcomes: studies with positive findings

Study	Respondents	Outcome variables	Results
Ljungberg et al., 1991 ⁽⁵⁹⁾ . Skane province, Sweden; observational study.	182 "active participants" of NSP	Seroprevalence in south Sweden compared with Scandinavian sub-populations with comparable drug problems.	HIV seroprevalence among IDU in south Sweden maintained at ~1% contrasted with up to 60% in other Scandinavian sub-populations.
Heimer et al., 1993 ⁽⁶⁰⁾ . New Haven, USA.	Random sample of returned syringes at the New Haven NSP.	Percentage of syringes containing HIV.	Within three months of initiating syringe exchange, percentage of syringes containing serum with HIV declined by one third.
Des Jarlais et al., 1996 ⁽⁶¹⁾ . New York City, USA; prospective cohort study using pooled data from three studies in a high prevalence area.	601 IDUs at several exchange sites.	HIV incidence among continuing NSP users compared with non-users.	Multivariate proportional-hazards analysis, not using an NSP was associated with a Hazard Ratio of 3.35 (95% CI 1.29, 8.65) for incident HIV compared with using an NSP.
Hurley et al., 1997 ⁽⁶²⁾ . ecological study of 81 cities between 1988 and 1993.	Data from reports on HIV seroprevalence linked with details of NSP implementation in 81 cities world-wide.	HIV seroprevalence among IDU in 52 cities with NSP compared with that in 29 cities without NSPs.	On average HIV seroprevalence increased by 5.9% per year in cities without NSPs and declined by 5.8% per year in cities with NSPs. Average annual change in seroprevalence was 11% lower in cities with NSPs (95% CI -17.6 to -3.9, p=0.004).
Monteroso et al., 2000 ⁽⁶³⁾ . Five United States cities; observational study.	Some 2306 street IDUs recruited from 5 United States cities and a state women's prison and followed up eight months later.	HIV incidence among NSP participants compared with non-participants.	Participation in NSPs associated with substantially reduced risk of HIV acquisition, but not statistically so.
Health Outcomes International (HOI), 2002 ⁽⁶⁴⁾ . Ecological study of 778 calendar years of data from 103 cities worldwide.	Details of NSP implementation and HIV seroprevalence measurements for 67 cities without NSP, 36 cities with NSP.	HIV seroprevalence compared in cities with and without NSPs.	HIV seroprevalence in cities with NSPs declined by a mean annual 18.6% compared to an 8.1% increase in cities without NSPs.

Table 3b. Efficacy of needle syringe programming. NSP use and HIV seroprevalence or seroconversion as outcomes: studies with negative findings

Study	Respondents	Outcome variables	Results
Bruneau et al., 1997 ⁽⁶⁵⁾ . Montreal, Canada; nested case-control study.	408 treated and untreated IDU; any versus no NSP use, last 6 months.	HIV seroconversion	Exclusive NSP users four times more likely to seroconvert than never-users. OR=4.2 (95% CI, 1.5-11.5). Non-exclusive NSP users three times more likely to seroconvert than never-users. OR=3.3 (95% CI, 1.6-6.7). Consistent NSP use strongly associated with seroconversion. OR=10.5 (95% CI, 2.7-41.0).
Bruneau et al., 1997 ⁽⁶⁵⁾ . Montreal, Canada; prospective cohort study.	1599 treated, untreated IDU. NSP users compared with non-users. Mean follow-up period 21.7 months.	HIV seroconversion	Substantially increased risk of HIV seroconversion associated with NSP use. AOR=2.2 (95% CI, 1.5-3.2).
Strathdee et al., 1997 ⁽⁶⁶⁾ . Vancouver, Canada; observational study.	1006 untreated IDU. Frequent NSP attenders compared to non-attenders.	HIV seroprevalence.	Frequent NSP attenders more likely to be HIV positive than non-attenders.

Table 3c. Efficacy of needle syringe programming. NSP use and HIV seroprevalence or seroconversion as outcomes: studies with indeterminate findings

Study	Respondents	Outcome variables	Results
Patrick et al., 1997 ⁽⁶⁸⁾ . Vancouver, Canada; case-control study.	281 untreated IDU. Ever-users of NSP compared with never-users.	HIV seropositivity	No association between ever using a NSP and HIV seropositivity.
Schechter et al., 1999 ⁽⁶⁷⁾ . Vancouver, Canada. prospective cohort study.	694 treated and untreated IDU followed for 15 months. Frequent attenders vs infrequent NSP attenders.	HIV incidence	No differences in HIV incidence between frequent attenders and infrequent attenders.

Table 4a Efficacy of needle syringe programming. NSP use and HIV risk behaviour outcomes: studies with positive findings.

Study	Respondents	Outcome variables	Results
Hartgers et al., 1989 ⁽⁶⁹⁾ Amsterdam, the Netherlands; observational study.	145 untreated IDUs in community sample. NSP users vs non-users.	Syringe borrowing	NSP users less likely to borrow than non-users in previous month (10% compared with 23%) and also in previous 2 years (33% compared with 57%).
Donoghoe et al., 1989 ⁽⁷⁰⁾ . Scotland and England; prospective cohort study, pre-post (2 months) comparison.	282 NSP users and non-NSP control group.	Syringe-sharing	Significant decline in syringe- sharing among NSP users in previous month compared with no change in control group.
Kaplan et al., 1991; Kaplan et al., 1994; Kaplan et al., 1995 ⁽⁸⁸⁻¹⁰⁰⁾ . New Haven, USA; syringe tracking and modelling studies.		Syringe exchange rate, syringe return rate, syringe circulation time	The syringe exchange rate per IDU and the return rate of programme syringes both increased, implying a decreased mean circulation time for each syringe.
Frisher & Elliott, 1993 ⁽¹⁹⁶⁾ . Glasgow, Scotland; observational study	503 IDU community sample. NSP users in last 6 months vs non-users.	Syringe borrowing or lending	NSP attenders less likely (mean 4.5 times/mo) than non- attenders (mean 9.2 times/mo) to borrow used syringes, despite legal pharmacy sale of syringes.
Keene et al., 1993 ⁽⁷²⁾ . Wales, UK; observational study	328 mostly untreated IDU. NSP attenders vs non- attenders.	Syringe-sharing in last year and last 4 months	NSP attenders less likely to share syringes in last year and last 4 months.
Watters et al., 1994 ⁽⁷³⁾ . San Francisco, USA; observational study	752 treated, untreated IDU. NSP users vs non-users.	Syringe-sharing Injection frequency	NSP use was strong independent predictor of not sharing syringes. OR=0.71 (95% CI, 0.59-0.87). Median number of injections declined following NSP attendance, from 1.9 injections/day to 0.7 injections/day
Des Jarlais et al., 1994 ⁽⁷⁴⁾ . New York City; multiple cross-sectional study.	1115 IDU entering methadone treatment.	Syringe borrowing, lending	Quarterly level of NSP use correlated negatively with proportion of IDU reporting borrowing and lending of syringes ($X_{-} = -0.67$, $p < 0.02$ and $X_{-} = -0.44$, $p < 0.13$ respectively).
Oliver et al., 1994 ⁽⁷⁵⁾ . Portland, USA; prospective pre-post NSP evaluation study.	115 NSP clients, pre-and post-NSP attendance. No comparison group.	Syringe sharing, renting and borrowing	Substantial decline in sharing (20% to 7%), renting (9% to 3%) and also borrowing of syringes.

Study	Respondents	Outcome variables	Results
Oliver et al., 1994 ⁽⁷⁵⁾ . Portland, USA; prospective cohort study.	412 untreated IDU followed for 6 months. NSP users compared to outreach IDU.	Syringe borrowing	NSP users borrowed less and outreach clients (who bleached more).
Paone et al., 1994 ⁽⁷⁶⁾ . New York City; retrospective pre-post comparison study.	1269 NSP clients	Syringe borrowing	Substantial decline in borrowing used syringes (from 29% to 12%) and in renting or buying a used syringe (from 22% to 6%).
Peak et al., 1995 ⁽⁷⁷⁾ . Kathmandu, Nepal; multiple cross-sectional study.	586 NSP clients	Number of sharing partners and sharing occasions.	Median number of sharing partners declined from 2 to 1 and median number of sharing occasions declined from 14 to 2 following NSP attendance.
Guydish et al., 1995 ⁽⁷⁸⁾ . San Francisco, USA; observational study	50 NSP clients; compared number of months since first used NSP.	Number of sharing partners	Recent NSP users had fewer sharing partners and number of sharing partners was negatively correlated with number of NSP visits in past 30 days.
Schoenbaum et al., 1996 ⁽⁷⁹⁾ . New York City; prospective cohort study.	329 treated IDU, NSP users compared with non-users.	Syringe-sharing	NSP users significantly less likely than non-users to report syringe sharing 4 years after the NSP was introduced.
Vlahov et al., 1997 ⁽⁸⁰⁾ . Baltimore, USA; prospective cohort study.	221 NSP clients pre-NSP, 2 week, 6 month, follow-ups. No comparison group.	Syringe-borrowing, -lending and indirect sharing	Substantial declines in syringe borrowing (22% to 8%) and syringe lending (27% to 12%).
Singer et al., 1997 ⁽⁸¹⁾ . Hartford, USA; multiple cross-sectional study.	710 untreated IDU; Pre-post comparison.	Syringe reuse (a proxy for syringe sharing)	Respondents significantly reduced their 'reuse' of syringes following introduction of NSP and legalization of pharmacy sale of syringes.
Guydish et al., 1998 ⁽⁸²⁾ . San Francisco, USA; observational study	114 NSP clients; Compared on basis of proportion of syringes	Syringe-sharing	Those who obtained a higher proportion of syringes from the NSP 92% vs 81% were less likely to report the sharing of syringes.
Heimer et al., 1998 ⁽⁸³⁾ . New Haven, San Francisco, Baltimore and Chicago; retrospective analysis of data.	Large sample of NSP attenders; first visit data compared with later visits.	Syringe reuse	Self reported reuse of injection equipment declined by at least half in three of the four cities. In the fourth city different methods of data collection (including syringe tracking) corroborated these findings.

Study	Respondents	Outcome variables	Results
Gleghorn et al., 1998 ⁽⁶⁴⁾ . Seven metropolitan centres, USA; observational study.	Broad sample of IDUs.	Source of most recent syringe (reliable/unreliable)	IDUs were most likely to have used a reliable source to obtain their most recent syringe in cities with a NSP. OR=5.3 (95% CI 3.3-8.5).
Bluthenthal et al., 1998 (85). Oakland, USA; observational study.	1304 untreated IDU in community sample. Compared NSP users with non-users.	Syringe-sharing	NSP use conferred a greater than 40% protective effect on syringe sharing. AOR=0.57 (95% CI 0.46-0.72).
Bluthenthal et al., 2000 ⁽⁸⁶⁾ . Oakland, USA; controlled cohort study.	340 high-risk IDU. NSP users compared with non-users.	Syringe-sharing cessation	IDU who began using the NSP were more likely to stop sharing than non-users (AOR=2.68; 95% CI, 1.35-5.33), as were IDU who continued using the NSP (AOR=1.98; 95% CI, 1.05-3.75).
Cox et al., 2000 ⁽⁶⁷⁾ . Dublin, Ireland; evaluation study of NSP.	IDU who attended the NSP; compared data at first visit and 3 months later.	Sharing of injection paraphernalia.	Significant reductions in borrowing and lending of syringes.
Monterroso et al., 2000 ⁽⁶³⁾ . Five United States cities and a State Women's prison; prospective study.	2306 street IDUs; NSP participants compared with non-participants. 8 months follow-up.	Syringe reuse	Reported use of NSP was significantly associated with not using previously used needles. (OR _{adj} =2.08; 95% CI, 1.15-3.85, p=0.015).
Power et al., 2002 ⁽⁶⁸⁾ . Sverdlovsk Oblast, Russia; short-term process evaluation of three NSPs.	IDU attenders compared with non-attenders 6 months after NSP opened.	HIV risk behaviours	NSP attenders reported less HIV risk behaviour than non-attenders. The following risk behaviours were statistically significant at P<.0005: only use own syringe; only use own needle; only use own filter; only use own drug solution; use another's syringe for measuring drug dose.
Gibson et al., in press ⁽⁶⁰⁾ . San Francisco; prospective cohort study.	259 IDU followed for mean period of 10.7 months. NSP users compared with non-users.	HIV risk behaviour	NSP use had a substantial protective effect against HIV risk behaviour (a two-fold decreased odds of HIV risk behaviour), compared with non-use. Controlled for baseline risk behaviour and exchange use as markers of risk-taking tendency, and other potential confounders.

Table 4b. Efficacy of needle syringe programming. NSP use and HIV risk behaviour outcomes: studies with negative findings.

Study	Respondents	Outcome variables	Results
Klee et al., 1991 ⁽⁹¹⁾ . Northwest England, UK; observational study.	217 treated, untreated IDU; Regular NSP users compared with rare or never users.	Syringe lending	Regular use of NSP associated with passing of syringes.

Table 4c. Efficacy of needle syringe programming. NSP use and HIV risk behaviour outcomes: studies with indeterminate findings

Study	Respondents	Outcome variables	Results
Donoghoe et al., 1992 ⁽⁹²⁾ . London, UK; observational study.	207 untreated IDU; NSP users compared with non-users.	Syringe-sharing	NSP users and non-users equally likely to share used injection equipment.
Hartgers et al., 1992 ⁽⁹³⁾ . Amsterdam, the Netherlands; observational study.	131 HIV-seronegative IDU; mostly NSP users	Syringe-borrowing	Regular NSP use not associated with increased or decreased borrowing.
Van Ameijden et al., 1992 ⁽⁹⁷⁾ . Amsterdam, the Netherlands; case-control study.	232 untreated IDU; NSP users compared with non-users.	Proportion of syringes exchanged	No protective effect associated with proportion of syringes exchanged at the NSP.
Van Ameijden et al., 1994 ⁽⁹⁴⁾ . Amsterdam, the Netherlands; observational study.	Community sample of 616 treated, untreated IDU. NSP users compared with non-users, previous year.	Syringe borrowing and lending	Bivariate negative association with borrowing and lending of syringes. Later multivariate analysis (1998) adjusted for possible confounders discounted these negative findings.
Klee et al., 1995 ⁽⁹⁵⁾ . Northwest England, UK; observational study.	Community sample of 663 treated, untreated, opiate, non-opiate IDU in three studies; Regular NSP users compared	HIV risk behaviour	Mixed pattern of NSP use and HIV risk behaviour in three studies.
Van Haastrecht et al., 1996 (101). Amsterdam, the Netherlands; prospective cohort study.	632 treated, untreated IDU followed over 8 years; NSP users compared with non-users.	Predictors of mortality among HIV positive and HIV negative IDU.	Mortality rate of NSP attenders about the same as that for non-attenders.
Van Ameijden et al., 1998 ⁽⁹⁶⁾ . Amsterdam, the Netherlands; observational study.	Community sample of 879 treated, untreated IDU seen at 6645 visits; NSP users compared with non-users, previous year.	Syringe borrowing and lending	Irregular NSP users at statistically greater risk of borrowing and lending of syringes than regular users or non-users.

Table 4d. Tally of studies finding positive versus negative or null effects of syringe exchange broken down by presence or absence of legal access to pharmacy syringes^{1 (89)}

		Positive	Negative/null	Total
Legal pharmacy access?	Yes	5	13	18
	No	7	0	7
Total		12	13	25

¹ Relationship between positive versus negative or null findings and legal pharmacy access significant by Fisher's exact test at $p < 0.002$.

Table 5. Impact of pharmacy sale of syringes upon HIV prevalence, incidence and risk behaviours

Intervention study	Respondents	Outcomes	Results
Caslyn et al., 1991 ⁽¹⁶²⁾ Seattle, Washington State	Structured interviews with 313 IDUs receiving treatment.	Sharing equipment Median number of people shared syringes with	Significantly less sharing when main source of syringes is the pharmacy (16.2%) compared with other sources (30.6%) ($p < 0.01$) IDUs who obtained needles from pharmacies shared with significantly fewer people (median-2.0) than IDUs who obtained needles from other sources (median-3.0) ($p < 0.05$)
Gleghorn et al., 1995 ⁽¹¹⁹⁾ Baltimore, Maryland, USA.	Structured interviews with 466 IDUs	Pharmacy as usual source of needles & syringes	IDUs were less likely to use shooting galleries: (AOR 0.33; 95%CI 0.14, 0.75) and less likely to have been in jail (AOR 0.45; 95%CI 0.23, 0.87) (add comparison group)
Groseclose et al., 1995 ⁽¹⁶⁴⁾ Connecticut, USA.	Structured interview with IDUs before and after legalization of purchase and possession of syringes.	Syringe sharing Ever shared syringes Obtaining syringes from street	A substantial decrease from 52% to 31% A substantial decrease from 68% to 52% A substantial decrease from 88% to 74%
Hunter et al., 1995 ⁽¹⁶³⁾ London (metropolitan area), UK.	Annual survey of ~515 IDUs over 4 years.	HIV prevalence	A substantial decrease in HIV prevalence among IDUs from 12.8% in 1990 to 6.9% in 1993

Intervention study	Respondents	Outcomes	Results
Ingold & Ingold, 1989 ⁽¹⁶¹⁾ . Paris, Bordeaux, Marseille, France.	Structured interview of 280 IDUs from street and in treatment.	No syringe sharing	Liberalization had significant impact on behaviour of IDUs, with 52% street sample, 40% in treatment purchased syringes from pharmacies and never shared with others
Nelson et al., 1991 ⁽¹⁷¹⁾ . Baltimore, United States	Structured interview with 2921 IDUs.	HIV seroprevalence Used equipment no one else had used <i>greater than half the time</i> Used equipment used by someone else <i>less than half the time</i> Shared needles > 1 person	A significantly lower proportion of diabetic IDUs (9.8%) had HIV compared with non-diabetic IDUs (24.3%) (p=0.03). Significantly more diabetic IDUs (77%) shared less than non- diabetic IDUs (64%) (p<0.05) Significantly more diabetic IDUs (90%) did not use equipment after someone else compared with non-diabetic IDUs (78%) (p<0.01) A lower proportion of diabetic IDUs (37%) shared needles compared with non-diabetic IDUs (48%) (p<0.14)
Richard et al., 2002 ⁽¹⁶⁷⁾ . Houston, Texas	Structured interviews with 108 IDUs.	Inject after person that is not sexual partner Has new syringes	Less likely when IDU has a new syringe: AOR 0.236 (95%CI 0.06, 0.89) More likely to be a heroin user (AOR 1.49; 95%CI 1.18, 1.88) and have higher social desirability score (AOR 1.69; 95% CI 1.11, 2.56)
Syringe vending machines			
Heinemann & Gross, 2001 ⁽¹⁶⁶⁾ . Cross-sectional study of IDUs in prison	Hamburg, Germany	HIV seroprevalence Needle-sharing	No cases identified during program Decreased significantly
Obadia et al., 1999 ⁽¹⁶⁵⁾ . Questionnaires applied to 343 IDUs	Marseille, France	HIV seropositivity	IDUs whose primary source of syringes is from SVM are less likely to have positive HIV (OR 0.5; 95%CI 0.2, 0.9) not significant after adjustment

Table 6. Summary of studies on the disposal of needles and syringes

Study	Description	Study objective	Outcomes
Toews et al., 1995 ⁽¹⁹⁷⁾ . Florida, USA.	Containers provided by hospital and Public Health Units (PHU). Publicity re project by brochure & local paper advertisements, disseminated by the Chamber of Commerce, Social Services Officer, and PHU.	To provide highly visible and easily accessible disposal containers (in public places and private dwellings)	Annual costs: <US\$200 Well accepted by community. Relationship between PHU and community strengthened.
Zamora et al., 1998 ⁽¹⁹⁸⁾ . Madrid, Spain.	Presence of HIV-1 assessed in 28 syringes discarded in public places, 10 from NSP, and 10 controls (of which 5 had blood from HIV positive patient, and 5 had blood from HIV negative patient).	To assess the presence of HIV-1 in discarded syringes in public places (and compare to those from NSP)	Little or no risk of HIV-1 infection by casual needle injury from a discarded syringe left by an IDU in a public place.
Springer et al., 1999 ⁽¹⁹⁹⁾ . New York City.	Qualitative exploration of syringe disposal interventions for injecting drug users (IDUs) – interviews with injecting and non injecting community members.	To gauge IDUs' and non-IDUs' support for NSPs as syringe disposal interventions.	Non-IDUs favoured a one-way drop box, but IDUs identified fear of arrest for possession of syringes as an important obstacle to use of drop box.
Riley et al., 1998 ⁽²⁰⁰⁾ . Baltimore, USA.	To assess acceptability and use of a community-based needle and syringe disposal intervention.	3 red drop boxes provided for disposal of used needles and syringes in high IDU area. Acceptance of boxes measured by focus groups of residents, IDUs and police - before and after project implementation. Use was measured by weekly counts of needles (in boxes and public places); sample of all deposited needles was randomly chosen for needle washing and subsequent HIV antibody testing.	In the first 10 months, 2971 needles were collected. Of 156 needles tested, 10.9% were positive for HIV antibody. Needle counts on the street did not change in box areas compared with control areas. Red boxes were accepted by the community and drug users. Police officers also used the boxes to dispose of confiscated needles. All focus groups expressed support of project expansion.
Macalino et al., 1998 (201). Baltimore, Maryland, USA	To review issues related to discarded syringes in the community and to describe community-based programmes for the safe disposal of used needles and syringes.	Literature review to identify community-based syringe disposal programmes (other than NSP). Workshop held.	15 programmes for the safe disposal of syringes were identified in Australia, Canada and the United States – only 3 primarily for IDUs. For IDUs, criminal penalties for possession of syringes are a substantial deterrent to participation in community-based efforts to improve safe disposal of used syringes.

7. REFERENCES

1. Burns SM et al. The epidemiology of HIV infection in Edinburgh related to the injecting of drugs: an historical perspective and new insight regarding the past incidence of HIV infection and derived from retrospective HIV antibody testing of stored samples of serum. *The Journal of Infection*, 1996, 32:53-62.
2. Buning EC et al. Preventing AIDS in drug addicts in Amsterdam. *Lancet*, 1986, 1:1435.
3. Bradford Hill A. The environment and disease: association or causation. *Procedures of the Royal Society of Medicine*, 1965, 58:295-300.
4. Lurie P. Invited commentary: le mystere de Montreal. *American Journal of Epidemiology*, 1997a, 146:1003-6.
5. Drucker E et al. Measuring harm reduction: the effects of needle and syringe exchange programmes and methadone maintenance on the ecology of HIV. (Review) (105 refs). *AIDS*, 1998, 12(Suppl. A):S217-30.
6. Normand J, Vlahov D & Moses, LE, eds. *Preventing HIV transmission: the role of sterile needles and bleach*. Washington DC, National Academy Press, 1995.
7. www.lindesmith.org/library/lipp14.html, *Fourteen article abstracts on syringe and needle exchange*. Drug Policy alliance, 2002.
8. www.lindesmith.org/library/syringe_index2.html, *Needle exchange/syringe availability & HIV/AIDS*. Drug Policy alliance, 2002.
9. www.dogwoodcentre.org/references/Satcher00b2.html, Satcher D, MD. *Annotated bibliography: scientific research on syringe exchange programmes published since April 1998 - part 2*. Washington, DC, US Department of Health and Human Services, 2000.
10. Gibson DR, Flynn NM & Perales D. Effectiveness of syringe exchange programmes in reducing HIV risk behaviour and HIV seroconversion among injecting drug users. (Review) (67 refs). *AIDS*, 2001, 15(11):1329-41.
11. Druce J & Birch C. A review of the literature on disinfection of Human Immunodeficiency virus, Hepatitis B Virus and Hepatitis C virus. In: McGeorge J, Crofts N, & Burrows C, eds. *Disaffected or disinfected? The redevelopment of disinfection and safe injecting messages*, Victoria, Australia. The Epidemiology and Social Research Unit, Macfarlane Burnet Centre for Medical Research, Fairfield, 1995, 3-14.
12. Bradford Hill A. *Principles of medical statistics*. 9th ed. London, The Lancet Limited, 1971.
13. Spitzer WO. Bias versus causality: interpreting recent evidence of oral contraceptive studies. *American Journal of Obstetrics and Gynecology*, 1998, 179(3 Suppl.):43S-50S.
14. Chaisson RE et al. HIV, bleach, and needle-sharing. *Lancet*, 1987, 1(8547):1430.
15. Vlahov D et al. HIV seroconversion and disinfection of injection equipment among intravenous drug users. *Epidemiology*, 1991, 2(6):444-6.
16. Titus S et al. Bleach use and HIV seroconversion among New York City injection drug users. *Journal of Acquired Immune Deficiency Syndromes*, 1994, 7(7):700-4.
17. Vlahov D et al. Field effectiveness of needle disinfection among injecting drug users. *Journal of Acquired Immune Deficiency Syndromes*, 1994, 7(7):760-6.
18. Kapadia F et al. (Second Collaborative Injection Drug User Study, Group), Does bleach disinfection of syringes protect against hepatitis C infection among young adult injection drug users? *Epidemiology*, 2002, 13(6):738-41.
19. Hagan H et al. Sharing of drug preparation equipment as a risk factor for hepatitis C. *American Journal of Public Health*, 2001, 91(1):42-6.
20. Clatts MC et al. HIV-1 transmission in injection paraphernalia: Heating drug solutions may inactivate HIV-1. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1999, 22(2):194-199.
21. Shah SM et al. Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1996, 11(3):301-6.

- 22.** Nyamathi AM et al. Barriers to condom use and needle cleaning among impoverished minority female injection drug users and partners of injection drug users. *Public Health Reports*, 1995, 110(2):166-72.
- 23.** Carlson RG et al. A preliminary evaluation of a modified needle-cleaning intervention using bleach among injection drug users. *AIDS Education & Prevention*, 1998, 10(6):523-32.
- 24.** Chitwood DD et al. HIV seropositivity of needles from shooting galleries in South Florida. *American Journal of Public Health*, 1990, 80:150-152.
- 25.** Shapshak P et al. HIV-1 RNA load in needles/syringes from shooting galleries in Miami: a preliminary laboratory report. *Drug & Alcohol Dependence*, 2000, 58(1-2):153-7.
- 26.** Wodak A et al. Antibodies to the HIV virus in needles and syringes used by intravenous drug abusers. *Medical Journal of Australia*, 1987, 147:275-276.
- 27.** Abdala N et al. Survival of HIV-1 in syringes. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1999, 20(1):73-80.
- 28.** McCoy CB et al. Parenteral transmission of HIV among injection drug users: assessing the frequency of multi-person user of needles, syringes, cookers, cotton and water. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1998, 18(Suppl. 1):S25-29.
- 29.** MacDonald M et al. HIV prevalence and risk behaviour in needle exchange attenders: a national study. The Collaboration of Australian Needle Exchanges. *Medical Journal of Australia*, 1997, 166(5):237-40.
- 30.** Heimer R et al. Three years of needle exchange in New Haven: what have we learned? *AIDS Public Policy Journal*, 1994, 9:59-74.
- 31.** Nelles J & Harding T. Preventing HIV transmission in prison: a tale of medical disobedience and Swiss pragmatism. *Lancet*, 1995, 346:1507-8.
- 32.** Dolan KA & Wodak A. HIV transmission in a prison system in an Australian State. [Comment]. *Medical Journal of Australia*, 1999, 171(1):14-7.
- 33.** Nguyen TA et al. Risk factors for HIV-1 seropositivity in drug users under 30 years old in Haiphong, Vietnam. *Addiction*, 2001, 96(3):405-13.
- 34.** Abdala N et al. Can HIV-1-contaminated syringes be disinfected? Implications for transmission among injection drug users. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 2001, 28(5):487-94.
- 35.** Weber DJ et al. The effect of blood on the antiviral activity of sodium hypochlorite, a phenolic, and a quaternary ammonium compound. *Infection Control & Hospital Epidemiology*, 1999, 20(12):821-7.
- 36.** Van Bueren J et al. *Inactivation of HIV-1 by chemical disinfectants: sodium hypochlorite.* *Epidemiology & Infection*, 1995, 115(3):567-79.
- 37.** Shimakoshi Y et al. A micro-suspension-test for evaluation of disinfectants against human immunodeficiency virus. *Kansenshogaku Zasshi - Journal of the Japanese Association for Infectious Diseases*, 1995, 69(5):532-8.
- 38.** Shimakoshi Y. Micro-carrier-test: evaluating disinfectants for HIV. *Kansenshogaku Zasshi - Journal of the Japanese Association for Infectious Diseases*, 1995, 69(10):1151-8.
- 39.** Druce JD, Locarnini SA & Birch CJ. Syringe cleaning techniques and transmission of HIV. *AIDS*, 1995, 9(9):1105-7.
- 40.** Druce JD et al. Susceptibility of HIV to inactivation by disinfectants and ultraviolet light. *Journal of Hospital Infection*, 1995, 30(3):167-80.
- 41.** Shapshak P et al. Preliminary laboratory studies of inactivation of HIV-1 in needles and syringes containing infected blood using undiluted household bleach. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1994, 7(7):754-9.
- 42.** Flynn N et al. In vitro activity of readily available household materials against HIV-1: is bleach enough? *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1994, 7(7):747-53.
- 43.** Watters J.K et al. Household bleach as disinfectant for use by injecting drug users. *Lancet*, 1993, 342(8873):742-3.

44. Shapshak P et al. Inactivation of human immunodeficiency virus-1 at short time intervals using undiluted bleach. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1993, 6(2):218-9.
45. Gordon V et al. Assessment of chemical disinfectants against human immunodeficiency virus: overcoming the problem of cytotoxicity and the evaluation of selected actives. *Journal of Virological Methods*, 1993, 45(3):247-57.
46. Aranda-Anzaldo A, Viza D & Busnel RG. Chemical inactivation of human immunodeficiency virus in vitro. *Journal of Virological Methods*, 1992, 37(1):71-81.
47. Newmeyer J, Drew L & Miner R. HIV transmission in simulated conditions of sharing of hypodermic equipment. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1990, 3(10):1019-21.
48. Resnick L et al. Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. *Journal of the American Medical Association*, 1986, 255(14):1887-91.
49. Martin LS, McDougal JS & Loskoski SL. Disinfection and inactivation of the human T lymphotropic virus type III/Lymphadenopathy-associated virus. *Journal of Infectious Diseases*, 1985, 152(2):400-3.
50. Spire B et al. Inactivation of lymphadenopathy associated virus by chemical disinfectants. *Lancet*, 1984, 2(8408):899-901.
51. Contoreggi C et al. Effects of varying concentrations of bleach on in vitro HIV-1 replication and the relevance to injection drug use. *Intervirology*, 2000, 43(1):1-5.
52. Romanelli F, Smith KM & Pomeroy C. Reducing the transmission of HIV-1: needle bleaching as a means of disinfection. *Journal of the American Pharmaceutical Association*, 2000, 40(6):812-7.
53. Jamner MS, Corby NH & Wolitski RJ. Bleaching injection equipment: influencing factors among IDUs who share. *Substance Use & Misuse*, 1996, 31(14):1973-93.
54. Rietmeijer CA et al. Increasing the use of bleach and condoms among injecting drug users in Denver: outcomes of a targeted, community-level HIV prevention programme. *AIDS*, 1996, 10(3):291-8.
55. McCoy HV et al. Skills for HIV risk reduction: evaluation of recall and performance in injecting drug users. *Substance Use & Misuse*, 1997, 32(3):229-47.
56. Bird AG et al. Harm reduction measures and injecting inside prison versus mandatory drugs testing: results of a cross sectional anonymous questionnaire survey. The European Commission Network on HIV Infection and Hepatitis in Prison. *British Medical Journal*, 1997, 315(7099):21-4.
57. Dolan K et al. A mathematical model of HIV transmission in NSW prisons. *Drug & Alcohol Dependence*, 1998, 50:197-202.
58. Taylor A et al. Outbreak of HIV infection in a Scottish prison. *British Medical Journal*, 1995, 310(6975):289-292.
59. Ljungberg B et al. HIV prevention among injecting drug users: three years of experience from a syringe exchange programme in Sweden. *Journal of Acquired Immune Deficiency Syndromes*, 1991, 4(9):890-5.
60. Heimer R et al. Needle exchange decreases the prevalence of HIV-1 Proviral DNA in returned syringes in New Haven, Connecticut. *The American Journal of Medicine*, 1993, 95(2):214-220.
61. Des Jarlais DC et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. *Lancet*, 1996, 348(9033):987-91.
62. Hurley SF, Jolley DJ & Kaldor JM. Effectiveness of needle-exchange programmes for prevention of HIV infection. *Lancet*, 1997, 349(9068):1797-1800.
63. Monterroso ER et al. Prevention of HIV infection in street-recruited injection drug users. The Collaborative Injection Drug User Study (CIDUS). *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 2000, 25(1):63-70.
64. Health Outcomes International (HOI). *Return on investment in needle and syringe programmes in Australia*. Canberra, Commonwealth Department of Health and Ageing, 2002.

- 65.** Bruneau J et al. High rates of HIV infection among injection drug users participating in needle exchange programmes in Montreal: Results of a cohort study. *American Journal of Epidemiology*, 1997, 146:994-1002.
- 66.** Strathdee SA et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. *AIDS*, 1997, 11(8):F59-65.
- 67.** Schechter M et al. Do needle exchange programmes increase the spread of HIV among injection drug users: an investigation of the Vancouver outbreak. *AIDS*, 1999, 13(6):F45-51.
- 68.** Patrick DM et al. Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver. *International Journal of STD & AIDS*, 1997, 8:437-445.
- 69.** Hartgers C et al. The impact of the needle and syringe-exchange programme in Amsterdam on injecting risk behaviour. *AIDS*, 1989, 3(9):571-6.
- 70.** Donoghoe MC et al. Changes in HIV risk behaviour in clients of syringe-exchanges schemes in England and Scotland. *AIDS*, 1989, 3:267-272.
- 71.** Frischer M & Elliot L. Discriminating needle exchange attender from non-attenders. *Addiction*, 1993, 88:681-687.
- 72.** Keene J et al. Evaluation of syringe-exchange for HIV prevention among injecting drug users in rural and urban areas of Wales. *Addiction*, 1993, 88(8):1063-70.
- 73.** Watters JK et al. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. *Journal of the American Medical Association*, 1994, 271(2):115-20.
- 74.** Des Jarlais DC et al. Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. *Journal of the American Medical Association*, 1994, 271(2):121-7.
- 75.** Oliver KJ et al. Behavioural and community impact of the Portland syringe exchange programme. In: Normand J, Vlahov D & Moses LE eds., *Proceedings: Workshop on needle exchange and bleach distribution programmes*, Washington, DC, National Academy Press, 1994:35-46.
- 76.** Paone D et al. *New York City syringe exchange: an overview*. In: *Workshop on Needle Exchange and Bleach Distribution Programmes*. Washington, National Academy Press, 1994.
- 77.** Peak A et al. Declining risk for HIV among injecting drug users in Kathmandu, Nepal: the impact of a harm-reduction programme. *AIDS*, 1995, 9(9):1067-70.
- 78.** Guydish J et al. Evaluation of needle exchange using street-based survey methods. *Journal of Drug Issues*, 1995, 25:33-41.
- 79.** Schoenbaum EE, Hartel DM & Gourevitch MN. Needle exchange use among a cohort of injecting drug users. *AIDS*, 1996, 10:1729-1734.
- 80.** Vlahov D et al., Reductions in high-risk drug use behaviours among participants in the Baltimore needle exchange programme. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1997, 16:400-406.
- 81.** Singer M et al. Changing the environment of AIDS risk: findings on syringe exchange and pharmacy sales of syringes in Hartford, CT. *Medical Anthropology*, 1997, 18(1):107-30.
- 82.** Guydish J et al. Evaluating needle exchange: a description of client characteristics, health status, programme utilization, and HIV risk behaviour. *Substance Use & Misuse*, 1998, 33:1173-1196.
- 83.** Heimer R et al. Syringe use and reuse: effects of syringe exchange programmes in four cities. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1998, 18(Suppl. 1):S37-44.
- 84.** Gleghorn AA, Wright-De Aguero L & Flynn C. Feasibility of one-time use of sterile syringes: a study of active injection drug users in seven United States Metropolitan areas. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1998, 18(Suppl. 1):S30-6.
- 85.** Bluthenthal RN et al. Use of an illegal syringe exchange and injection-related risk behaviours among street-recruited drug users in Oakland, California, 1992 to 1995. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1998, 18(5):505-511.
- 86.** Bluthenthal RN et al. The effect of syringe exchange use on high-risk injection drug users: a cohort study. *AIDS*, 2000, 14(5):605-11.

- 87.** Cox GM et al. Syringe exchanges: a public health response to problem drug use. *Irish Medical Journal*, 2000, 93(4).
- 88.** Power R & Nozhkina N. The value of process evaluation in sustaining HIV harm reduction in the Russian Federation. *AIDS*, 2002, 16(2):303-304.
- 89.** Gibson DR & Flynn NM. *Some observations concerning the contrary evidence of syringe exchange effectiveness*. San Francisco, AIDS Research Institute, University of California, 2001.
- 90.** Gibson DR et al. Two- to six-fold decreased odds of HIV risk behaviour associated with use of syringe exchange. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, in press.
- 91.** Klee H et al. The sharing of injection equipment among drug users attending prescribing clinics and those using needle exchange. *British Journal of Addiction*, 1991, 86:217-223.
- 92.** Donoghoe MC, Dolan K, Stimdon GV. Life-style factors and social circumstances of syringe sharing in injecting drug users. *British Journal of Addiction*, 1992, 87:993-1003.
- 93.** Hartgers C et al. Needle-sharing and participation in the Amsterdam syringe exchange programme among HIV-seronegative injecting users. *Public Health Reports*, 1992, 107(6):675-81.
- 94.** van Ameijden EJC et al. Injecting risk behaviour among drug users in Amsterdam, 1986 to 1992 and its relationship to AIDS prevention programmes. *American Journal of Public Health*, 1994, 84:275-281.
- 95.** Klee H & Morris J. The role of needle exchanges in modifying sharing behaviour: cross-study comparisons 1989-1993. *Addiction*, 1995, 90:1635-1645.
- 96.** van Ameijden EJ & Coutinho RA. Maximum impact of HIV prevention measures targeted at injecting drug users. *AIDS*, 1998, 12:625-633.
- 97.** van Ameijden EJ et al. The harm reduction approach and risk factors for human immunodeficiency virus seroconversion in injecting drug users, Amsterdam. *American Journal of Epidemiology*, 1992, 136:236-243.
- 98.** Kaplan EH. Evaluating needle exchange programmes via syringe tracking and testing. *AIDS and Public Policy*, 1991, 6:109-15.
- 99.** Kaplan EH, Khoshnood K & Heimer R. A decline in HIV-infected needles returned to New Haven's needle exchange program: client shift or needle exchange? *American Journal of Public Health*, 1994, 84:1991-1994.
- 100.** Kaplan EH. & Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1995, 10:175-176.
- 101.** Van Haastrecht HJA et al. Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. *American Journal of Epidemiology*, 1996, 143:380-391.
- 102.** Lurie P & Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. *Lancet*, 1997, 349(9052):604-608.
- 103.** Bastos FI & Strathdee SA. Evaluating effectiveness of syringe exchange programmes: current issues and future prospects. *Social Science & Medicine*, 2000, 51(12):1771-82.
- 104.** Coutinho RA. Needle exchange, pragmatism, and moralism. [Letter;comment]. *American Journal of Public Health*, 2000, 90(9):1385-7.
- 105.** Strathdee SA & Vlahov D. The effectiveness of needle exchange programmes: a review of the science and policy. *AIDS Science*, 2001, 1(16).
- 106.** Lowndes CM & Alary M. [Re:] High rates of HIV infection among injection drug users participating in needle exchange programmes in Montreal: results of a cohort study [Letter]. *American Journal of Epidemiology*, 1998, 148:713-714.
- 107.** Safaeian M et al. Validity of self-reported needle exchange attendance among injection drug users: implications for programme evaluation. *American Journal of Epidemiology*, 2002, 155(2):169-75.
- 108.** Broadhead RS, van Hulst Y & Heckathorn DD. The impact of a needle exchange's closure. *Public Health Reports*, 1999, 114:439-447.

- 109.** Paone D, Des Jarlais DC & Shi Q. Syringe exchange use and HIV risk reduction over time. *AIDS*, 1998, 12(1):121-3.
- 110.** Des Jarlais DC et al. Behavioural risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. *American Journal of Public Health*, 2000, 90(7):1112-1116.
- 111.** McCoy CB et al. HIV-1 prevention: interdisciplinary studies and reviews on efficacy of bleach and compliance to bleach prevention protocols. In: *Workshop on Needle Exchange and Bleach Distribution Programmes*. Washington DC, National Academy Press, 1995.
- 112.** McCoy CB et al. HIV-1 prevention: interdisciplinary studies on the efficacy of bleach and development of prevention protocols. [Review]. *Archivum Immunologiae et Therapiae Experimentalis*, 1995a. 43(1):1-9.
- 113.** Page JB et al. Intravenous drug use and HIV infection in Miami. *Medical Anthropology*, 1990, 4:56-71.
- 114.** Samuels JS et al. The practice of "frontloading" among intravenous drug users: association with antibody. *AIDS*, 1991, 5:343-345.
- 115.** Inciardi JA et al. The risk of exposure to HIV-contaminated needles in shooting galleries. In: Inciardi & McElrath K, eds. *The American Drug Scene*, Los Angeles, Roxbury Press, 1994.
- 116.** Chitwood DD et al. Risk factors for HIV-1 seroconversion among injection drug users: a case-control study. *American Journal of Public Health*, 1995, 85(11):1538-1542.
- 117.** Nelson KE et al. Human immunodeficiency virus infection in diabetic intravenous drug users. *Journal of the American Medical Association*, 1991, 266(16):2259-2261.
- 118.** Latkin CA & Forman VL. Patterns of needle acquisition and socio-behavioural correlates of needle exchange programme attendance in Baltimore, Maryland, U.S.A. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 2001, 27(4):398-404.
- 119.** Gleghorn AA et al. Acquisition and use of needles and syringes by injecting drug users in Baltimore, Maryland. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1995, 10(1):97-103.
- 120.** van Ameijden EJ et al. Continuing injecting risk behaviour: results from the Amsterdam Cohort Study of drug users. *Addiction*, 1999, 94(7):1051-61.
- 121.** Crofts N, Aitken CK & Kaldor MJ. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. *Medical Journal of Australia*, 1999, 170:220-221.
- 122.** Coutinho RA. HIV and hepatitis C among injecting drug users: success in preventing HIV has not been mirrored for hepatitis C. *British Medical Journal*, 1998, 317(7156):424-425.
- 123.** Hagan H et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange programme. *American Journal of Public Health*, 1995, 85(11):531-7.
- 124.** Weaver H, Smith G & Kippax S. School-based sex education policies and indicators of sexual health among young people: a comparison of the Netherlands, France, Australia and the United States. *Reproductive Health Matters*, submitted for publication 2003.
- 125.** Lurie P et al. An economic analysis of needle exchange and pharmacy-based programmes to increase sterile syringe availability for injection drug users. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1998, 18(Suppl. 1):S126-132.
- 126.** Holtgrave DR et al. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1998, 18(Suppl. 1):S133-8.
- 127.** Gold M et al. Needle exchange programmes: an economic evaluation of a local experience. *Canadian Medical Association Journal*, 1997, 157(3):255-262.
- 128.** Jacobs P et al. Cost effectiveness of Streetworks' needle exchange programme of Edmonton. *Canadian Medical Association Journal*, 1999, 90(3):168-71.
- 129.** Kahn JG et al. *Updated estimates of the impact and cost of HIV prevention in injection drug*

- users. San Francisco, Centres for Disease Control, Institute for Health Policy Studies, University of California, 1992.
- 130.** Kahn J & Haynes Sanstad KC. The role of cost-effectiveness analysis in assessing HIV-prevention interventions. *AIDS & Public Policy Journal*, 1997, 12(1):21-30.
- 131.** Laufer FN. Cost-effectiveness of syringe exchange as an HIV prevention strategy. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 2001, 28(3):273-8.
- 132.** Kumaranayake L et al. *The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus: Draft*. Geneva, UNAIDS, 2000.
- 133.** Kahn JG & DeCarlo P. *Is HIV prevention a good investment?* Centre for AIDS Prevention Studies (CAPS), 1996.
- 134.** Kahn J. Economic evaluation of primary HIV prevention in injection drug users. In: Holtgrave DR, ed., *Handbook of Economic Evaluation HIV Prevention Programmes*, New York, Plenum Press, 1998.
- 135.** Wolk J et al. The effect of a needle and syringe exchange on a methadone maintenance unit. *British Journal of Addiction*, 1990, 85(11):1445-50.
- 136.** Guydish J et al. Evaluating needle exchange: are there negative effects? *AIDS*, 1993, 7:871-876.
- 137.** van Ameijden EJ & Coutinho RA. Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions. *Journal of Epidemiology & Community Health*, 2001, 55(5):356-63.
- 138.** Junge B et al. Syringe exchange not associated with social network formation: results from Baltimore. *AIDS*, 2000, 14(4):423-6.
- 139.** Oliver KJ et al. *Impact of a needle exchange programme on potentially infectious syringes in public places*. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1992, 5:534-35.
- 140.** Doherty MC et al. The effect of needle exchange programme on numbers of discarded needles: a 2-year follow-up. *American Journal of Public Health*, 2000, 90(6): p. 936-9.
- 141.** Bluthenthal RN et al. Factors associated with readiness to change drug use among needle-exchange users. *Drug & Alcohol Dependence*, 2001, 62:225-230.
- 142.** Weber U & Schneider W. Syringe exchange in Germany. [Review] [61 refs]. *Substance Use & Misuse*, 1998, 33(5):1093-112.
- 143.** Quan VM, Chung A & Abdul-Quader AS. The feasibility of a syringe-needle-exchange programme in Vietnam. *Substance Use & Misuse*, 1998, 33(5):1055-67.
- 144.** Gray J. Operating needle exchange programmes in the hills of Thailand. *AIDS Care*, 1995, 7(4):489-99.
- 145.** Vickerman P & Watts C. The impact of an HIV prevention intervention for injecting drug users in Svetlogorsk, Belarus: model predictions. *International Journal of Drug Policy*, 2002, 13:149-164.
- 146.** Vogt RL et al. Hawaii's state-wide syringe exchange program. *American Journal of Public Health*, 1998, 88(9):1403-1404.
147. Des Jarlais DC et al. Maintaining low HIV seroprevalence in populations of injecting drug users. *Journal of the American Medical Association*, 1995, 274(15):1226-31.
- 148.** Heimer R. Can syringe exchange serve as a conduit to substance abuse treatment? *Journal of Substance Abuse Treatment*, 1998, 15(3):183-91.
- 149.** Hagan H et al. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. *Journal of Substance Abuse Treatment*, 2000, 19(3):247-52.
- 150.** Gibson DR. Two- to seven-fold decreased risk associated with use of needle exchange. In: *University-wide AIDS Research Programme. University of California 3rd annual Conference on AIDS Research in California, 17th Annual AIDS Investigators' Meeting; February 25, 2000; South San Francisco*, 2000.
- 151.** Strathdee SA et al. Needle-exchange attendance and health care utilization promote entry into detoxification. *Journal of Urban Health*, 1999, 76(4):448-60.

- 152.** Dolan K, Rutter S, & Wodak AD. Prison based syringe exchange programmes: A review of international research and development. *Addiction*, 2003, 98:153-158.
- 153.** Fennema JS et al. Young and recent-onset injecting drug users are at higher risk for HIV. *Addiction*, 1997, 92(11):1457-65.
- 154.** Telles PR et al. Risk behaviour and HIV seroprevalence among injecting drug users in Rio de Janeiro, Brazil. *AIDS*, 1997, 11(Suppl. 1):S35-42.
- 155.** Sears C et al. Investigation of a secondary syringe exchange program for homeless young adult injection drug users in San Francisco, California, U.S.A. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 2001, 27(2):193-201.
- 156.** Paone D et al. HIV risk behaviours of current sex workers attending syringe exchange: the experiences of women in five US cities. *AIDS Care*, 1999, 11:269-280.
- 157.** Nelson KE et al. Changes in sexual behaviour and a decline in HIV infection among young men in Thailand. *The New England Journal of Medicine*, 1996, 335(5):297-303.
- 158.** Ungchusak K et al. First national sentinel seroprevalence survey of HIV-1 infection in Thailand, June 1989. *Thai AIDS Journal*, 1989, 1:57-74.
- 159.** Lima ES et al. Risk factors for HIV-1 seroprevalence among drug injectors in the cocaine-using environment in Rio de Janeiro. *Addiction*, 1994, 89(6):689-98.
- 160.** Jenkins C et al. Measuring the impact of needle exchange programmes among injecting drug users through the National Behavioural Surveillance in Bangladesh. *AIDS Education & Prevention*, 2001, 13(5):452-461.
- 161.** Ingold FR & Ingold S. The effects of the liberalization of syringe sales on the behaviour of intravenous drug users in France. *Bulletin on Narcotics*, 1989, 1:67-81.
- 162.** Caslyn DA et al. Needle-use practices among intravenous drug users in an area where needle purchase is legal. *AIDS*, 1991, 5:187-193.
- 163.** Hunter GM et al. Changes in the injecting risk behaviour of injecting drug users in London, 1990-1993. *AIDS*, 1995, 9(5):493-501.
- 164.** Groseclose SL et al. Impact of increased access to needles and syringes on practices of injecting-drug users and police officers—Connecticut, 1992-1993. *Journal of Acquired Immune Deficiency Syndromes*, 1995, 10:82-89.
- 165.** Obadia Y et al. Syringe vending machines for injection drug users: an experiment in Marseille, France. *American Journal of Public Health*, 1999, 89(12):1852-1854.
- 166.** Heinemann A & Gross U. Prevention of blood-borne virus infections among drug users in an open prison by syringe vending machines. *Sucht*, 2001, 47(1):57-65.
- 167.** Richard AJ, Mosier V & Atkinson JS. New syringe acquisition and multi-person use of syringes among illegal drug users. *Journal of Public Health Policy*, 2002, 23(3):324-343.
- 168.** Wong K & Lee S. Maintaining low HIV seroprevalence among injecting drug users (Letter to the Editor). *Journal of the American Medical Association*, 1996, 275(8):596.
- 169.** Stark K, Leicht A, & Muller R. Characteristics of users of syringe vending machines in Berlin. *Sozial und Praventivmedizin*, 1994, 39(4):209-216.
- 170.** De Jong W, Tsagarelli T & Schouten E. Rapid assessment of injection drug use and HIV in the Republic of Georgia. *Journal of Drug Issues*, 1999, 29(4):843-860.
- 171.** Valleroy LA et al. Impact of increased legal access to needles and syringes on community pharmacies' needle and syringe sales—Connecticut, 1992-1993. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*, 1995, 10:73-81.
- 172.** Singer M et al. Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut. *Public Health Reports*, 1998, 113(1):81-89.
- 173.** Tsai R et al. Prevention of human immunodeficiency virus infection among intravenous drug users in New South Wales, Australia: the needles

- and syringes distribution programme through retail pharmacies. *Asia-Pacific Journal of Public Health*, 1988, 2(4):245-251.
- 174.** Sheridan J et al. Role of community pharmacies in relation to HIV prevention and drug misuse: findings from the 1995 national survey in England and Wales. *British Medical Journal*, 1996, 313:272-274.
- 175.** Compton WM et al. Legal needle buying in St. Louis. *American Journal of Public Health*, 1992, 82:595-596.
- 176.** Glanz A, Byrne C, & Jackson P. Role of community pharmacies in prevention of AIDS among injecting drug misusers: findings of a survey in England and Wales. *British Medical Journal*, 1989, 299:1076-79.
- 177.** Case P, Beckett GA, & Jones TS. Access to sterile syringes in Maine: pharmacy practice after the 1993 repeal of the syringe prescription law. *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*, 1998, 18(Suppl. 1):94-101.
- 178.** Farley TA et al. Attitudes and practices of pharmacy managers regarding needle sales to injection drug users. *Journal of the American Pharmaceutical Association*, 1999, 39(9):23-26.
- 179.** Coffin P. Syringe availability as HIV prevention: a review of modalities. (Review) (130 refs). *Journal of Urban Health - Bulletin of the New York Academy of Medicine*, 2000, 77(3):306-30.
- 180.** Friedman SR, Perlis T & Des Jarlais DC. Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence. *American Journal of Public Health*, 2001, 92(5):791-793.
- 181.** Burris S, Lurie P & Ng M. Harm reduction in the healthcare system: the legality of prescribing and dispensing syringes to drug users. *Health Matrix*, 2001, 11(1):5-64.
- 182.** Kochems LM et al. The transition from underground to legal syringe exchange: the New York City experience. *AIDS Education and Prevention*, 1996, 8(6):471-89.
- 183.** Heimer R et al. Three years of needle exchange in New Haven: what have we learned? *AIDS & Public Policy Journal*, 1994, 9(2):59-74.
- 184.** Burris S et al. The Legality of Selling or Giving Syringes to Injection Drug Users. *Journal of the American Pharmaceutical Association*, 2002, 42(6, Suppl. 2):S13-S18.
- 185.** Sarkar S, Mookerjee P & Roy AE. Descriptive epidemiology of intravenous heroin users: a new risk group for transmission of HIV in India. *Journal of Infectious Diseases*, 1991, 23:201-207.
- 186.** Ismail R. HIV/AIDS in Malaysia. *AIDS*, 1998, 12:S1-S10.
- 187.** General Accounting Office. *Needle Exchange Programs: Research Suggests Promise as an AIDS Prevention Strategy*. Washington DC, United States Government Printing Office, 1993.
- 188.** National Commission on AIDS. *The Twin Epidemics of Substance Use and HIV*. HIV, Washington DC, 1991.
- 189.** Lurie P & Reingold AL, eds. *The public health impact of needle exchange programs in the United States and abroad*, Vol. 1. Atlanta, Centers for Disease Control and Prevention, 1993.
- 190.** Office of Technology Assessment of the US Congress. *The Effectiveness of AIDS Prevention Efforts*. Washington DC, US Government Printing Office, 1995.
- 191.** National Institutes of Health Consensus Panel. *Interventions to prevent HIV risk behaviours*. Bethesda, National Institutes Health, 1997.
- 192.** Satcher D, Surgeon General. *Evidence-based findings on the efficacy of syringe exchange programs: an analysis of the scientific research completed since April 1998*. Washington, DC, United States Department of Health & Human Sciences, 2000.
- 193.** Institute of Medicine of the National Academy of Science. *No Time to Lose: Getting More from HIV Prevention*. Washington DC, National Academies Press, 2001.
- 194.** Paone D et al. Syringe-exchange programs in the United States: where are we now? *AIDS & Public Policy Journal*, 1996, 11(3):144-7.
- 195.** Paone D et al. Syringe Exchange in the United States, 1996: A National Profile. *American Journal of Public Health*, 1999, 89(1):43-46.

-
- 196.** Frischer M et al. Do needle exchanges help to control the spread of HIV among injecting drug users? *AIDS*, 1993, 7:1677-1678.
- 197.** Toews DW. A community-wide needle/syringe disposal program. *American Journal of Public Health*, 1995, 85(10):1447-8.
- 198.** Zamora AB et al. Detection of infectious human immunodeficiency type 1 virus in discarded syringes of intravenous drug users. *Pediatric Infectious Disease Journal*, 1998, 17:655-657.
- 199.** Springer KW et al. Syringe disposal options for injection drug users: a community-based perspective. *Substance Use & Misuse*, 1999, 34(13):1917-34.
- 200.** Riley E et al. Operation Red Box: A pilot project of needle and syringe drop boxes for injection drug users in East Baltimore. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1998, 18(Suppl. 1):S120-125.
- 201.** Macalino GE et al. Community-based programmes for safe disposal of user needles and syringe. *Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology*, 1998, 18(Suppl. 1):S111-119.

GLOSSARY*

BACKLOADING	Transferring the drug from one syringe to another by removing the plunger from the receiving syringes.
BOOTING	Booting is the practice performed after registering and administering the drug solution. In this process, with the needle still in the vein, the injector draws back on the plunger of the syringe to fill the barrel with blood and then re-injects the blood, sometimes repeating this practice several times. More commonly reported with cocaine than with heroin injection, this practice allegedly enhances the euphoria associated with the drug's effects.
FRONTLOADING	The parcelling out of individual portions from a mixer/distributor's syringe to the other participants' syringes by removing the needles from the receiving syringes.
RCT	Randomized Controlled Trial
REGISTERING	Registering means that once a needle is inserted, the drug user will draw back the plunger of the syringe to examine for the presence of blood to ensure that the needle has been properly placed into the vein.
SHOOTING GALLERY	A clandestine location where injecting drug users go to rent needles and syringes. Since used syringes are returned to a common container to be rented again, this process amounts to anonymous sharing of needles and syringes.

* *Definitions from Normand et al. (1995)⁶⁹*



ORIGINAL CONTRIBUTIONS

High Rates of HIV Infection among Injection Drug Users Participating in Needle Exchange Programs in Montreal: Results of a Cohort Study

Julie Bruneau,¹ François Lamothe,² Eduardo Franco,³ Nathalie Lachance,² Marie Désy,⁴ Julio Soto,⁵ and Jean Vincelette²

Needle exchange programs (NEPs) are designed to prevent human immunodeficiency virus (HIV) transmission among injection drug users. Although most studies report beneficial effects in terms of behavior modification, a direct assessment of the effectiveness of NEPs in preventing HIV infection has been lacking. A cohort study was conducted to assess the association between risk behaviors and HIV seroprevalence and seroincidence among injection drug users in Montreal, Canada. The association between NEP use and HIV infection was examined in three risk assessment scenarios using intensive covariate adjustment for empirical confounders: a cross-sectional analysis of NEP use at entry as a determinant of seroprevalence, a cohort analysis of NEP use at entry as a predictor of subsequent seroconversion, and a nested case-control analysis of NEP participation during follow-up as a predictor of seroconversion. From September 1988 to January 1995, 1,599 subjects were enrolled with a baseline seroprevalence of 10.7%. The mean follow-up period was 21.7 months. The adjusted odds ratio for HIV seroprevalence in injection drug users reporting recent NEP use was 2.2 (95% confidence interval 1.5–3.2). In the cohort study, there were 89 incident cases of HIV infection with a cumulative probability of HIV seroconversion of 33% for NEP users and 13% for nonusers ($p < 0.0001$). In the nested case-control study, consistent NEP use was associated with HIV seroconversion during follow-up (odds ratio = 10.5, 95% confidence interval 2.7–41.0). Risk elevations for HIV infection associated with NEP attendance were substantial and consistent in all three risk assessment scenarios in our cohort of injection drug users, despite extensive adjustment for confounders. In summary, in Montreal, NEP users appear to have higher seroconversion rates than NEP nonusers. *Am J Epidemiol* 1997;146:994–1002.

cohort studies; HIV; needle exchange programs; substance abuse; substance abuse, intravenous

Injection drug use is now recognized as one of the major routes for transmission of HIV infection. For the past 15 years, several strategies have been developed to reduce HIV transmission among drug users, and needle exchange programs (NEPs) have constituted one of the most favored (1). These programs aim at increasing accessibility to sterile needles and syringes and removing circulating contaminated injecting material (2).

There are many difficulties and pitfalls in trying to assess the effectiveness of NEPs in reducing HIV transmission. Accessibility to the injecting drug user

(IDU) population is difficult because of legal barriers surrounding drug use. Random assignment of participants to interventions can rarely be achieved, introducing potential for selection bias in subsequent program evaluations. NEPs are often initiated in the community along with other intervention measures, causing difficulties in the interpretation of the specific effects for each component of the entire intervention program. Such considerations have been recently and extensively reviewed by a panel of experts (3).

The first studies on NEPs were conducted in Europe, mostly among heroin users, and they showed

Received for publication December 18, 1995, and accepted for publication January 2, 1997.

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; IDU, injection drug user; NEP, needle exchange program; OR, odds ratio.

¹ Department of Psychiatry, University of Montreal, Montreal, Quebec, Canada.

² Department of Microbiology and Immunology, University of Montreal, Montreal, Quebec, Canada.

³ Department of Oncology, McGill University, Montreal, Quebec, Canada.

⁴ Epidemiology and Biostatistics Unit, Armand-Frappier Institute, Laval, Quebec, Canada.

⁵ Laval Public Health Unit, Laval, Quebec, Canada.

Reprint requests to Dr. Julie Bruneau, Pavillon Saint-Luc, Centre Hospitalier de l'Université de Montréal, 1058 Saint-Denis Street, Montréal, QC, Canada H2X 3J4.

encouraging results. In London, England, and Glasgow, Scotland, a significant reduction in injecting behaviors was observed among recent NEP attenders (4–6). In the United Kingdom, a prospective survey between 1987 and 1988 reported higher levels of risk behaviors among nonattenders and a decrease in syringe sharing from 34 to 27 percent among attenders (7). In Australia, there was no increase of intravenous drug use due to the implementation of a NEP among clients of a methadone maintenance unit (8).

In North America, several studies have been conducted in recent years. In Hartford, Connecticut, and in New York City, NEP attenders reported decreased equipment sharing (9, 10). In Tacoma, Washington, in a case-control study among IDUs entering a methadone program, the nonuse of the NEP was associated with a significant risk for hepatitis B and hepatitis C (11, 12). A 4-year study evaluating the impact of NEPs among IDUs admitted for treatment in San Francisco, California, detected no negative consequences (13).

As stated earlier, changes in the rate of HIV infection among NEP attenders have been difficult to monitor. In Sweden, a small NEP was found useful in maintaining a low HIV seroprevalence among heroin and amphetamine IDUs (14). In the NEP of Portland, Oregon, one HIV seroconversion was observed in 162 person-years at risk (15). Kaplan and Heimer (16) used an innovative, albeit indirect, method of assessing HIV transmission by testing the returned syringes; and they estimated that incidence had declined among IDUs attending a NEP in New Haven, Connecticut. In Amsterdam, the Netherlands, where a large NEP was established in 1984, HIV seroprevalence remained at approximately 30 percent; and the seroconversion rate decreased from 9.2 percent in 1986 to 2.5 percent per year in 1992 (17). This decrease in incidence could not be directly attributed to the impact of the NEP. In two recent reviews by individuals commissioned to study the impact of NEP (1, 3), the authors concluded that such programs are generally useful in halting the progression of HIV infection in IDUs.

In Canada, implementation of NEPs started in 1989—almost simultaneously in Vancouver, Toronto, and Montreal. In 1988, our group began to accrue subjects in a cohort investigation of active IDUs in downtown Montreal. This cohort is an observational study and was not designed to study or evaluate NEPs. However, preliminary results on risk factors as predictors for HIV seroconversion among IDUs recruited in this cohort indicated a significant independent association between HIV seroconversion and the following variables: street recruitment, previous imprisonment, cocaine as drug of choice, number of injections in the last month, having two or more sharing partners in the

last month, sharing with an HIV-seropositive partner, having HIV-seropositive acquaintances, and finally, having attended a NEP at least once in the last 6 months (18). Because of the potential consequences of these findings on policies and prevention of HIV among IDUs, we present herein an extensive analysis of the association between NEP use and baseline HIV seroprevalence and cumulative seroincidence in our cohort.

MATERIALS AND METHODS

Subjects

Cohort members were actively recruited from three main sources. The Detoxification Unit of Saint-Luc Hospital in downtown Montreal contributed 33 percent of the recruitment, and referral from collaborating institutions catering to the needs of IDUs in the city such as shelters, private and public readaptation centers, therapeutic communities, and community-based agencies including city street workers contributed 5 percent of the cohort. With IDU groups gradually becoming aware of our ongoing investigation, direct self-referral became more and more important with 62 percent of the total recruitment. A \$10 fee (in Canadian dollars) was given at each visit as an incentive to participate in the study. Recruitment is ongoing and has been stable, with a mean of 23 new subjects enrolled each month.

IDUs were eligible if they had injected drugs within the last 6 months. After providing an informed consent at admission, subjects underwent a structured, questionnaire-based interview to elicit detailed information on sociodemographic characteristics, knowledge and attitudes concerning HIV infection, drug use, and sexual behavior. A follow-up questionnaire probed for similar information during all subsequent returns. All interviews were conducted by trained nurses with extensive experience with drug users. The first follow-up return was scheduled at 3 months and subsequent visits, every 6 months thereafter. A venous blood sample was drawn at each visit for serologic testing. Presence of anti-HIV antibodies was detected with a commercial enzyme-linked immunoassay (BioChem ImmunoSystems Inc., Montreal, Canada) and confirmed at the Quebec Provincial Public Health Laboratory by Western blot or radioimmunoprecipitation assay.

Of the 1,599 subjects enrolled from September 1988 to January 1995, 171 were seropositive at enrollment, for a seroprevalence rate of 10.7 percent. Subjects included in the cohort are those who have been followed up at least once after their initial visit. Among the initially seronegative subjects, 377 (26.4 percent)

were lost to follow-up. The present cohort analysis includes 974 HIV-negative subjects after elimination of 77 enrolled after October 1994 to ensure that all participants had been followed for at least 3 months. The mean follow-up period was 21.7 months, with a median of 15.4 months and intervals ranging from 3 months to 5 years, and with each subject contributing follow-up information since the date of entry until the date of a positive HIV serology for seroconverters or until the date of the last visit for those remaining seronegative.

Regression analyses

Three risk assessment scenarios were used to study the association between NEP use and HIV infection. In the first scenario, as subjects were enrolled into the cohort, their initial serologic status was ascertained along with baseline questionnaire information on risk factors. NEP use in the entry questionnaire is a dichotomous variable, and the subject was asked whether he or she had attended a NEP to get his/her equipment in the past 6 months or in the past 3 months in the case of the follow-up questionnaire. This scenario is akin to a cross-sectional study of NEP use at entry as a marker associated with baseline HIV seroprevalence, and it also allowed a comparison of NEP attenders with nonattenders.

After eliminating those who were seropositive at entry, a cohort of seronegative individuals was assembled for continued surveillance. In this second scenario, NEP use reported in the entry questionnaire was treated as a possible predictor of subsequent seroconversion during follow-up.

In the third scenario, NEP participation during follow-up at the time of seroconversion was examined as a predictor of seroconversion in the cohort. A nested case-control design was used, whereby seroconverters were considered cases and up to four matched controls were randomly chosen from among those of the same gender, age (5-year groups), language (French vs. other), and year of enrollment who remained seronegative at the time their index case seroconverted. Information on NEP use was obtained from the interview at the time of the first visit, when the subject tested seropositive for cases, and from the last follow-up interview, for controls.

The odds ratio (OR), computed in unconditional logistic regression models, measured the magnitude of the association between NEP use at entry and HIV seroprevalence (first scenario) (19, 20). The hazard ratio, computed in Cox's proportional hazards regression models, was the estimate of effect for NEP use in all cohort analyses (second scenario) (21, 22). For the nested case-control analyses, due to the matched na-

ture of the data, conditional logistic regression models were computed to derive ORs for the association between NEP use and HIV risk (third scenario) (19, 20).

Adjustment for confounders

A major concern in the assessment of a statistical association between NEP participation and risk of HIV seropositivity is the potential existence of confounders related to drug utilization and sexual practices. Confounders were identified empirically, i.e., by comparing the magnitude of the association between NEP use and HIV risk in regression models containing NEP use adjusted for the covariate of interest with that observed in crude models where NEP was the sole variable. The ratio between the adjusted and the crude estimates gauged the magnitude of the confounding effect for a given variable. An empirical confounder was considered any variable whose model produced an adjusted estimate for NEP that was either higher or lower than the crude estimate for NEP by at least two specified thresholds, 10 percent and 4 percent. Multivariate models of increasing complexity were computed by adding the confounders selected at the 10 percent level followed by those at the 4 percent level, corresponding respectively to models 2 and 3 in tables 2-5. In all analyses, covariate data were always derived from the same interview eliciting information on NEP use.

RESULTS

Seroprevalence analysis

Most subjects recruited in the study were male ($n = 1,274$, 79.7 percent). The mean age at entry was 32.2 years (median 32 years). Women were slightly younger (28.9 vs. 33 years) with half of them (162 of 325) reporting involvement in prostitution. Most participants reported consumption of multiple drugs lasting an average of 9.1 years, with cocaine the drug of choice for 64.2 percent of them; 82 percent reported having injected drugs in the previous month. Seven hundred sixty-seven (48 percent) IDUs reported NEP attendance at entry.

In table 1, the differences between NEP attenders and nonattenders are outlined, and NEP attenders are defined as those who reported having obtained their clean equipment at least once in a NEP in the 6 months before enrollment in the study. Prevalences of HIV and hepatitis B markers were significantly higher among NEP attenders; they were younger, had a lower income, and had been in treatment for addiction less frequently. They reported homo- or bisexual orientation and involvement in prostitution activities more frequently. In general, NEP attenders reported higher frequencies of risk behaviors related to drug injection.

TABLE 1. Characteristics of subjects according to their needle exchange program (NEP) attendance at study entry among intravenous drug users in Montreal, Quebec, Canada, 1988-1995*

Variables	NEP attenders (n = 767) (48%)	NEP non-attenders (n = 832) (53%)	P value†
HIV‡ seropositive	16	5.8	<0.001
anti-HBC‡ positivity	59	45.7	<0.001
Gender			
Male	81	78.5	0.22
Female	19	21.5	
Age (years)			
≤25	21.8	14.5	0.002
26-30	23	26.8	
31-35	25.8	27.8	
≥36	29.5	30.9	
Income (Canadian dollars)			
<10,000	38.7	32.4	0.003
10-24,999	32.5	30.3	
25-49,999	15.5	21.8	
≥50,000	13.4	15.5	
Homo-/bisexual reported orientation	11.1	7.5	0.01
Have ever engaged in prostitution activity	26.6	19	<0.001
Cocaine as drug of choice (vs. other)	65.4	63.2	0.6
Presently in treatment for addiction	37.4	61.3	<0.001
No. of injections previous month			
0	13.3	22.1	<0.001
1-29	24.1	28.5	
30-100	34.2	26.1	
>100	28.4	23.3	
Borrowed IV‡ equipment in the last 6 months	78.2	72.1	0.005
Disinfected IV equipment with "javel" last 6 months	57.4	25.7	<0.001
Used IV drugs in shooting galleries last 6 months	22.9	12.7	<0.001
Practiced booting in the last 6 months	25.7	18.8	<0.001
No. with three or more HIV-positive acquaintances	30.4	16.9	<0.001
Shared IV equipment with HIV-positive partner	14.7	6.9	<0.001

* All data shown are percentages.

† Significance from chi-square test.

‡ HIV, human immunodeficiency virus; HBC, hepatitis B core antigen; IV, intravenous.

There were no significant differences between the two groups for language, living status (alone vs. with other people), schooling, number of recent sexual partners, drug of choice, drug use in prison, and number of recent intravenous users from whom they had borrowed syringes. Borrowing was defined as either borrowing a used syringe from another person or using a used syringe from an unknown origin. Borrowing

from an HIV-seropositive person is based on the reported HIV status of the lender.

In table 2, the association between NEP participation and seropositivity at entry for all subjects and for males only, with additional stratification for sexual orientation, is shown. All minimally adjusted ORs (controlling for age, entry period, gender, and language, taken as a priori confounders) indicate moderate but significant higher risks associated with NEP use that were of comparable magnitude across all sexual strata. The additional and incremental two-step adjustment for empirical confounders (10 percent threshold for OR2 and 4 percent threshold for OR3 as described in Methods) reduced the magnitude of the associations but still revealed consistent risk elevations in all subsets.

Incidence analysis

Seronegative subjects included in the cohort study ($n = 974$) were different from those lost to follow-up ($n = 377$) on the following parameters: the proportion of male subjects (81 vs. 74 percent) and francophones (80 vs. 72 percent), declaring a lower income (11.5 vs. 21 percent), cocaine as drug of choice (64 vs. 57 percent), sharing in the last 6 months (78 vs. 68 percent), having more than two sharing partners in the last month (23 vs. 17 percent), and getting syringes and needles at the drug dealer (57 vs. 33 percent). Subjects lost to follow-up more often reported sharing with an HIV-positive partner (11 vs. 7 percent). There were no differences for the following variables: mean age, prostitution, getting syringes and needles from pharmacies, injecting in shooting galleries, and attending a NEP.

With 89 incident cases of HIV seroconversion during follow-up, overall incidence was 5.1 per 100 person-years (95 percent confidence interval (CI) 4.1-6.2). Incidence was 7.9 per 100 person-years (95 percent CI 6.0-10.2) among NEP attenders and 3.1 per 100 person-years (95 percent CI 2.1-4.4) among non-attenders. The cumulative probability of HIV seroconversion during follow-up according to NEP participation can be seen in figure 1. The difference between the two curves is highly significant ($p < 0.0001$, log rank test). In table 3, it can be seen that although the nearly threefold elevation in risk associated with NEP use at entry is considerably reduced upon adjustment by empirical confounders, hazard ratios remain significantly greater than unity for all subjects and for males only, indicating that NEP use during the 6 months before entry is a predictor for HIV seroconversion during follow-up in the cohort.

TABLE 2. Odds ratios (ORs) and 95% confidence intervals (CIs) of human immunodeficiency virus (HIV) seropositivity among injection drug users at enrollment associated with participation in needle exchange program within the last 6 months in Montreal, Quebec, Canada, 1988–1995

Subjects Included In the analysis	No.	OR1*	95% CI	OR2†	95% CI	OR3‡	95% CI
All subjects	1,599	3.1	2.2–4.5	2.3	1.6–3.4	2.2	1.5–3.2
Heterosexuals	1,147	2.9	1.8–4.6	2.3	1.4–3.7	2.1	1.3–3.5
Homosexuals and prostitutes	447	2.7	1.5–4.8	2.0	1.1–3.7	1.9	1.0–3.6
All male subjects	1,274	3.6	2.4–5.3	2.7	1.8–4.1	2.5	1.6–3.8
Heterosexuals	1,000	3.3	2.0–5.4	2.6	1.5–4.3	2.4	1.4–4.1
Homosexuals and prostitutes	270	3.0	1.5–6.1	2.4	1.1–5.2	2.4	1.0–5.4

* Adjusted for age, entry period, gender (for all subjects only), and language.

† Adjusted for variables above and additionally for number of acquaintances known to be HIV positive, treatment for addiction, and other sources of intravenous (IV) equipment (pharmacy, shooting gallery, dealer) in the last 6 months.

‡ Adjusted for all of the above and additionally for number of times IV drugs were used in previous month, number of times new IV equipment was used in previous month, sharing IV equipment with an HIV-positive person, living status, and drug of choice.




FIGURE 1. Cumulative human immunodeficiency virus seroconversion among needle exchange program (NEP*) participants and nonparticipants in the Montreal Saint-Luc cohort, Canada, between 1988 and 1995.

Nested case-control analysis

In table 4, the results of the nested case-control analysis can be seen, with 88 seroconversion cases and their 320 matched controls (one case that had no controls fulfilling the matching criteria was excluded) based on use of the questionnaire at the time of seroconversion. In the nested case-control analysis, participation was further categorized as exclusive or nonexclusive, depending on whether subjects also obtained their intravenous equipment from sources other than the NEP, e.g., pharmacies, dealers, friends, and in shooting galleries. There were substantial risk eleva-

tions among NEP users, both exclusive and nonexclusive, that persisted after adjustment for confounders, for all subjects, and for males only.

We also investigated whether consistency of NEP attendance influenced risk of HIV seroconversion in the cohort using the information on NEP attendance from baseline and follow-up interviews. Consistent attenders were defined as those who reported some NEP attendance at all visits, whereas those with no reported NEP attendance in any of the interviews were considered nonattenders. Those reporting intermittent NEP attendance were subdivided according to the proportion of interviews with reported NEP attendance. Consistent attenders, when compared with nonattenders and intermittent attenders at baseline, were more likely to identify cocaine as their drug of choice (84.6 percent), had injected more often in the last month (76 percent with 30 injections or more), had more sharing partners in the last month, reported more booting in the last 6 months, and reported getting their equipment less often at shooting galleries. However, they had used brand new equipment more often in the previous month and had disinfected their equipment more often in the last 6 months. As shown in table 5, there was a clear tendency for risks of seroconversion to increase with frequency of NEP use over time. Upon adjustment for confounders, significant elevations remained only among self-reported consistent users for all subjects and for males only.

In searching for interaction effects between NEP attendance and other variables, period of admission into the cohort was found to yield a marginally significant interaction with NEP ($p = 0.06$). The association between HIV seroconversion and NEP attendance appears to have decreased in magnitude for those recently admitted into the cohort. After stratifying the cohort by entry periods, the following crude hazard ratios for NEP attendance were found: Septem-

TABLE 3. Hazard ratios (HRs) and 95% confidence intervals (CIs) of becoming seropositive to the human immunodeficiency virus during follow-up associated with participation in a needle exchange program within the last 6 months at entry in a cohort of injection drug users in Montreal, Quebec, Canada, 1988–1995*

Subjects included in the analysis	No.	HR1†	95% CI	HR2‡	95% CI	HR3§	95% CI
All subjects	974	2.6	1.7–4.0	1.8	1.1–2.9	1.7	1.0–2.7
Males only	787	3.1	1.9–5.0	2.1	1.3–3.5	1.9	1.1–3.3

* Results by Cox proportional hazards regression.

† Adjusted for age, entry period, gender (for all subjects only), and language.

‡ Adjusted for variables above and additionally for drug use during occasional encounters in last 6 months, ever having borrowed intravenous (IV) equipment from an HIV-positive person, treatment for addiction, and other sources of IV equipment (pharmacy, shooting gallery, dealer) in the last 6 months.

§ Adjusted for all of the above and additionally for drug of choice, number of times IV drugs were used in previous month, drugs used with regular partners in last 6 months, drug used at dealer's in previous month, number of times new IV equipment was used in previous month, number of acquaintances known to be HIV positive, living status, and practice of disinfection.

TABLE 4. Odds ratios (ORs) and 95% confidence intervals (CIs) of becoming seropositive to the human immunodeficiency virus during follow-up in a cohort of injection drug users between 1988 and 1995, associated with participation in a needle exchange program 3 months before the last visit*

Needle exchange program use	No.	OR1†	95% CI	OR2‡	95% CI	OR3§	95% CI
All subjects	408						
Nonusers	273	1.0	Referent	1.0	Referent	1.0	Referent
Users, nonexclusive	104	6.8	3.9–12.1	3.3	1.6–6.7	4.2	1.6–11.0
Users, exclusive	31	7.8	3.1–19.2	4.2	1.5–11.5	6.5	1.8–23.8
Males only	367						
Nonusers	240	1.0	Referent	1.0	Referent	1.0	Referent
Users, nonexclusive	96	6.1	3.4–11.1	3.5	1.6–7.5	4.2	1.5–12.2
Users, exclusive	31	7.2	2.9–17.9	4.3	1.5–12.1	10.0	2.3–43.9

* Results from the nested case-control analysis by conditional logistic regression.

† From analysis conditioned on age, gender, year of admission, and language.

‡ Adjusted additionally for intravenous (IV) drug use since last visit, number of times IV drugs were used in previous month, borrowed IV equipment since last visit, number of times new IV equipment was used in previous month, and practice of disinfection.

§ Adjusted for variables above and additionally for drug of choice, drug use alone in last 3 months, drug use with regular partners in last 3 months, drug use during occasional encounters in last 3 months, drug use with friends in last 3 months, number of partners from whom IV equipment was borrowed in last month, borrowed IV equipment from an HIV-positive person since last visit, number of acquaintances known to be HIV positive, practiced booting in last 3 months, drug use while in prison, and living status.

ber 1988 through September 1991, 2.73 (95 percent CI 1.6–4.6); January 1991 through December 1993, 3.7 (95 percent CI 1.2–11.1); January 1994 through January 1995, 0.7 (95 percent CI 0.16–2.8).

DISCUSSION

As shown by the seroprevalence data at entry into the cohort, the Montreal NEP appears to have attracted subpopulations of IDUs with a higher baseline rate of HIV and hepatitis B infections. Consistent NEP attenders also have a higher profile of high risk behaviors than other IDUs.

In spite of these differences among NEP attenders and nonattenders, a positive association between NEP attendance and risk of HIV infection emerged consistently in the three risk assessment scenarios of this study. Recent NEP attendance, a single exposure vari-

able, was a strong predictor of the risk of seroconversion during follow-up among those initially seronegative. In addition, NEP attendance during follow-up was also predictive of seroconversion. Most of the excess risk appeared to be experienced by those reporting consistent and exclusive attendance at NEPs, which was their primary source of new intravenous equipment.

We hypothesized initially that the direction of this association represented simply the net confounding effect by behavioral characteristics biasing the NEP use-risk association toward an effect that would be opposite from the expected protective one. Interviews conducted at entry and on multiple opportunities during follow-up elicited detailed information on numerous potential confounders. These variables were identified empirically by comparing crude and adjusted

TABLE 5. Odds ratios (ORs) of becoming seropositive to the human immunodeficiency virus during follow-up among injection drug users associated with overall history of participation in a needle exchange program in Montreal, Quebec, Canada, 1988–1995*

Needle exchange program	No.	OR1†	95% CI	OR2‡	95% CI	OR3§	95% CI
All subjects	408						
Nonusers	129	1.0	Referent	1.0	Referent	1.0	Referent
Users <50% of time	110	1.3	0.5–3.2	0.9	0.3–2.7	0.7	0.7–2.5
Users ≥50% of time	104	3.9	1.7–8.7	2.6	1.0–6.7	2.2	0.6–5.7
Consistent users	65	22.9	8.4–62.3	10.2	3.3–31.5	13.1	2.7–41.0
Males only	367						
Nonusers	116	1.0	Referent	1.0	Referent	1.0	Referent
Users <50% of time	95	1.4	0.5–3.8	0.9	0.3–2.8	0.7	0.2–2.8
Users ≥50% of time	93	4.0	1.7–9.6	2.7	1.0–7.4	2.9	0.6–6.5
Consistent users	63	21.8	7.7–61.5	10.2	3.1–33.1	19.1	2.6–50.1

* Results from the nested case-control analysis by conditional logistic regression.

† From analysis conditioned on age, gender, year of admission, and language.

‡ Adjusted for intravenous (IV) drug use since last visit, number of times IV drugs were used in previous month, borrowed IV equipment since last visit, number of times new IV equipment was used in previous month, and practice of disinfection.

§ Adjusted for variables above and additionally for drug of choice, drug use alone in last 3 months, drug use with regular partners in last 3 months, drug use during occasional encounters in last 3 months, drug use with friends in last 3 months, number of partners from whom IV equipment was borrowed in last month, borrowed IV equipment from HIV-positive person since last visit, number of acquaintances known to be HIV positive, practiced booting in last 3 months, drug use while in prison, and living status.

estimates of effect for the NEP-risk association. All plausible sociodemographic, behavioral, and drug consumption variables available were examined as potential confounders.

Because of the low threshold for selecting empirical confounders, the regression models included an extensive list of covariates. This may have decreased the precision of the estimates of effect for NEP attendance, further adding an element of conservatism to our strategy. The fact that the association between NEP attendance and HIV infection risk persisted after being scrutinized with such a conservative analytical approach bolsters our conclusion that it is internally valid and merits further attention.

Before we address the possible implications of our study, it is important to consider its limitations. Our study is observational and was not specifically designed to evaluate the efficacy of NEP in preventing HIV infection. We cannot generalize its findings to other IDU populations in Montreal or elsewhere because of the type of recruitment and of the differences between participants and those lost to follow-up. It is also possible that despite the exhaustive data-driven process to identify confounders, some had been left unaccounted for in the analysis because they were absent from the list of variables derived from the interviews. However, this is unlikely, at least for individual variables, because our questionnaires probed repeatedly for detailed information on risk behaviors and other HIV determinants. Any irrelevant variable with respect to HIV risk that could be linked to NEP attendance would be unlikely to confound the associ-

ation because confounding ensues only if a factor is associated with the outcome as well as with the exposure.

Misclassification bias could explain our results if we assume that at least one of the following conditions occurred: 1) HIV-positive attenders falsely reported NEP participation, or 2) HIV-negative NEP attenders underreported participation. These are unlikely to have occurred, however, because subjects were unaware of their serologic status before the follow-up interviews.

Substantial misclassification of confounder variables would also lead to a decreased ability to control for their effects in the regression analysis. The extent of the impact of such a misclassification is difficult to predict.

Apart from the statistical issues described above, what are the possible explanations for our results? In our cohort, subject recruitment has relied mostly on self-selection based on informal word-of-mouth advertisement about the existence of our investigation. One possibility is that this method may have led to oversampling of high risk (HIV infection-prone) individuals among NEP attenders in the cohort, affecting the external validity of our study. Even if subjects lost to follow-up did not differ on NEP attendance, differential attrition might have occurred. However, it is reassuring that an independent study among IDUs recruited at CACTUS-Montreal has found seroprevalence and seroincidence rates comparable with those in our study despite use of a different methodology (23).

Differences in baseline prevalence between groups of IDUs have already been pointed out as a predictor for seroconversion in a study of HIV incidence in different cities of the United States (24). This study may have targeted a subpopulation of IDUs attending NEP who are at particularly high risk for the propagation of HIV.

NEPs are often developed within a global organization of prevention and care for drug users. In Montreal, NEPs have been implemented in an environment where needles and syringes are readily available through pharmacies and where policies encouraging pharmacists to sell intravenous equipment to IDUs were introduced in 1988, a year before the first NEP (25). Among opiate users from Manchester in the United Kingdom, the access to sterile equipment through local pharmacies was thought to have reduced the effects of a NEP on sharing habits (26).

It is also conceivable that through a combination of factors, the dynamics in Montreal might have favored HIV acquisition among NEP attenders. NEPs were developed as multifaceted prevention programs offering additional services such as primary health care, support, and counseling. To achieve these goals, the exchange of needles and syringes in the various programs was deliberately limited in an effort to encourage multiple visits and binding to the program. CACTUS, the largest NEP in Montreal, has a needle and syringe exchange policy based on a ratio of one for one, with a maximum of 15 syringes exchanged per person per night. In view of the high risk population attending NEPs, the number of needles distributed may have been less than the actual number needed. Because of availability of clean equipment through pharmacies, which are often conveniently located in the neighborhood, NEPs might have attracted existing core groups of marginalized, high risk individuals. More importantly, NEP implementation, through new socialization among IDUs, also may have facilitated formation of new sharing networks, with the programs becoming gathering places for isolated IDUs. Nonuniform needle sharing among core group members of NEP attenders also may have contributed to the risk differentials seen in our study. The trends toward a decrease of the association over time in our study might be related to changes in the social dynamics around NEPs as well as to long-term effects of such programs.

In view of the higher baseline prevalence for NEP attenders, the risk of HIV acquisition per sharing episode with another NEP attender may be higher than for nonattenders. With a greater incidence around NEPs, sharing during the seroconversion phase may contribute further to HIV transmissibility because of

the high viral load in the donor blood during that period (27–29). The predominance of closely related and possibly more infectious HIV strains among NEP attenders is also another hypothesis to consider (30).

In summary, Montreal NEP users appear to have higher HIV seroconversion rates than NEP nonusers. This study also indicates that at least in Montreal, HIV infection is associated with NEP attendance. These findings cannot be explained solely on the basis of the concentration around NEPs of a higher risk IDU population with a greater baseline HIV prevalence. Since NEPs have been viewed as a credible preventive intervention for drug users who continue to inject (1, 2), we believe that caution is warranted before accepting NEPs as uniformly beneficial in any setting. Our investigation was not designed to address a possible causal relation between NEP attendance and HIV infection; its conclusions were derived purely from an observational rather than an experimental study design. NEP implementation involves complex dynamics of individual and collective behaviors that may have different and possibly deleterious effects on HIV transmission. The impact of NEPs may be much more context sensitive and locally dependent than previously realized. It is also possible that the apparent impact of a NEP might diminish over time (31). In Amsterdam, a comparison of the injecting behavior of drug users who seroconverted for HIV with a control group that did not seroconvert yielded no evidence overall of a protective effect, except possibly in the early stages of the program (32). It may be possible also that impact of a NEP may have a longer latency period.

Public health authorities have been informed of our findings, and measures have already been implemented at CACTUS since January 1995—notably, removal of the individual quota on syringe distribution. Our work firmly suggests that NEP programs should be fine-tuned to local needs. More studies are needed to elucidate the mechanisms implicated on the transmission of HIV around NEPs in Montreal or elsewhere and to further assess the potential advantages of this intervention. Such expanded studies should include viral load measures, molecular epidemiology analyses of HIV strains, and qualitative investigations of risk behaviors and networking around NEPs.

ACKNOWLEDGMENTS

This research was funded by National Health Research and Development Program grant NHRDP 6605–2936AIDS from Health Canada.

The authors thank Chantal Clément, Solanges Dion, and Diane Labrie for conducting the interviews, Claudine Chouinard for technical assistance, and Elisabeth Deschênes for secretarial assistance.

REFERENCES

- Lurie P, Reingold AL, Bowser B, et al. The public health impact of needle exchange programs in the United States and abroad: summary, conclusions and recommendations. School of Public Health, University of California, Berkeley. San Francisco, CA: Institute for Health Policy Studies, University of California, October 1993.
- Alcades P, Freedland G. Injection drug use and human immunodeficiency virus infection. *Clin Inf Dis* 1995;20:1467-79.
- Normand J, Vlahov D, Moses LE, eds. Preventing HIV transmission: the role of sterile needles and bleach. Panel on Needle Exchange and Bleach Distribution Programs, Commission on Behavioral and Social Sciences and Education, National Research Council and Institute of Medicine. Washington, DC: National Academy Press, 1995.
- Hart GJ, Carvell ALM, Woodward N, et al. Evaluation of needle exchange in central London: behaviour change and anti-HIV status over one year. *AIDS* 1989;3:261-5.
- Frischer M, Elliott L. Discriminating needle exchange attenders from nonattenders. *Addiction* 1993;88:681-7.
- Keene J, Stimson GV, Jones S, et al. Evaluation of syringe-exchange for HIV prevention among injecting drug users in rural and urban areas of Wales. *Addiction* 1993;88:1063-70.
- Donoghoe MC, Stimson GV, Dolan K, et al. Changes in HIV risk behaviour in clients of syringe-exchange schemes in England and Scotland. *AIDS* 1989;3:267-72.
- Wolk J, Wodak A, Guinan JJ, et al. The effect of a needle and syringe exchange on a methadone maintenance unit. *Br J Addict* 1990;85:1445-50.
- Singer M, Weeks MR, Himmelgreen D. Sale and exchange of syringes. (Letter). *J Acquir Immune Defic Syndr* 1995;10:104.
- Paone D, DesJarlais DC, Caloir S, et al. New York City syringe exchange: an overview. Proceedings from the Workshop on Needle Exchange and Bleach Distribution Programs. National Research Council and Institute of Medicine. Washington, DC: National Academy Press, 1994:47-63.
- Hagan H, DesJarlais DC, Purchase D, et al. The Tacoma syringe exchange. *J Addict Dis* 1991;10:81-8.
- Hagan H, DesJarlais DC, Freedman SR, et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. *Am J Public Health* 1995;85:1531-7.
- Guydish J, Bucardo J, Young M, et al. Evaluating needle exchange: Are there negative effects? *AIDS* 1993;7:871-6.
- Ljungberg B, Christensson B, Tunving K, et al. HIV prevention among injection drug users: three years of experience from a syringe-exchange program in Sweden. *J Acquir Immune Defic Syndr* 1991;4:890-5.
- Oliver K, Friedman SR, DesJarlais DC. Behavioral and community impact of the Portland syringe exchange program. Proceedings from the Workshop on Needle Exchange and Bleach Distribution Programs. National Research Council and Institute of Medicine. Washington, DC: National Academy Press, 1994:35-46.
- Kaplan EH, Heimer R. HIV incidence among needle exchange participants: estimates from syringe tracking and testing data. *J Acquir Immune Defic Syndr* 1994;7:182-9.
- van Ameijden EJC, van den Hoek JAR, Coutinho RA. A substantial decline in injecting risk behavior among drug users in Amsterdam from 1986 to 1992, and its relationship to AIDS-prevention programs. *Am J Public Health* 1994;84:275-81.
- Lamothe F, Bruneau J, Soto J, et al. Risk factors for HIV seroconversion among injecting drug users in Montreal: the Saint-Luc cohort experience. Presented at the Tenth International Conference on AIDS, Yokohama, Japan, August 1994.
- Campos-Filho N, Franco EL. A microcomputer program for multiple logistic regression by unconditional and conditional maximum likelihood methods. *Am J Epidemiol* 1989;129:439-44.
- Campos N, Franco EL. Microcomputer-assisted multivariate survival data analysis using Cox's proportional hazards regression model. *Comput Methods Programs Biomed* 1990;31:81-7.
- Breslow NE, Day NE. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. (IARC scientific publication no. 32). Lyon: International Agency for Research on Cancer, 1980:248-79.22. Cox DR. Regression models and life-tables. *J R Stat Soc* 1972; B34:187-220.
- Hankins CA, Gendron S, Bruneau J, et al. Evaluating Montreal's needle exchange CACTUS-Montréal. Proceedings from the Workshop on Needle Exchange and Bleach Distribution Programs. National Research Council and Institute of Medicine. Washington, DC: National Academy Press, 1994:83-90.
- Friedman SR, Jose B, Deren S, et al. Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. *Am J Epidemiol* 1995;142:864-74.
- Canadian Pharmaceutical Association Executive Council. Norm 010-02. Ottawa, Canada: September 1988.
- Klee H, Faugier J, Hayes C, et al. The sharing of injecting equipment among drug users attending prescribing clinics and those using needle-exchange. *Br J Addict* 1991;86:217-23.
- Clark SJ, Saag MS, Don Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. *N Engl J Med* 1991;324:954-60.
- Piatak M, Saag MS, Yang LC, et al. High level of HIV-1 in plasma during all stages of infection determined by competitive PCR. *Science* 1993;259:1749-54.
- Baumberger C, Kinloch-de-Loes S, Yerly S, et al. High levels of circulating RNA in patients with symptomatic primary HIV-infection. *AIDS* 1993;7(suppl 2):S59-64.
- Kunanusont C, Foy HM, Kreiss JK, et al. HIV-1 subtypes and male-to-female transmission in Thailand. *Lancet* 1995;345:1078-83.
- Coutinho RA. Annotation: needle exchange programs—Do they work? *Am J Public Health* 1995;11:1490-1.
- van Ameijden EJC, van den Hoek JAR, van Haastrecht HJA, et al. The harm reduction approach and risk factors for human immunodeficiency virus (HIV) seroconversion in injecting drug users, Amsterdam. *Am J Epidemiol* 1992;136:236-43.